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Abstract 
Non-Alcoholic Fatty Liver Disease (NAFLD) is a chronic and dangerous condition which has 
grown in prevalence over recent decades due to increasing rates of obesity, affecting roughly 
a quarter of adults globally. This thesis develops a useable NAFLD definition which can be 
applied to large retrospective data sets consisting of medical records for selected cohorts. The 
morbidity and mortality associated with NAFLD is investigated, especially related to 
extrahepatic cancer. This thesis also aims to identify genetic modifiers of NAFLD risk in 
Scottish and South Indian populations. 
Data from three retrospective Scottish cohorts with electronic health records (EHRs) were 
analysed in the current thesis. These were the GoDARTS, SHARE and Tayside and Fife 
Diabetics cohorts. Genotypic data was available for a number of patients in GoDARTS and 
SHARE. Data from the Dr Mohan’s Diabetes Speciality Clinic (DMDSC) were also 
analysed, which consisted of clinical measurements from clinic visits, and genotypic data. 
An accurate and practical NAFLD definition based on two raised ALT levels was developed, 
which had a sensitivity of 97.4% in the GoDARTS cohort. This definition was used for 
subsequent NAFLD analyses. Patients with NAFLD experienced significantly more hospital 
admissions, and earlier death than those without NAFLD. We found NAFLD is associated 
with increased risk of cancer incidence, and cancer death, which accounts for a large portion 
of the excess morbidity and mortality seen in NAFLD patients. GWAS analyses revealed that 
PNPLA3 rs738409 is a major genetic risk factor in both Scottish and South Indian 
populations. Candidate gene studies revealed variants associated with endothelin function and 
with GLP1 receptors had significant effects on NAFLD. 
This thesis applies an accurate and novel NAFLD definition to retrospective cohorts with 
EHRs, and found increased morbidity and mortality in individuals with this phenotype. A 
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large proportion of this is explained by increased cancer incidence and cancer death seen in 
these individuals. A number of genetic risk factors for NAFLD are described, including novel 
loci in endothelin and GLP1R related genes. 
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1 Introduction  
1.1 Introduction to Non-Alcoholic Fatty Liver Disease 
Non-Alcoholic Fatty Liver Disease (NAFLD) is a chronic condition which affects roughly 
25.2% of the adult population globally, and is now the leading cause of liver disease.1 
Prevalence of NAFLD has risen in recent decades, and continues to rise due to increased rates 
of obesity.2 There is currently no recommended pharmacological intervention for NAFLD.3 
The high prevalence of this disease and associated morbidity and mortality make NAFLD a 
key research priority, with the aims of improving assessment of NAFLD risk and informing 
drug discovery.4 
1.2 NAFLD Overview 
NAFLD is a multi-stage disease which can have deadly consequences.5 These stages are 
shown in figure 1-1 below.6 Though each of these stages is associated with NAFLD, they do 
not necessarily occur in a linear fashion, as some patients may have fibrosis with no 
steatohepatitis for example. 
The first stage of NAFLD is simple steatosis, where macrovesicular steatosis is present in 
>5% of hepatocytes.7 Steatosis is the fatty infiltration of hepatocytes, without inflammation 
or fibrosis present. Triglyceride droplets form in the cytoplasm of the liver cells in large 
quantities, outside of normal ranges. There are many mechanisms involved in the build-up of 
steatosis, but these mainly involve dysregulation of lipid metabolism and increased 
availability of lipids, due to conditions such as obesity and diabetes.8 Simple steatosis is the 
Figure 1-1 Stages of NAFLD Progression 
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most common form of NAFLD, with a minority of patients progressing to more severe stages 
per year of disease.7  
Non-Alcoholic Steatohepatitis(NASH) occurs where NAFLD causes inflammation in the 
liver cells.9 It is estimated that 25% of patients progress from simple steatosis to NASH over 
a three year period.5 NASH is characterised by inflammation of the hepatocytes due to fatty 
degeneration, though this inflammation does not correlate closely with the severity of 
steatosis. This causes injury to the hepatocytes and leads to cell death. The triglycerides 
which form the steatosis are not toxic to hepatocytes, therefore it is thought that lipid 
intermediates and oxidative stress are likely to be the cause of the toxicity and therefore 
damage to the cells.10,11 NASH is reversible, and improvements in NASH have been reported 
in patients following bariatric surgery.12 NASH is most accurately diagnosed by biopsy, and 
has distinct properties compared with NAFLD. Histologic features of NASH are mainly 
inflammation, hepatocyte ballooning, and Mallory-Denk bodies.13 There are however issues 
with sampling variability with biopsies for NASH diagnosis, as lesions can be spread 
unevenly throughout the liver, and inter-observer variability can affect diagnosis.14 
Hepatic fibrosis can occur in those with NAFLD.5 This is characterised by the deposition of 
extracellular matrix in the parenchyma of the liver.15 Fibrogenesis in the liver is usually the 
result of a chronic wound healing process, in response to damage caused by NASH in the 
case of NAFLD.15 As part of the response to repair the liver, fibrotic tissue is produced by 
hepatic stellate cells. (HSCs) These cells are usually in a dormant state, and have a role in the 
storage of vitamin A.16 When the wound healing processes are activated in the liver however, 
HSCs are activated and proliferate. They produce large amounts of extracellular matrix, 
which cause major structural changes in the liver. It is estimated that 20% - 30% of patients 
with NAFLD progress to fibrosis over three years.5 Patients with fibrosis progress at one 
18 
 
fibrosis stage per decade.17 Initially thought to be irreversible, there is now some evidence to 
show that fibrosis can be reversed to some extent.18 
Cirrhosis occurs in extreme cases of fibrosis, where a portion of the liver is replaced by the 
scar tissue formed by fibrosis, and regenerative nodules of hepatocytes form.19 This 
drastically changes the structure of the liver, causing reductions in function, and portal 
hypertension.20 In cirrhosis, regenerative nodules of hepatocytes form between strands of scar 
tissue (septa), as the liver tries to repair itself.21 Cirrhosis is extremely dangerous, and can 
lead to liver failure. It is thought that up to 38% of patients with fibrosis progress to cirrhosis. 
Hepatocellular carcinoma (HCC) is a complication which can occur in cirrhotic livers. It is 
the 6th most common cancer and is a major cause of cancer death globally.22,23 A number of 
pathological changes occur in cirrhotic livers to provide an environment conducive to 
neoplasia.24 Inflammation is thought to play a large role in this, influencing several genetic 
and epigenetic transformations leading to neoplasia.24 Regenerative nodules in the liver often 
show dysplasia, leading to HCC. A small but significant portion of patients with NAFLD 
develop HCC. The proportion is estimated to be 2.4% - 12.8% in patients with NASH over a 
3.2–7.2 year period.5 Around 20% of HCC occurs in non-cirrhotic patients, though a certain 
amount of this may be due to sampling variability in biopsies and missed cirrhosis 
diagnoses.23 
Though NAFLD is common, it is underdiagnosed in clinical settings.25 This is due to the 
challenges of diagnosing NAFLD, which is often asymptomatic.26 There is evidence that 
NAFLD is a key contributor to cryptogenic cirrhosis.27 The full scale of the risk posed by 
NAFLD, as well as its epidemiology cannot be understood without accurate diagnostic 
techniques. The gold standard technique is biopsy, though this invasive and can have 
complications which can lead to death in some cases.28,29 Imaging and biochemical methods 
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of diagnosis are more commonly used, though vary in accuracy and the validity of some 
measures is debated.30,31 
The concept of NAFLD dates back to the early 80’s when Ludwig et al. first described 
NASH in a landmark paper; though NAFLD research was not undertaken intensively until 
later in the 1990’s.32 Prior to this, it was assumed that all patients who reported zero or low 
alcohol use, and had fatty livers were dishonest about their alcohol intake. NAFLD and its 
alcoholic related counterpart, alcoholic liver disease (ALD) have a large amount of 
pathophysiological overlap, and are indistinguishable in many ways.33 NAFLD is defined as 
the presence of fatty infiltration of the liver in the absence of excess alcohol intake or other 
cause of liver disease. Therefore, upper limits of alcohol intake are set to prevent ALD being 
categorised as NAFLD. Other causes of liver disease including virological and 
immunological insults must also be ruled out too to diagnose NAFLD. 
The use of “Non-Alcoholic” in NAFLD and NASH was used as the definition was being 
presented as an alternative to ALD, and compared to it.32 In recent times, the limitations of 
this definition have been discussed an updated terminology suggested. The term metabolic 
associated fatty liver disease or “MAFLD” has been proposed to more accurately describe the 
condition, as it provides a description of the aetiology of the disease.34 The author thought 
this to be important as the condition can coexist with a number of other liver diseases, 
including ALD, which is an important factor in understanding the disease. Though 
“MAFLD” is a more descriptive and appropriate name, to maintain consistency and clarity, 
the term NAFLD will be used throughout this thesis as this is the terminology used in almost 
all previous literature and is still widely used. 
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1.3 NAFLD Pathogenesis 
A number of factors influence the pathogenesis of NAFLD, shown below in figure 1-2 from 
the 2016 paper by Buzzetti et al, “The multiple-hit pathogenesis of non-alcoholic fatty liver 
disease (NAFLD)”.35 
 
This diagram does not show all pathways involved in the development of NAFLD, NASH 
and fibrosis, but includes many key features. Firstly dietary factors such as high carbohydrate 
and fat intake increase risk of obesity.36 Outside of the liver this leads to increased adipose 
tissue and dysfunction. The adipose tissue releases inflammatory adipokines which can lead 
to mitochondrial dysfunction in the liver, and inflammation.37 In the gut, the microbiome is 
affected, and the gut becomes more porous to factors including endotoxins.38 Obesity and 
insulin resistance increase the free fatty acid (FFA) and cholesterol content of the blood, and 
Figure 1-2 NAFLD Pathogenesis 
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much of these are absorbed by the liver. Hepatic insulin resistance increases de novo 
lipogenesis, which further increases the total FFA content of the liver. Much of this excess 
FFA is converted to triglycerides, stored in the hepatocytes.35 This excess triglyceride storage 
is steatosis. Triglycerides themselves are not hepatotoxic, however it is thought that when the 
liver is no longer able to store FFA’s as triglycerides, the FFA’s can be harmful to 
hepatocytes. FFA’s which are not converted to triglycerides can increase risk of 
mitochondrial dysfunction and endoplasmic reticulum stress. These processes increases 
number of reactive oxygen species and unfolded protein response respectively.39,40 These 
processes lead to inflammation which characterises NASH. Inflammatory adipokines also 
contribute to inflammation of the cell. This cellular damage leads to cell death, and 
subsequent injury response in the form of fibrosis, from activated hepatic stellate cells.13 This 
fibrosis can take over large portions of the liver, becoming cirrhosis. 
A number of other factors contribute to the pathogenesis of NAFLD, many influenced by 
genetics. There is significant heterogeneity in the clinical presentation of patients with 
NAFLD and NASH, as some can have normal BMI for example.41 In these individuals, it is 
likely that dysfunction has occurred in a process downstream of obesity. 
1.4 NAFLD in Clinical Practice 
NAFLD is in the first instance suspected by a physician based on overall clinical presentation 
based on risk factors including age >50, being male, obese, high cholesterol and other lipids. 
NAFLD is usually diagnosed first via elevated liver function tests.42 Alanine transaminase 
(ALT) is an important marker used in the preliminary diagnosis of NAFLD, and is covered in 
more detail in the following chapter.  NAFLD can also be suspected in the first instance by 
incidental findings in ultrasonography.42  The majority of patients who are diagnosed with 
NAFLD are obese, and often have other comorbidities such as T2DM and hypertension. 
Though progression to more severe stages in NAFLD is relatively uncommon, the prevalence 
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of the disease and association with other conditions such as T2DM make diagnosis of 
NAFLD important. No pharmacological treatments are currently suggested, though lifestyle 
modification through diet and exercise have been found to lower liver fat content. 43 NICE 
guidelines state that lifestyle modification is the only evidence based method for treatment of 
NAFLD.44  Physicians encourage these lifestyle modifications in patients, and target the 
lowering of liver enzymes and weight loss.42 This management policy for NAFLD patients is 
sufficient for most, though severe cases can be referred to hepatologists for closer 
monitoring. 
Significant debate exists as to whether blanket screening for NAFLD should be carried out in 
primary care.45 The key concern is balancing practicality, cost and invasiveness against the 
clinical utility and improvement to patient care gained by screening. Screening for NAFLD in 
the population is not recommended in the NICE guidelines, as there is insufficient evidence 
to suggest this would be worthwhile.44 Nascimbeni et al. reviewed NAFLD screening 
guidance from a number of international and national hepatological societies and found none 
recommended screening for NAFLD in the general population .46 Most guidance 
recommends targeted screening for those considered to be at greater risk of NAFLD. 45,47 
Patients with features of metabolic syndrome, and insulin resistance in particular are targeted, 
and some studies have found these techniques to be cost effective.48 
Others suggest that screening for NAFLD is unjustified, and wastes resources and time. The 
majority of NAFLD does not progress to fibrosis or HCC, and appears to be benign in many, 
therefore treatment of NAFLD many not provide benefit.49 Lifestyle modification is at 
present the main intervention, and given the fact obesity, T2DM and other features of 
metabolic syndrome are so highly correlated with NAFLD it is likely patients will be advised 
to lose weight by their clinician regardless of NAFLD status. Rowe suggests in his paper 
“Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease”, 
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that screening for NAFLD even in at-risk groups is problematic as it risks incursion of harm 
to patients who are falsely diagnosed.50 Other such as Malnick also suggest over treatment of 
NAFLD is harmful, and that the considerable amount of money being spent of 
pharmacological interventions would be better placed improving public health facilities and 
helping enable lifestyle modifications.51 Others have presented similar economic arguments, 
suggesting it is not cost effective to screen for NAFLD. It may be cheaper and more effective 
to advocate weight loss and lifestyle modification than to screen and treat NAFLD. The risk 
with this approach however is that lean individuals and those without the traditional 
comorbidities of NAFLD may not be diagnosed and therefore progress to more serious stages 
of NAFLD without intervention. 
NAFLD is common, but it is underdiagnosed in clinical settings.25 This is due to the 
challenges of diagnosing NAFLD, which is often asymptomatic.26  Aside from improving 
NAFLD screening and diagnosis techniques to improve patient care, this will also aid 
scientific research, the full scale of the risk posed by NAFLD, as well as its epidemiology 
cannot be understood without accurate diagnostic techniques. This will allow GWAS and 
other genetic analyses to be conducted to find further genetic risk factors for NAFLD. One of 
the gold standard techniques is biopsy, though this invasive and can have complications 
which can lead to death in some cases.28,29 Imaging and biochemical methods of diagnosis are 
more commonly used, though vary in accuracy and the validity of some measures is 
debated.30,31 Different methods of screening may also be employed to increase practicality 
and reduces costs, including applying NAFLD diagnosis algorithms to retrospective medical 
records to determine those at risk of NAFLD. This method is used in the current thesis.  
The concept of NAFLD dates back to the early 80’s when Ludwig et al. first described 
NASH in a landmark paper; though NAFLD research was not undertaken intensively until 
later in the 1990’s.32 Prior to this, it was assumed that all patients who reported zero or low 
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alcohol use, and had fatty livers were dishonest about their alcohol intake. NAFLD and its 
alcoholic related counterpart, alcoholic liver disease (ALD) have a large amount of 
pathophysiological overlap, and are indistinguishable in many ways.33 NAFLD is defined as 
the presence of fatty infiltration of the liver in the absence of excess alcohol intake or other 
cause of liver disease. Therefore, upper limits of alcohol intake are set to prevent ALD being 
categorised as NAFLD. Other causes of liver disease including virological and 
immunological insults must also be ruled out too to diagnose NAFLD. 
The use of “Non-Alcoholic” in NAFLD and NASH was used as the definition was being 
presented as an alternative to ALD, and compared to it.32 In recent times, the limitations of 
this definition have been discussed an updated terminology suggested. The term metabolic 
associated fatty liver disease or “MAFLD” has been proposed to more accurately describe the 
condition, as it provides a description of the aetiology of the disease.34 The author thought 
this to be important as the condition can coexist with a number of other liver diseases, 
including ALD, which is an important factor in understanding the disease. Though 
“MAFLD” is a more descriptive and appropriate name, to maintain consistency and clarity, 
the term NAFLD will be used throughout this thesis as this is the terminology used in almost 
all previous literature and is still widely used. 
1.4.1 Prevalence of NAFLD and Clinically Significant NAFLD 
There are many estimates of the prevalence of NAFLD globally. 25,52–54 Younossi et al. meta-
analysed 86 studies from 22 countries, and calculated a global average of 25.24% prevalence 
of NAFLD in adults. Significant heterogeneity was seen between countries and ethnicities, 
though it is unclear how much of this is due to differences in case ascertainment and 
reporting.55 Particularly high prevalence has been found in South American countries; as high 
as 30.45% based on ultrasound findings.49 Lower prevalence overall is seen in China, 
estimated to be around 15%, although this varies by region and is as high as 27% in some 
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urban populations. These rates are highly correlated with lifestyle factors which can vary 
drastically between different communities. 
The overall prevalence of NAFLD is high, though the more advanced stages are rarer. 
Younossi et al. estimate global prevalence of NASH to be 3% in their meta-analysis.1 They 
also calculated that approximately 41% of patients with NASH will progress to fibrosis. It is 
clear from these figures that a small but significant portion of individuals progress to the 
more harmful stages of NAFLD.  
Simple steatosis in NAFLD is commonly described as a benign condition in the absence of 
fibrosis and cirrhosis.56 In NAFLD, advanced fibrosis is the strongest predictor of disease 
specific mortality.57 Some suggest the majority of NAFLD is not clinically significant, as it is 
unlikely to progress and become harmful, and is relatively harmless on its own. There is 
growing evidence that this is not the case however, as significant excess mortality has been 
found in those with even simple steatosis, and increased incidence of extrahepatic cancer is a 
major cause of this.58–60 Allen et al. found those with NAFLD live on average 4 years shorter 
than those without, and cancer is a large part of this.58 This is covered in detail in a later 
chapter of this thesis. Further to this increased mortality, NAFLD is also a risk factor for 
development of T2DM.61 
These factors complicate the notion of clinically significant NAFLD, as non-progression to 
NASH and fibrosis does not necessarily mean that steatosis is not causing harm. The risk to 
health conferred by NAFLD must be assessed in the context of the intra and extrahepatic 
conditions it is associated with. It is therefore important that further study of NAFLD should 
aid prediction of these conditions, and determine the cause of these associations.  
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1.5 NAFLD Risk Factors 
Despite association with increased age and body fatness, NAFLD can affect almost anyone, 
with paediatric and geriatric cases reported in significant numbers, and in every age group in 
between.62 It can also affect lean individuals as well as those who are overweight and obese.41 
Despite this, there are a number of risk factors associated with NAFLD which increase risk of 
steatosis and the subsequent stages of NAFLD.63 
The key risk factor for NAFLD is excess body fat.37 Studies suggest that NAFLD is over four 
times more prevalent in obese patients.64 In obese patients, the release of free fatty acids 
(FFAs) from visceral fat is increased which leads to an increase in uptake of FFAs by the 
liver leading to steatosis.65 Though overall fatness predicts NAFLD, central obesity is more 
of a risk factor for NAFLD.66 Visceral fat is metabolically active, and insulin resistance forms 
a large part of the relationship between NAFLD and obesity, as steatosis severity correlates 
with hepatic insulin resistance.65 Reduction in bodyweight has been found to be effective in 
reducing NAFLD.67 Exercise has been shown to reduce liver fat, independently of weight 
loss.68 An association between low levels of physical activity and NAFLD has also been 
shown.69 It is however possible for lean individuals (BMI < 25kg/m2) to have NAFLD.41 
Estimates suggest that prevalence of lean NAFLD is as high as 7% in the USA, and 19% in 
parts of Asia.70 
Age is a non-linear risk factor for NAFLD.62 Age is associated with increased steatosis, as 
well as a number of other changes in the liver, including: increased fibrosis, decreased 
regeneration ability, increased inflammatory changes and increased oxidative stress. These 
factors increase the damage to the liver caused by NAFLD. Most studies suggest an inverse U 
shaped curve of NAFLD risk versus age, with peak risk around 50 to 60 then a decline in risk 
thereafter.19,71,7272 Men are likely to get NAFLD 10 years earlier than women, but being post-
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menopausal increases risk in women.62 Paediatric NAFLD is relatively less common than 
NAFLD in adults, though prevalence is rising with increased paediatric obesity.58 
Type 2 diabetes is a large risk factor for NAFLD.73 In the general population, the rate of 
NAFLD globally is ~25%, but in those with T2DM the prevalence is much higher, with 
estimates at 68% in European cohorts.55,74,75 NASH, fibrosis and cirrhosis are also more 
prevalent in those with T2DM.55 The liver contributes to the insulin resistance seen in T2DM, 
and hepatic insulin resistance is a key factor in NAFLD.76 Insulin resistance promotes the 
accumulation of triglycerides in the liver, leading to steatosis. Many studies have investigated 
the causal direction of the association between NAFLD and T2DM, and found NAFLD is a 
risk factor for T2DM; patients with NAFLD are five times more likely to develop T2DM.77,78 
Dyslipidaemia is a condition characterised by abnormal amounts of lipids in the blood, and 
often accompanies T2DM and obesity.79 This can be a risk factor for NAFLD independently, 
as circulating triglycerides and cholesterol are taken up by the liver and are stored, causing 
steatosis.80 
The risk factors outlined above are the main phenotypic risk factors for NAFLD, but a 
number of others also affect NAFLD development. These include hypothyroidism, sleep 
apnoea, hypopituitarism and polycystic ovary syndrome.81,82 Often individuals have several 
of the discussed risk factors, contributing various amounts to NAFLD risk.  
1.6 NAFLD Genetic Background 
NAFLD is complex and multifactorial, and as a result there are many genetic influences 
affecting different pathways associated with the disease. The first risk variant discovered by 
GWAS and most widely replicated result is PNPLA3 rs738409, discovered in 2008.52 This 
variant increases risk of simple steatosis as well as NASH and fibrosis.83 The protein encoded 
by PNPLA3 is adiponutrin, which plays an important part in the breakdown of triglycerides in 
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the liver (lipolysis). As a consequence of this downregulation of lipolysis, triglycerides build 
up to high levels causing steatosis. Further to the increased steatosis, PNPLA3 rs738409 is 
also associated with inflammation and fibrosis, through regulation of NF-κB.84 This PNPLA3 
variant is common, with a MAF of ~0.20 in Europeans and ~0.50 in Hispanics.85 It has been 
the focus of a number of studies as a drug target but so far without success.86 
Subsequently, variants affecting all stages of NAFLD have been discovered through GWAS 
and candidate gene studies. 87 Notable genes are shown in table 1 below, with their effect and 
the pathway which they act on. 
Table 1 Genetic Variants Associated with NAFLD 
Gene SNPID Discovery Primary Effect Role 
PNPLA3 rs738409 GWAS Increased steatosis Decreases lipolysis 
TM6SF2 rs58542926 GWAS Increased steatosis Decreases VLDL 
secretion 
GCKR rs780094 GWAS Increased steatosis Increases hepatic 
glucose uptake 
NCAN rs2228603 GWAS Increased steatosis, 
NASH and fibrosis 
Association with 
TM6SF2 
COL13A1 rs1227756 GWAS Liver enzymes and 
NASH 
Inflammatory response 
MBOAT7 rs641738 GWAS Steatosis and fibrosis Reduced protein 
production, not fully 
understood 
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The majority of genetic variants known to influence NAFLD have been discovered via 
GWAS, though a number of effects have been found through candidate gene studies.88 These 
include the variant MTP rs1800591, which alters the activity of lipid transporters increasing 
steatosis.89 
Heritability estimates for NAFLD vary between 20% and 70%, with a large portion of 
genetic variance shared between NAFLD and fibrosis.90 Despite several genes having 
significant effects, genetic risk scores for NAFLD have been inconsistent in their ability to 
predict NAFLD. Nobili et al. found a genetic risk score based on 4 SNPs predicted NASH 
better than a clinical model.91 Other studies have found genetic models to perform worse than 
those based on clinical parameters, and some that adding genetic data does not improve 
accuracy of clinical models.92,93 
As well as prediction, analysis of genetic influences of disease can aid understanding of the 
pathology of the condition. This in turn can aid drug discovery, as it can elucidate pathways 
which can be up or downregulated to treat the disease.94 This method has been applied to 
NAFLD, with research investigating the efficacy of inhibiting HSD17-B13  for example.95 
1.7 Gaps in Understanding and Research 
A large number of research questions regarding NAFLD remain unanswered in current 
literature and require further research. One of the key questions is why certain individuals get 
NAFLD and others do not. Another clinically important question is why certain individuals 
progress to more severe stages of NAFLD, whereas some do not. Phenotypic and genotypic 
risk factors for NAFLD are known there remains large amounts of thus far unexplained 
variance in the previous two research questions. Factors such as diet, exercise, smoking, 
lifestyle and socioeconomic status have been investigated and found to have significant 
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effects on NAFLD, and must be taken into account when describing a full model of NAFLD 
risk.4,96 
Much of the pathogenesis of NAFLD has been studied, and mechanisms of steatosis, NASH 
and fibrosis have been explained.97 There are numerous pathways involved however, and a 
complete model of NAFLD has not been illustrated. Analysis of correlates of NAFLD, both 
phenotypic and genotypic, are both common methods of elucidating factors which affect 
NAFLD. 
NAFLD is challenging to diagnose, as it lacks outward signs and symptoms in  most cases.25 
This means that NAFLD is underdiagnosed in most clinical settings. This thesis will 
investigate NAFLD diagnosis methods and apply a definition to the GoDARTS, SHARE and 
Tayside and Fife cohorts from Scotland, as well as the DMDSC cohort from Chennai, India. 
This definition will be validated against other known NAFLD definitions and correlates. An 
investigation into the morbidity and mortality of patients with NAFLD will be conducted, 
with particular emphasis on analysing causes of death. Recent studies have found NAFLD to 
be associated with a range of extrahepatic conditions, including cancer.58,59 This thesis will 
investigate whether NAFLD has any association with cancer incidence, as well as the effect 
of this on the shorter lifespans seen in those with NAFLD. 
GWAS methods will be used to investigate genetic modifiers of NAFLD risk in the Scottish 
and Indian cohorts. Studies of the genetics of NAFLD in individuals of European descent are 
plentiful in the literature, though not specifically of Scottish cohorts.98 Genetic studies of 
NAFLD in India have been published, findings significant effects of many known NAFLD 
risk variants.99,100 There have been no reported GWAS studies of NAFLD in Indian 
individuals. This thesis will run GWAS analyses in Scottish and Indian cohorts, and compare 
the effects of different NAFLD risk variants in each population.  
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Co-agonists for GLP1R and GCGR have been deployed with some success for the treatment 
of diabetes, and have been investigated as a NAFLD therapy also.101–103 A number of variants 
in the GCGR and GLP1R genes have significant effects on their namesake receptors, altering 
clinically relevant parameters to NAFLD, such as blood sugar and response to anti-diabetic 
drugs .104,105 Effects of variants in these genes have never been shown in for NAFLD. This 
thesis will investigate the role of variants in these genes in NAFLD, and interactions between 
variants in GLP1R and GCGR. If variants with significant effects are found, this data may be 
effective in the application of personalised medicine to the deployment of GLP1R/GCGR co-
agonists for the treatment of NAFLD. 
Endothelin receptor antagonists (ETRAs) have been used successfully for the treatment of 
pulmonary arterial hypertension (PAH).106–108 A number of pathological overlaps between 
PAH and NAFLD mean that ETRAs have been investigated as a potential treatment for 
NAFLD. It is thought that the downregulation of the endothelin receptors will reduce activity 
of the hepatic stellate cells (HSCs) which are primarily responsible for the production 
extracellular matrix (ECM) which characterises fibrosis.109–111 There are a number of 
common genetic variants in PHACTR1, EDN1, EDNRA and EDNRB which have effects on 
endothelin and endothelin receptor activity.112–115 No studies have previously reported 
associations between variants in these genes, and NAFLD. The current thesis will explore 
these genes and their associations with NASH, fibrosis and a number of related phenotypes. 
Showing effects of these genes on NASH and fibrosis would demonstrate clear effects of 
endothelin on the development of the conditions, and potentially allow for personalised 
medicine in those treated with ETRAs for NAFLD. 
1.8 Aims of the Current Study 
The aims of the current project are as follows: 
32 
 
-Develop a NAFLD definition and apply it to the GoDARTS, SHARE and Tayside and Fife 
Diabetics cohorts in Scotland, and the DMDSC cohort in India. 
-Describe NAFLD and related phenotypes, and investigate morbidities and mortalities 
associated with NAFLD in Scottish cohorts. 
-Analyse genetic determinants of NAFLD in Scottish and Indian cohorts using GWAS 
methods. 
-Investigate the effects of specific candidate gene SNPs (related to GLP1R and endothelin) 
on NAFLD and associated phenotypes in Scottish and Indian phenotypes. 
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2 Development of a NAFLD Definition 
2.1 Abstract 
NAFLD is a chronic disease which often goes unnoticed due to the challenges of diagnosis. 
This is due to the lack of apparent signs and symptoms in most patients. A number of 
diagnosis methods exist with varying practicality and accuracy. The aim of this chapter is to 
develop and validate an accurate technique of defining NAFLD in large retrospective cohorts. 
NAFLD diagnosis techniques from previous literature are considered and described. A 
NAFLD diagnosis technique based on elevated alanine transaminase (ALT) levels is used, as 
ALT is a commonly measured marker of liver damage. This definition is applied to the 
GoDARTS, SHARE and Tayside and Fife Diabetics (T&F) cohorts. A similar definition 
based on a single ALT level is applied to the DMDSC cohort. 
A NAFLD definition based on two raised ALT levels measured at least months apart was 
applied, and had good sensitivity in GoDARTS. (97.4%) This definition was also accurate in 
SHARE and T&F, with sensitivities of 75.3% and 94.6% respectively. Thresholds of 19U/L 
and 30U/L (for women and men respectively) were used as upper limits of normal, based on 
recommendations of previous literature. An interval of at least 3 months between raised 
measurements was applied to reduce the likelihood of misclassifying acute liver injuries as 
NAFLD. This measure is practical, as most patients in GoDARTS have had a number of ALT 
measured. (Mean = 32.5 measurements each) 
An accurate and practical NAFLD diagnosis method is developed and validated in this 
chapter. This novel definition may be useful for defining NAFLD in future studies using 
large retrospective cohorts, and analysing the genetics and epidemiology of NAFLD in these. 
This also may serve as a useful clinical risk estimating tool. 
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2.2 Introduction 
The diagnosis of NAFLD can be challenging, as the condition is usually asymptomatic, 
progresses slowly and often has a benign clinical course.116,117 This chapter covers the 
development of a NAFLD case definition based on raised alanine transaminase levels, in 
three large retrospective cohorts which had data for electronic health records (EHRs). The 
aim of this study is to develop a sensitive, accurate and functional NAFLD phenotype which 
can be used clinically and applied in research utilising retrospective cohorts 
NAFLD usually lacks outwardly visible symptoms or signs, making it challenging to 
diagnose.118 NAFLD can cause fatigue and pain in the upper right abdomen, but is usually 
completely symptomless.119 More advanced liver disease in NAFLD, such as cirrhosis, can 
be accompanied by visible signs such as ascites and jaundice.120 These symptoms usually 
occur in advanced liver disease, which only a minority of NAFLD patients progress to.4 
Diagnosis of the condition long before this happens is desirable as early intervention can 
improve disease outcomes.121 
Many diseases don’t present immediately obvious symptoms, and require clinical 
investigation to diagnose. These often have a reliable marker that can be used to infer the 
presence of the disease. An example of this is type 2 diabetes (T2DM). HbA1c is commonly 
used to diagnose T2DM, as it is an indicator of blood glucose levels over the last 2-3 
months.122 HbA1c is a simple blood test, which can be performed routinely and is cost 
effective.123 Although there are a number of methods and tests for NAFLD, currently there is 
not a perfect, universally accepted and practical method for the diagnosis of NAFLD in real 
world cohorts.124 
One of the main motivations for diagnosis of disease is to allow treatment. This is somewhat 
more complex in NAFLD, as there is currently no specific pharmacological intervention 
35 
 
recommended for NAFLD.125 Despite this, there is evidence that NAFLD is reversible, even 
at the stage of cirrhosis in some cases.126 Lifestyle modification has been the standard 
recommendation for NAFLD treatment for some time, and is included in NICE guidelines.44 
Weight loss and physical exercise have both been shown to reduce steatosis severity 
independently of each other. 68,127  
Diagnosing NAFLD is useful for research purposes.128 An accurate NAFLD phenotype may 
be key factor in the epidemiological and genetic studies that seek to characterise the disease. 
These studies may aid drug development, pathways highlighted as important in the 
pathogenesis of NAFLD can be targeted. For NAFLD clinical trials, a NAFLD phenotype 
which is sensitive and specific is important in assessing the efficacy of potential treatments. 
These factors mean that despite the lack of a specific pharmacological treatment for NAFLD, 
there is great scientific and medical interest in developing methods to diagnose NAFLD.129 
A key epidemiological phenomenon of NAFLD is underdiagnosis in most populations.25 
There are a number of estimates of global NAFLD prevalence, but the prevalence of 
diagnosed NAFLD lags far behind even conservative estimates. Alexander et al. found that 
the prevalence of NAFLD diagnoses was 1.85% in analysis of four large European cohorts. 
This is in contrast to the estimate of 20% NAFLD prevalence which Alexander et al. suggest, 
which is modest compared to the estimates of other studies such as Younossi et al. provide a 
global estimate of 25% prevalence.49 This is higher in many regions, as Latino individuals 
tend to experience younger onset of NASH compared with Caucasian individuals for 
example.130 
The current chapter considers existing literature on the diagnosis of NAFLD with the use of a 
number of methods. The advantages and disadvantages of each method are compared with 
respect to accuracy and practicality as a method of diagnosing NAFLD in large retrospective 
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cohort studies. A NAFLD case definition based on elevated ALT levels was developed and 
validated in the GoDARTS, SHARE, and T&F cohorts. ALT was selected as it is a specific 
marker of liver damage, and is routinely measured, making it an effective method of NAFLD 
diagnosis in large retrospective cohort studies.131 
2.3 Methods of NAFLD Diagnosis 
A number methods of diagnosing NAFLD have been developed and used, and generally there 
is a trade-off between the accuracy and practicality of measures. The following section 
discusses NAFLD diagnosis methods with their merits and disadvantages. 
2.3.1 Biopsy 
The gold standard method of NAFLD diagnosis is liver biopsy.132 A small core tissue sample 
of the liver is taken with a needle which is then evaluated by a pathologist.133 This method is 
accurate for detecting the presence of steatosis in hepatocytes and for diagnosing later stages 
of NAFLD such as fibrosis and cirrhosis. Liver biopsies are invasive procedures, and can lead 
to serious complications. These include haemorrhage, pneumothorax, biliary peritonitis, and 
even death.134 As well as the risks of biopsy, inter-clinician variability in evaluation can 
influence the accuracy of diagnosis. 14 Steatosis, inflammation and fibrosis can often present 
unevenly throughout the liver, with some areas unaffected while others show severe NAFLD 
progression. This can lead to inaccuracy and false negative results. These factors combined 
with the high prevalence of NAFLD mean that biopsy is an impractical method of diagnosis, 
and often the risk is not worth the reward. Biopsy can be a useful tool for patients who are 
considered at greater risk of advanced stages of NAFLD such as fibrosis and cirrhosis, but 
non-invasive methods are more appropriate for NAFLD diagnosis.125 
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2.3.2 Imaging 
Imaging methods such as ultrasound and MRI can be used for NAFLD diagnosis.135 These 
methods can be accurate in detecting the presence of steatosis in the liver, as well as fibrosis 
and cirrhosis.136 The primary advantage of imaging methods over biopsy is that they are non-
invasive and do not pose the same risk of complications that biopsy does. Eddowes et al. 
found MRI was more cost effective than biopsy for diagnosing NAFLD. In two cohorts from 
NHS hospitals in the UK, the study showed MRI could save £150,218 per 1000 patients.137 
Ultrasound scanning techniques can be used at a patient’s bedside in clinical settings, giving 
immediate results.138 
Ultrasound is used effectively to grade fatty liver disease, and is more cost effective than 
MRI.139 Ultrasound has been shown to accurately detect moderate-severe NAFLD from no 
NAFLD present.140 As well as a binary diagnosis of NAFLD or not NAFLD, the severity of 
steatosis can be assessed by ultrasound. Clinicians often grade NAFLD on a 4 point scale: 
normal, intermediate, moderate and severe. Ultrasound techniques are not as accurate as 
biopsy, but provide more information about the current NAFLD status than a binary 
outcome.141 
Similarly to biopsy however, Hamer et al. found the accuracy of imaging methods can be 
affected by inter-clinician variability.142 Accuracy may also be affected by variation in 
equipment, equipment settings and the specific imaging modality used. Imaging methods 
may not be as accurate as biopsy, nor provide as much information about the status of liver 
disease in some instances. For example, Saadeh et al. found that there was no reliable method 
of discerning NAFLD from NASH using any radiological technique.143 Further to the issues 
of accuracy, imaging techniques may be impractical due to resource limitations and time 
consumption. Patients may experience waiting times of several weeks for diagnostic 
procedures which are in high demand within health services.144 Imaging processes are not 
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usually available at GP surgeries which means they are not practical for NAFLD diagnosis in 
the general population. 
2.3.3 Blood Biomarkers 
Blood based biomarkers are routinely used for quick and accurate diagnosis in many diseases 
including NAFLD.31 These are non-invasive, rapid and usually economical when compared 
with biopsy or imaging.145 Another advantage over biopsy or imaging is that blood can be 
drawn in general practice surgeries or in the community, making this form of testing for 
NAFLD very accessible. Many patients have blood taken routinely, allowing consistent 
monitoring of biomarkers. Multiple biomarkers can be tested at once and results combined to 
make disease scores, as considered below. Common biomarkers used for NAFLD and more 
advanced stages thereof include alanine transaminase (ALT), aspartate transaminase (AST), 
gamma-glutamyltransferase (GGT), ferritin and platelets.146 These are considered liver 
function tests. (LFTs) Among these LFTs, ALT is a commonly used biomarker in NAFLD 
research and clinical practice.131 
2.3.4 Scores and Indices 
Scores and indices to estimate the likelihood and severity of NAFLD have been developed. 
These use a variety of often biochemical and anthropometric measures, and combine them in 
some numerical formula. An example of this is the NAFLD activity score (NAS).147 This 
uses a combination of observed steatosis, lobular inflammation and liver damage to diagnose 
NAFLD and NASH. This is impractical as a method for diagnosis of NAFLD in the general 
population however, due to the pitfalls of biopsy discussed above. 
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FLI 
A non-invasive scoring system for NAFLD is the Fatty Liver Index (FLI).148 This combines 
BMI, waist circumference, GGT and triglycerides using the formula in figure 2-1 below. 
 
Bedogni et al. found that the FLI could detect NAFLD with an accuracy of 0.84. They found 
that ALT was predictive of NAFLD, but GGT performed better in their model. Subsequent 
studies have validated FLI against other NAFLD diagnosis methods such as imaging 
techniques, and found it performs well.149 
This can be applied in the GoDARTS cohort where 4,164 eligible patients had the required 
data to calculate their FLI score. This represents about 30% of the eligible GoDARTS 
population, so is useful for replication and verification of results but the missingness of GGT 
measurements make FLI less useful for NAFLD diagnosis than definitions using more 
commonly taken measures. 
Hepatic Steatosis Index 
Another score for NAFLD diagnosis is the Hepatic Steatosis Index (HSI).150 This uses 
AST(U/L), ALT(U/L), BMI(kg/m2), sex and diabetes in the formula below to rule in or out 
NAFLD. 
 
Figure 2-1 Fatty Liver Index calculation formula 
Figure 2-2 Hepatic Steatosis Index calculation formula 
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This index can also be applied to a subset of GoDARTS where 1,493 patients had the 
requisite data measured before sign up to the study. Like the FLI, this is useful for 
verification of results in GoDARTS and SHARE, but the number of patients without AST 
levels measured make this impractical as a main NAFLD definition. 
APRI 
The APRI (AST to Platelet Ratio Index) score is also used to diagnose hepatic fibrosis.151,152 
APRI is calculated as follows. 
 
The upper limit for normal AST is taken as 40U/L in most studies.151 This index has been 
found to correlate strongly with fibrosis and cirrhosis, but has little predictive value for 
steatosis however.153 
The FLI, HIS and APRI indices are useful markers for steatosis and fibrosis, but the lack of 
availability of certain data, especially AST measurements, make these impractical as a main 
technique for defining NAFLD for the analysis in the current study, as the analytical 
requirements of these measures would result in the exclusion of a significant portion of the 
GoDARTs, SHARE and T&F cohorts. 
2.3.5 Summary of Techniques 
The previous section covers a number of techniques used for the diagnosis of NAFLD in 
clinical and research settings. Based on evidence from previous literature, and the availability 
of relevant data, a NAFLD definition based on elevated ALT levels is selected for the current 
Figure 2-3APRI calculation formula 
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study. The following section describes the association between NAFLD and ALT, covers the 
development of a NAFLD definition based on ALT levels. 
2.4 ALT Based NAFLD Definition 
2.4.1 Biology 
ALT is part of the gluconeogenesis process and plays a major role in metabolic homeostasis. 
It is an enzyme which catalyses the transfer of α-amino acids from alanine to create pyruvic 
acid.154 This process occurs in the liver, and thus ALT is found in its highest concentrations 
in the liver and in low concentrations elsewhere in the body.155 ALT is found in the 
cytoplasm of hepatocytes, and when hepatocellular injury occurs, ALT is released into the 
bloodstream. As a result, ALT levels are commonly used biomarker of liver damage.156 The 
mean half-life of serum ALT is 47 hours, meaning that measured ALT levels can be affected 
by acute events.154  
Elevated ALT levels have been observed in those with NAFLD in numerous studies. 31,157–160 
ALT levels are known to correlate with liver fat percentage; Phillips et al. estimate this 
correlation to have R2= 0.51 for example.161 Other studies have found ALT to be a useful 
predictor of NAFLD in those with steatosis confirmed by MRI.162 Maximos et al. found that 
ALT levels were a strong predictor of hepatic triglyceride content.163 A number of previous 
epidemiological studies have used ALT levels to define their NAFLD cases. Wong et al. 
investigated the showed the link between T2DM and NAFLD with ALT as a surrogate 
marker.164 Cross sectional case-control studies such as Yoo et al. in 2008 used ALT to define 
paediatric NAFLD.165 ALT has been used as a surrogate marker to track resolution or 
progression of NAFLD also. 166,167 
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2.4.2 Practicality 
An ALT based NAFLD definition is a pragmatic choice for defining NAFLD in the cohorts 
used in this project for a number of reasons. A key factor which makes ALT a useful 
biomarker for NAFLD is that ALT levels are commonly measured in both GP and hospital 
settings. The majority of patients in GoDARTS and SHARE have ALT measurements taken, 
and in many individuals a large number of measurements have been taken over many years. 
In GoDARTS for example, patients had a mean number of 32.5 ALT measurements each. 
This allows the assessment of NAFLD over a longitudinal period with some degree of 
regularity, and an interesting analysis of ALT levels over time compared with other clinical 
outcomes. This reflects what is seen in primary care settings in general, as ALT levels are 
monitored as a key indicator of NAFLD.42 
2.4.3 Specificity versus other diseases 
Serum ALT levels are specific markers of liver damage due to their high concentrations in 
the liver under normal circumstances. ALT is a general marker of hepatocellular injury 
however, and is not specific to NAFLD.156 There are a variety of causes of liver damage 
which result in raised ALT levels; therefore to use ALT for NAFLD diagnosis, all other 
causes of liver injury must be ruled out.  
One of the major alternative causes of abnormal ALT levels is alcoholic liver disease 
(ALD).168 Excessive alcohol consumption can cause steatosis of the liver much like 
NAFLD.169 The demarcation between ALD and NAFLD is not clear in a large portion of 
patients, as the two diseases have similar features, and can lead to fibrosis, cirrhosis and liver 
cancer. Patients with fatty liver disease may have their condition attributable to both alcohol 
and metabolic aetiologies.33 The generally accepted upper alcohol consumption limits for 
NAFLD are <20 grams per day for women and <30 grams per day for men.42 It is likely that 
in patients with fatty liver who drink alcohol but below these limits, alcohol may still 
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contribute to the disease. Previous studies have shown that ALT levels are more correlated 
with the non-alcoholic form of fatty liver disease, and AST tends to be higher in ALD.170 
Other liver insults which can raise ALT levels include viral and immunological hepatitis. 
These are usually diagnosed with blood tests, the results of which are reported in 
immunology and virology files in EHRs. Patients with positive serological tests for anti-
smooth muscle antibody, antinuclear antibodies or anti-mitochondrial antibodies, or any 
positive serology for hepatitis B surface antigen or hepatitis C antibody, or mention of cause 
of liver disease in medical records are excluded from the study. 
Aside from other liver disease, factors which do not warrant exclusion can affect ALT levels. 
There is evidence that certain drugs at therapeutic doses, including paracetamol, can raise 
ALT levels in the absence of any clinically evident liver damage.171 
2.4.4 Sensitivity for NAFLD 
Despite the large volume of evidence that NAFLD causes elevations in ALT levels, there 
have been a number of studies that report the complete spectrum of NAFLD in patients with 
normal ALT levels.172 Mofrad et al. found that some patients within the normal ALT range, 
50U/L for women and 75U/L for men, had steatosis, fibrosis and cirrhosis. These thresholds 
are however are considerably higher than those adopted by most modern studies, and may not 
reflect truly “normal” ALT values. Sanyal et al. had similar results, but they too used a high 
ALT threshold, at 40U/L.173 Despite higher thresholds, both studies identified individuals 
with low ALT < 15, with NAFLD. Both of these studies used cross-sectional techniques, with 
a single ALT measurement on the date of the study and this is a potential source of error as 
follows. In severe cases of cirrhosis, ALT levels can decrease as the number of hepatocytes 
diminishes and less ALT is released into the bloodstream.174 Lominadze et al, found many 
patients with cirrhosis had normal ALT levels.175 In GoDARTs there are patients with normal 
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ALT levels at the time of cirrhosis diagnosis, but had previously had raised ALT levels. ALT 
levels have also been found to vary by age, following an inverted U shape over a lifetime.176 
The retrospective application of a NAFLD definition based on ALT levels allows an “ever 
raised” case definition, increasing sensitivity compared with cross-sectional techniques. 
The sensitivity of ALT as a diagnostic marker for NAFLD has been found to differ between 
those with and without T2DM.177 Kotronen at el. found that individuals with T2DM have 
80% more liver fat than comparable non-diabetic individuals, but using ALT as a biomarker 
underestimates the prevalence of NAFLD in those with T2DM. Indeed, diabetic patients with 
comparable ALT levels had between 40% and 200% higher liver fat content than their 
matched non-diabetic counterparts. Given the high proportion of individuals with T2DM in 
GoDARTS, this may mean that an ALT based NAFLD definition will underestimate NAFLD 
in the cohort. 
2.4.5 Thresholds 
For diagnosing disease with ALT levels, a threshold between healthy and unhealthy is 
needed.  There have been many thresholds used clinically and in studies. The most commonly 
used threshold is 40U/L, which was first set in the 1950’s and is still commonly used.178 
There has been a trend towards lowering these limits. Studies in the 1990’s saw the limits of 
30U/L to 50U/L on average.178 
It is believed that many of the cohorts used to define abnormal ALT levels contained 
individuals with undiagnosed liver insults, leading to high ALT levels being used for 
thresholds of the healthy range.179 In 2002, Prati et al. suggested lowering these even further 
to 19U/L for women specifically, based on the results of their study looking at 6,835 
individuals without any viral liver insult.180 Using these values, Kunde et al. investigated the 
effect on the rate and accuracy of NAFLD diagnosis.179 They found that sensitivity was 
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improved, at the cost of decreased specificity. Tomizawa et al. found that using the threshold 
of 19U/L for both male and female patients was a useful marker for screening for NAFLD.157 
The thresholds suggested by Prati et al. (30U/L for men, 19U/L for women) were used for the 
current study. These were chosen as there is good evidence that these thresholds are the true 
ULNs for ALT in healthy individuals, and that these thresholds are useful in screening for 
and predicting NAFLD. 
2.4.6 Temporal Variation in ALT 
ALT levels can vary over time, therefore the time at which blood is drawn for ALT tests can 
affect the result. This can embed another source of variance in ALT levels which cannot be 
accounted for. The time of day at which a blood sample is drawn may affect the ALT 
measurement. In mice it has been found that liver function oscillates daily in response to 
circadian rhythms and ALT levels fluctuate throughout the day.181 Given the 47 hour half-life 
of serum ALT, this fluctuation is represents a delayed representation of ALT secretion into 
the bloodstream. There is some evidence that ALT levels vary by time of day in humans as 
well as mice, and that they are highest in the latter half of the day.182,183 Factors mentioned 
above, such as paracetamol intake or low level alcohol intake, can vary which may cause 
variation in ALT levels. 
Sattar et al. found that sustained increases in ALT levels were predictive of progression to 
T2DM, whereas isolated increases in ALT were not predictive.184 Given the link between 
NAFLD and development of ALT, the ALT level increases appear to be good markers of 
NAFLD in this study.185  Though this study looked at changes in ALT levels and the current 
study uses absolute values, this supports the notion of sustained ALT elevation as a useful 
diagnostic marker for NAFLD. 
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As mentioned above, cross-sectional techniques may underestimate the presence of NAFLD 
if based on ALT levels alone. Mofrad et al. showed all stages of NAFLD in a number of 
patients with healthy ALTs.172 In GoDARTs, there are a large number of patients who 
experience raised ALT levels followed by normal ALT levels. In fact, there is evidence that 
ALT levels decrease in the later stages of fibrosis.174 This could indicate that patients with 
severe fibrosis and normal ALT have previously had raised ALT levels. The sensitivity of the 
NAFLD definition in this study is improved by using longitudinal data, as raised ALT levels 
at any point in time are used to form the NAFLD phenotype.  
When making diagnoses based on biomarker levels, using a sequence of measurements taken 
at different times can be useful in increasing accuracy. This technique is established for 
diagnosis other diseases; for example chronic kidney disease, where changes in glomerular 
filtration rate and urine output over time are used for diagnosis and staging.186 Using several 
ALT measurements to define NAFLD can improve specificity, as acute cases of liver damage 
with raised ALT levels in a short period of time are not categorised as NAFLD events. The 
current study uses any two raised measurements that are a minimum of three months apart to 
define NAFLD. This means that single incidents of raised ALT levels are not counted as 
NAFLD, increasing specificity. The minimum interval of 3 months between raised ALT 
measurements makes this chronically raised ALT levels, consistent with the chronic nature of 
NAFLD cases. 
2.5 NAFLD Definition in the Current Study 
The ALT based NAFLD phenotype for this project is defined as follows; 2 or more raised 
ALT measurements in the absence of alternative cause of liver disease, at least 3 months 
apart. In contrast to previous literature, this adds a higher degree of certainty that the 
condition is chronic. The retrospective application of this definition allows increased 
sensitivity for NAFLD diagnosis, as discussed in the sections above. 
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The thresholds of 30U/L for men and 19U/L for women for the upper limit of normal ALT 
were chosen,  based on recommendations by Prati et al.180 
2.6 Application in GoDARTS, SHARE, and Tayside and Fife 
2.6.1 Introduction to cohorts 
Three large cohorts were available for analysis in this project. These comprised of patients 
within the Tayside and Fife NHS health boards.  
The first cohort used was GoDARTS.187 This was a case-control type 2 diabetes study based 
in Tayside, Scotland. This cohort comprised of electronic health records (EHRs) from 18,306 
individuals, 10,149 of whom have T2DM. On patients’ date of sign up they were phenotyped 
by biochemical and haematological investigations, anthropometric measurements and 
lifestyle questionnaires.  
The second cohort used was SHARE, a cohort of 73,024 individuals who volunteered to 
allow their medical records to be used for scientific research, and is open to anyone in 
Scotland over the age of 16.188 
The third cohort includes patients from the East of Scotland from population-level data on 
individuals with type 2 diabetes across the regions of Tayside & Fife (T&F) in Scotland. 
Clinical data is made available through the Scottish Care Information-Diabetes Collaboration 
(SCI-DC) system. This cohort comprise 89,553 individuals at the time of study. 
2.6.2 Data available: ALT, other necessary data such as immunology and virology 
Medical records from the NHS Tayside and Fife boards are available for patients in each 
cohort. These extend back as far as the beginning of 1987 in some cases, when records were 
digitised. These include admissions, deaths, prescriptions, biochemistry, demography and a 
number of other files for each patient in the cohort.  
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For the GoDARTS cohort, alongside the NHS EHR records, additional data was collected on 
the date of sign up. These records included data for biochemical measurements such as 
triglycerides, cholesterol and HbA1c, anthropometric measures such as BMI, Waist and 
Weight and lifestyle factors including smoking, drinking and exercise. 
2.6.3 Exclusions 
The exclusion of patients with other forms of liver disease which may affect the accuracy of 
NAFLD diagnosis is performed using data from EHRs. For each cohort a smoking and 
alcohol file is available for diabetic patients. This includes a column with patients mean 
alcohol intake per week. Men who drink more than 30g per day on average and women who 
drink over 20g per day on average are excluded. Patients are also excluded if they have any 
alcohol excess related condition reported in their medical records. In GoDARTS, 1,175 
individuals are excluded due to alcohol consumption or alcohol related hospital admission. 
Patients are excluded from analysis if they have features of other chronic liver disease, 
including: any positive serological tests for anti-smooth muscle antibody, antinuclear 
antibodies or anti-mitochondrial antibodies,  any positive serology for hepatitis B surface 
antigen or hepatitis C antibody, or mention of cause of liver disease in medical records. In 
GoDARTS, 1,200 individuals are excluded do to alternate causes of liver disease reported in 
EHRs. 
2.6.4 Prevalence rates in each cohort 
The lifetime prevalence rates were calculated for each cohort using all the data available for 
each patient, after patients with alternative causes of liver disease were excluded from 
analysis. This is calculated as the presence of NAFLD any time between first available 
medical record and last medical record, either due to death or the end of the study follow up 
period.  
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The lifetime NAFLD prevalence rates as assessed using the ALT based NAFLD definition 
outlined above are as follows: GoDARTS: 68.24%, SHARE: 49.26%, T&F: 64.09%. 
2.6.5 Specificity and sensitivity versus ICD10 codes, and NASH 
The NAFLD diagnosed by ALT were analysed compared to ICD10 codes recorded in EHRs’. 
The sensitivity of this definition was 97.4%, and the specificity was 32.0%. Using the same 
method, in SHARE this definition has a sensitivity of 75.3% and specificity of 54.2%, and in 
T&F the definition has a sensitivity of 94.6% and specificity of 38.3%. Due to the 
underdiagnosis of NAFLD in clinical settings, the specificity of the definition is of little 
utility or importance for validating NAFLD in the current study.25 
To further validate this phenotype, positive control tests are run against chronic kidney 
disease in GoDARTS, as this has been shown to associate with NAFLD.189 NAFLD was 
found to associate with increased incidence of chronic kidney disease in a Cox proportional 
hazards model adjusted for sex, T2DM, age, and BMI. (HR = 1.32(1.25 – 1.39), p = 4.8x10-5)   
A positive control test with the well-known NAFLD risk variant PNPLA3 rs738409 was 
conducted in the GoDARTS cohort.190  In a logistic regression with an additive model, 
adjusted for age and sex, PNPLA3 rs738409 was associated with increased NAFLD at the 
beginning of the study. (p = 1.09x10-8, OR = 1.32(1.24-1.41)) This result is similar to other 
results found for the effect of PNPLA3 on NAFLD, such as Wang et al. with an OR of 1.52. 
191 
2.7 Application in GoDARTS Cohort 
The NAFLD definition used in this project was decided upon after consultation of the current 
literature, and analysis of sensitivity and specificity versus NAFLD recorded in medical 
records, as diagnosed by physicians. Several other NAFLD definitions are considered in the 
sections above, using different ALT thresholds, and different temporal rules. The current 
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section outlines some commonly used or suggested alternative NAFLD diagnosis methods, 
and how these definitions performed in GoDARTS.  
2.7.1 Thresholds 
A number of thresholds for ALT were trialled. These are as follows: 
 30U/L for men, 19U/L for women – Prati et al. 180 
 30U/L for men, 30U/L for women – Kunde et al. 179 
 40U/L for men, 35U/L for women – Neuschwander-Tetri et al. 192 
 25U/L for men, 17U/L for women – Miyake et al. 31 
2.7.2 Number and Timings of Measurements 
A single case of a raised ALT is often used to diagnose liver disease, but as discussed above, 
using multiple measurements can improve accuracy. The following methods of using raised 
ALTs to define NAFLD were tested. 
 1 raised ever 
 2 raised ever 
 2 raised at least 3 months apart 
The definitions of NAFLD listed above were compared using a number of metrics. This is 
shown in the table below. This table displays the prevalence rate of NAFLD with each 
definition, stratified by T2DM. It also shows the sensitivity and specificity of the definition 
when compared to NAFLD diagnoses in EHRs coded by ICD10 codes. The sum of 
specificity and sensitivity for each NAFLD definition is included in table 1. Finally, the table 
shows the difference between expected NAFLD rate and actual rate, stratified by T2DM. The 
expected rates in T2DM and non-T2DM were considered to be 70% and 30% respectively. 
193 This calculation shows how much each definition is likely to over or underdiagnose 
NAFLD. This gives a notion of how credible each definition is, where a large difference 
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would suggest a poor definition of NAFLD. The results of this comparison are shown in the 
table below, with the main NAFLD definition for this project of two raised ALT 
measurements a minimum of three months apart highlighted in grey. 
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Table 2 - Comparison of Performance of NAFLD Diagnosis Methods in GoDARTS 
 
Method Male ALTs Female 
ALTs 
Prevalence 
Rate 
Sensitivity Specificity Specificity plus 
Sensitivity 
Diabetic NAFLD 
Rate 
Healthy NAFLD Rate Cumulative 
Difference from 
expected rate 
1 raised 25 17 89.51 100.00 10.54 110.54 96.61 82.21 78.81 
30 19 83.91 100.00 16.17 116.17 93.01 74.54 67.55 
30 30 72.53 98.55 27.60 126.15 85.78 58.90 44.68 
40 35 58.52 98.55 41.68 140.23 72.86 43.76 16.62 
2 raised outside 3 
months 
25 17 78.04 97.10 22.06 119.16 90.93 64.77 55.70 
30 19 68.24 97.40 31.90 127.55 83.01 53.02 36.04 
30 30 51.85 94.20 48.35 142.55 68.97 34.23 5.27 
40 35 35.81 85.51 64.43 149.94 50.77 20.42 28.81 
2 raised ever 25 17 82.30 100.00 17.79 117.79 93.77 70.49 64.26 
30 19 73.90 98.55 26.21 124.76 87.54 59.89 47.43 
30 30 59.57 97.10 40.44 137.54 76.37 42.65 19.01 
40 35 45.28 92.75 54.95 147.70 60.87 29.24 9.89 
2 raised in 1 year 25 17 72.83 98.55 27.30 125.85 89.29 55.89 45.18 
30 19 64.04 97.10 36.13 133.23 81.00 46.58 27.58 
30 30 50.01 94.20 50.14 144.34 67.20 32.46 5.26 
40 35 36.79 91.30 63.48 154.78 51.11 22.05 26.84 
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2.7.3 Comparison of Definitions 
The comparison table above shows the performance of each of the definitions. The common 
trade-off between specificity and sensitivity evident in the results as there is a range of 
overall NAFLD rates as given by the definitions. 
All definitions have fairly high sensitivity, ranging from 85.5% to 100%. Due to the 
relatively low number of cases of NAFLD reported in ICD10 codes, this test lacked the 
power to satisfactorily evaluate differences in sensitivity. However, consideration of ICD10 
codes demonstrated that a high proportion patients with a NAFLD diagnoses in admissions 
data have had elevated ALT measurements at some point. 
The specificity of the definitions is not as informative as the sensitivity, due to 
underdiagnosis of NAFLD in hospital admissions.25 This means that NAFLD defined in 
medical records is specific but not sensitive compared to ground truth. Despite the low 
specificity of ALT based NAFLD definitions when comparing to NAFLD admissions, the 
ALT based definitions are likely closer to the actual NAFLD rate in the population. 
 Definitions based on more than one raised ALT measurement are more specific than one 
single raised ALT level. Using two raised ALTs in a year, or two outside three months both 
gave good sensitivity to NAFLD as phenotyped by hospital admissions. 
The definition selected for this project (highlighted in the table) had good sensitivity but low 
specificity. This definition gave reasonable rates for NAFLD in diabetics and non-diabetics 
of 83.0% and 53.0% respectively. Although these are higher than rates estimated in current 
literature for diabetic and non-diabetic populations, the cohort has a high median age (73 
years), which may account for high prevalence.193 
Whilst some other ALT based NAFLD definitions that were tested have better performance 
metrics such as specificity, the definition for NAFLD of two raised ALTs separated by at 
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least three months was selected for a number of reasons. The thresholds of 30/19UL for men 
and women are chosen as the current literature suggests these are the true ULNs and two 
raised measurements at least three months apart as compared to cross-sectional techniques 
this increases specificity and diminishes risk of aberrant ALT fluctuation affecting the results. 
The measurements being at least three months apart ensures the definition is chronically 
raised ALTs, which adds accuracy as NAFLD is a chronic condition. 
2.7.4 Patient Profiles, Morbidity and Mortality in NAFLD 
The following section contrasts those with and without NAFLD, as defined by two raised 
ALT levels three months apart. Aside from differences in liver enzymes, individuals with 
NAFLD are known to differ from healthy individuals in a number of parameters. These are 
shown in the table 2 below, where the differences between groups for each variable are all 
statistically significant. (p< 0.05) 
Table 3 - Patient Profiles Stratified by NAFLD Status in GoDARTS 
 
Healthy SE NAFLD SE 
N 6731 
 
6950 
 
Diabetic 1662 24.7% 4605 66.3% 
Female 2796 41.5% 3865 55.6% 
BMI (kg/m2) 27.2 4.8 30.9 6.1 
Age (years) 61.9 13.7 64.9 11.5 
Waist (cm) 99.3 11.4 107.1 12.7 
 
87.1 13.3 98.4 14.8 
Weight (kg) 84.4 14.2 92.9 17.1 
 
70.2 14.4 79.6 18.3 
Baseline ALT (U/L) 21.0 8.1 36.3 18.7 
 
16.1 12.9 27.1 19.3 
Triglycerides (mmol/L) 1.6 1.0 2.1 1.4 
HDL (mmol/L) 1.6 0.5 1.4 0.4 
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LDL (mmol/L) 2.8 1.0 2.4 0.9 
Systolic Blood Pressure (mmHg) 137.5 20.1 140.5 19.1 
Diastolic Blood Pressure (mmHg) 78.9 10.7 78.0 11.1 
SIMD10 6.4 2.6 5.9 2.7 
 
Those with NAFLD weighed more, are more likely to be diabetic, had higher BMI, are older, 
and had larger waists and higher triglycerides. These are known risk factors/covariates of 
NAFLD, and demonstrate the wider ranging metabolic correlates of NAFLD.1,63 
2.7.5 Morbidity and NAFLD 
NAFLD is associated with a range of morbidities. These include the range of NAFLD 
outcomes and complications; NASH, fibrosis, cirrhosis and hepatocellular carcinoma.5 These 
more extreme endpoints are relatively uncommonly reported compared with NAFLD itself. 
NAFLD was associated with increased number of hospital admissions in GoDARTS, in a 
linear regression adjusted for sex, age, T2DM, BMI and SCSIMD10. (β = 2.13(0.11 -19.10), 
p < 2x10-16) Although some of these admissions are due to liver conditions, NAFLD is still 
associated with more admissions when these visits are excluded. (β = 2.11(0.11 - 19.34), p < 
2x10-16) This suggests that the majority of the increase in morbidity associated with NAFLD 
is not directly due to liver conditions. 
Previous literature has linked NAFLD with a number of cardiovascular endpoints, and 
suggested this is the predominant cause of morbidity and mortality in NAFLD.194 These 
include ischemic heart disease, myocardial infarction, and atrial fibrillation.58 In GoDARTS, 
NAFLD was significantly associated with increased cardiovascular disease incidence (HR 
=1.35(1.28 - 1.43), p < 2x10-16) and with increased cardiovascular death. (HR = 1.26(1.17 - 
1.37, p = 1.55x10-8) Other conditions such as chronic kidney disease have been associated 
with NAFLD, which was also replicated in GoDARTS. 189 
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2.7.6 Mortality and NAFLD 
NAFLD has been linked to increased mortality by a number of studies.5 Death caused 
directly by NAFLD, through failure of the liver due to cirrhosis or HCC, is the most common 
NAFLD related death cause investigated. These conditions are uncommonly reported in death 
certificates however. In GoDARTS for example, only 2.0% of individuals with NAFLD who 
have died have a NAFLD related condition listed in their causes of death. This is consistent 
with most findings about NAFLD mortality, which is dominated by cardiovascular and 
cancer death.58,120 
This large difference between individuals with and without NAFLD cannot be explained fully 
by NAFLD specific conditions, and is due to other causes. Some studies have found 
associations between NAFLD and cardiovascular death for example.120 To investigate this, 
individuals with NAFLD endpoints recorded in medical records are excluded from analysis. 
In GoDARTS, NAFLD (as diagnosed by ALT levels) still has a significant association with 
lowered death age. (β = -1.95(0.378  -5.15), p =2.74x10-7) This demonstrates that there is 
clear increased mortality among those with NAFLD which is not caused by direct NAFLD 
endpoints. Though some of this may be attributable to the underreporting of NAFLD, it is 
likely that there is another cause or multiple other causes of this difference. 
NAFLD has been associated with cardiovascular death, which is considered by some as the 
predominant cause of early death in NAFLD.58,120 There has been some research into the link 
between NAFLD and extrahepatic cancers, which is the focus of the next chapter in this 
thesis. This investigates the link between NAFLD and cancer incidence, and cancer mortality 
and considers the role these play in the increased morbidity and mortality in NAFLD patients. 
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2.7.7 Genetics and NAFLD 
NAFLD has a number of known genetic risk modifiers, including PNPLA3 rs738409 which 
was analysed with the current NAFLD definition above.52,90 This thesis investigates genetic 
determinants of NAFLD in subsequent chapters, beginning with a genome wide association 
study (GWAS). Candidate gene studies of variants related to GLP1R and endothelin are also 
conducted. The NAFLD definition developed in the current chapter provides an accurate and 
validated phenotype for these studies to produce valid results. 
 
2.8 Application in DMDSC South Indian Cohort 
Further to analysis in the GoDARTS, SHARE and T&F cohorts, access to a fourth cohort 
with clinical and genetic data was available. This cohort contained South Indian individuals, 
allowing for interesting comparison with Scottish cohort. 
2.8.1 Introduction to cohort 
The Indian cohort is from Dr. Mohan’s Diabetes Specialities Centre (DMDSC) based in 
Chennai, India.195 DMDSC is a large, privately-run chain of single-speciality hospitals and 
clinics for the treatment of diabetes and related comorbidities. This cohort comprises of 
75,952 patients from Chennai and the surrounding area, all of whom have T2DM. The 
majority of patients are of South Indian origin. 
2.8.2 Data Availability 
The data from these patients is from a set of measurements taken on their first visit to the 
DMDSC clinic. During this visit, each patient had a series of demographic and phenotypic 
measurements taken. These included; HbA1c, BMI, ALT, HDL, age and sex. 
Of the 75,952 unique patients with baseline biochemistry measurements, 33,194 of these 
patients had ALT measured at their first visit. This single ALT measurement is used to define 
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NAFLD in the DMDSC cohort. ALT measurements are available for patients at the date of 
their visit to the DMDSC centre. This allows a cross sectional analysis of the NAFLD 
prevalence in this cohort. The baseline measurements for most patients were taken within one 
year of their T2DM diagnosis date, allowing for interesting assessments of NAFLD in those 
recently diagnosed. 
A number of these patients had genotypic data available for analysis giving 3,150 patients 
with genotype data and sufficient data for analysis of NAFLD defined by ALT levels, and 
2015 patients had genotypic data and Fatty Liver Grade data. 
2.8.3 Suitability of ALT as NAFLD Surrogate 
The usefulness of ALT in this cohort is lessened due to lack of data providing other possible 
causes of liver disease. Due to the fact this data is from visits to a private clinic, routine 
healthcare similar to that of the GoDARTS and cohort was not available. This meant that it is 
not possible to exclude patients with alternative aetiologies for liver disease such as 
virological, immunological or alcohol related disease in the same manner as is done in 
GoDARTS. There is an alcohol consumption data field, with a binary yes/no whether the 
individual drinks alcohol. From this it is not possible to tell whether the individual drinks at 
levels which could cause ALD, therefore this variable is included as a covariate in the 
analysis.  
The nature of the data also means it is not possible to use more than one ALT measurement 
for NAFLD diagnoses as there was no access to routine measurements. This meant that the 
NAFLD definition was based on one single ALT measurement at the time of enrolment. 
2.8.4 Fatty Liver Grade in DMDSC 
13,367 of patients in the DMDSC cohort have had abdominal ultrasounds administered. In 
the report, each patient was assigned a Fatty Liver Grade. (FLG) This was an index of hepatic 
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fatty infiltration scored in four ordinal categories. These were no fatty infiltration -0, mild 
fatty infiltration – 1, moderate fatty infiltration – 2 and severe fatty infiltration -3.196 
Ultrasound has been demonstrated as an accurate method of detection for steatosis of the 
liver.157 Ultrasound is more specific for defining NAFLD than ALT levels, as liver fat itself is 
what is evaluated rather than liver enzymes. Where fatty infiltration is greater than 20% of 
hepatocytes, the sensitivity of ultrasound was found to be 90%.197 Ultrasound techniques 
however are less effective in diagnosing the inflammation seen in NASH, as well as 
fibrosis.198 Another caveat is that it is impossible to distinguish between NAFLD and ALD 
using this method, as they both cause steatosis and are histologically similar.199 
Due to the superior performance of ultrasound for NAFLD diagnosis, and the lack of key data 
regarding alternative liver disease, ultrasound defined Fatty liver Score is the optimal method 
for NAFLD phenotyping in this cohort. As a result, the ALT measurements can be used as an 
adjunct, either as an additional phenotype or to aid validation of ALT based NAFLD 
definitions in other cohorts. 
2.8.5 NAFLD Rate and Distribution of Fatty Liver Grade in the DMDSC Cohort 
At the time of baseline measurement, the prevalence of NAFLD was 50.8%. The distribution 
of Fatty Liver Grades is shown in the table 3 below, with additional mean statistics of each 
group.  
Table 4 - Comparison of Patients in DMDSC Cohort Stratified by Fatty Liver Grade 
Fatty Liver 
Grade 
0 1 2 3 
Number (%) 2500 (18.7%) 4559 (34.1%) 
 
5673 (42.4%) 
  
635 (4.75%) 
NAFLD Rate 
(ALT definition) 
20.65% 25.93% 37.27% 41.87% 
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ALT 
(female/male) 
25.24U/L / 
30.70U/L 
24.24U/L / 
34.65U/L 
32.19U/L / 45.19U/L 31.34U/L / 48.47U/L 
BMI 24.30kg/m2 25.90 kg/m2 27.96 kg/m2 30.75 kg/m2 
Sex (% Male) 58.98% 64.99% 68.16% 69.72% 
AST 26.34U/L 26.69U/L 31.90U/L 32.17U/L 
 
There was a strong association between FLG and NAFLD defined by ALT. (OR = 1.10(1.09 
– 1.11), p < 2x10-16) There were also significant associations between FLG and age, BMI, 
and AST. Higher FLG was seen in males. 
2.9 Conclusion and Limitations                                                                                                                                                                                                                                                                                                                                                                                        
To conclude, the current section reviews previous literature on NAFLD diagnosis methods, 
and proposes a NAFLD definition based on chronically raised ALT levels. This definition 
was validated in three large Scottish cohorts, and has good sensitivity when compared to 
NAFLD diagnoses in EHRs. This chapter outlines a practical method for the diagnosis of 
NAFLD in the large retrospective datasets for research purposes.  
This is an important finding, as diagnosing NAFLD remains an obstacle in NAFLD research 
and treatment. This methods uses data from retrospective medical records, thus requires no 
extra clinical measurements or investigations to take place making it cost effective and 
practical. Analysis revealed that patients with NAFLD were found to have greater risk of 
morbidity and mortality. This NAFLD definition is used in subsequent thesis chapters for the 
investigation of genetic modifiers of NAFLD risk. 
This NAFLD definition may be useful in large scale datasets with data for thousands of 
individuals, but it likely results in a small number of false positives and false negatives. It has 
been shown that ALT levels correlate well with liver fat content, and there is evidence that 
the limits of normal ALT used in this study are accurate.26,180 However, we are unable to 
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estimate the severity of the phenotype captured by our current NAFLD definition. This could 
mean that our NAFLD definition classifies those with liver fat <5% as NAFLD, 
overestimating the prevalence. The correlations with NASH as per medical records and other 
NAFLD indices suggests overall NAFLD is being captured reasonably well, but given the 
high prevalence positives cases for our definition in the cohorts, it likely overestimates 
slightly. This makes the definition of limited use on an individual level in clinical settings. 
The increased morbidity and mortality associated with this phenotype demonstrate the 
clinical relevance of the diagnosis method, though further work to stratify and identify those 
at risk may be more useful. The utility of diagnosing NAFLD in primary care settings is 
discussed in depth in the introduction to this thesis.   
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3 NAFLD and Cancer Incidence 
3.1 Abstract 
The aim of this study was to investigate the incidence of cancer in NAFLD patients and non-
NAFLD controls, and the role of BMI in this relationship. 
GoDARTS, SHARE and Tayside and Fife diabetics, three Scottish cohorts of 13,695, 62,438, 
and 16,312 patients respectively were analysed in this study. Participants in GoDARTS were 
a volunteer sample, with half having T2DM. SHARE were a volunteer sample. Tayside and 
Fife diabetics was a population level cohort. Patients with the relevant healthcare data 
available for analysis, and individuals with alternative causes of liver disease were excluded 
from the analysis. 
NAFLD increased cancer incidence with a hazard ratio of 1.31 in a cox proportional hazards 
model adjusted for sex, type 2 diabetes, BMI, and smoking status (95% CI = 1.27 – 1.35, p = 
1.8x10-10). This was replicated in two further cohorts, and similar associations with cancer 
incidence were found for Fatty Liver Index, FIB-4 and NASH. Homozygous carriers of the 
common NAFLD risk variant PNPLA3 rs738409 had increased risk of cancer. (HR = 1.27 
(1.02-1.58), p = 3.1x10-2) BMI was not independently associated with cancer incidence when 
NAFLD was included as a covariate. Finally, NAFLD was associated with increased risk of 
cancer death (HR = 1.40, 95% CI =1.33 - 1.47, p = 3.7x10-6). 
NAFLD is associated with increased risk of cancer incidence and death, as is PNPLA3 
rs738409, suggesting a causative relationship between NAFLD and cancer. NAFLD may be a 
major component of the relationship between obesity and cancer incidence. 
3.2 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
globally, affecting around 25.2% of adults worldwide.200 NAFLD, a spectrum of simple 
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steatosis to non-alcoholic steatohepatitis, is traditionally associated with endpoints which 
affect the liver, including fibrosis, cirrhosis and hepatocellular carcinoma (HCC).201 The 
previous chapter in this these developed a definition of NAFLD and found increased numbers 
of hospital admissions and increased mortality in patients with NAFLD. The majority of 
these patients (>98%) had never had any NAFLD or even hepatological condition recorded in 
their admissions or death records. This leaves an unexplained increase in morbidity in 
NAFLD patients, which is caused by alternative conditions. Recent studies have found 
associations between NAFLD and specific extrahepatic cancers, including colon and breast 
cancer, as well as overall cancer risk.59,202 The aim of the current chapter is to investigate the 
relationship between cancer incidence in NAFLD, and how this affects morbidity and 
mortality in NAFLD patients. 
 The relationship between NAFLD and cancer, as well as the synergy between NAFLD and 
other cancer risk modifiers is not fully understood. Hepatocellular carcinoma has long been 
associated with NAFLD and is widely recognised as one of the most severe endpoints of 
NAFLD.201,203,204 The intracellular environment created by the presence of NAFLD has been 
found to contribute to HCC in a number of ways.205 Damage to liver cells via oxidative stress, 
inflammation, and disruption of cytokines, adipokines and lymphokines are among the ways 
in which NAFLD contributes to the development of HCC.206,207 There is evidence that 
NAFLD has effects on cancer incidence that extend beyond the liver. 
Increased incidence of colorectal cancer has been found in patients with NAFLD in multiple 
studies; the first extrahepatic cancer found reliably associated with NAFLD.208–213  A number 
of these studies found increased colorectal cancer risk in those with NASH compared to 
NAFLD.210,214 Other sites linked to NAFLD include pancreas, oesophagus, stomach, breast, 
uterus, lung, ovary, and prostate.59,215–218 A number of these studies have found even in non-
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obese or non-overweight patients, that NAFLD is still associated with specific extrahepatic 
cancers.59 
A small number of studies have found increased incidence of overall cancer risk in those with 
NAFLD. Kim et al. found markers of hepatic fibrosis to be associated with all cancer, and 
NAFLD itself to be associated with specific extrahepatic cancers; including breast and 
colon.202 Allen et al. found increases in all cancer incidence in those with NAFLD.59 The 
evidence for NAFLD being associated with all cancer risk is limited in comparison compared 
with the evidence for association between NAFLD and specific cancer sites. Further, large 
scale study is required to determine the true relationship between NAFLD and extrahepatic 
cancer. 
To investigate the link between NAFLD and overall cancer incidence, it is important to 
disentangle NAFLD from other correlated cancer risk factors. Obesity, commonly defined as 
BMI equal or higher than 30kg/m2, is a major cause of NAFLD, with 51.3% of NAFLD 
patients also being obese.41,219 Obesity has also been linked with cancer incidence at 13 
different sites in the body; a number of which have been reported to be associated with 
NAFLD also.220 Wolin et al. estimate that excess weight or obesity accounts for 20% of all 
cancers.221 Mechanistically, several factors associated with increased fat mass have been 
proposed to cause cancer.222 For example, dysregulation of circulating hormones and 
cytokines including insulin, insulin–like growth factor signalling, adipokines, inflammation 
and sex hormones may disrupt normal cell cycle control and promote tumour formation.  
Indeed, there is significant overlap of many of such pathological abnormalities between both 
overweightness and NAFLD.223  The elements of shared pathophysiology of NAFLD and 
overweightness could potentially mean that the observed increases in cancer risk share a 
common aetiology. The increased risk of cancer incidence attributable with NAFLD and 
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obesity must be quantified to understand the role of each in previous associations observed. 
Allen et al. found that obese patients who did not have NAFLD were at only slightly higher 
risk of cancer incidence than those who were non-obese.59 They also found that patients who 
were not obese, but had NAFLD were at increased risk compared to non-NAFLD controls. 
This led them to conclude that the majority of the observed cancer risk in obese patients is 
due to increased rates of NAFLD. It was found however that the effect of NAFLD compared 
to obesity differed depending on which cancer site was analysed. This may suggest a synergy 
between NAFLD and obesity for cancer risk. 
Leading on from previous research in the area, the aim of this study was to analyse the effects 
of NAFLD on overall and specific cancer incidence. In addition to this, the study aimed to 
investigate the roles of BMI and NAFLD in increased risk cancer incidence. This study also 
investigated whether the relationship between NAFLD and cancer was causal or not. 
3.3 Methods 
3.3.1 Data 
3.3.1.1 GoDARTS 
This study aimed to analyse the incidence of all cancer longitudinally. The first cohort used 
was GoDARTS, a case-control type 2 diabetes study based in Tayside, Scotland. Key 
descriptive statistics and demographic attributes of this cohort are shown in Table 4. 
Table 5 - Mean Characteristics of GoDARTS Patients Stratified by NAFLD Status at Time of Enrolment to GoDARTS 
Characteristic Non NAFLD Number NAFLD p 
Number 6726 6969  
% Diabetic 24.65%(n = 1,658) 66.34%(n = 4,623) < 0.0001 
BMI 27.22kg/m2(SD = 4.76) 30.90kg/m2(SD = 6.07) < 0.0001 
Weight (Males/Females) 84.44kg(SD = 14.18) 92.89kg(SD = 17.04) < 0.0001 
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/70.20kg (SD = 14.38) /79.64kg(SD = 18.30) /< 0.0001 
Female 41.48% (n = 2790) 55.46% (n = 3865) < 0.0001 
Smoker 55.14% (n = 3709) 57.67% (n = 4019) 2.3x10-3 
Age at Signup 61.88 years(SD = 13.72) 64.9 years(SD = 11.54) < 0.0001 
Follow-up Length 9.24years(SD = 2.50) 8.58 years(SD = 2.88) < 0.0001 
 
This cohort was used for discovery and comprised of electronic health records (EHRs) from 
13,695 eligible individuals.224 The mean age at sign up was 63.41 years and participants had a 
mean follow up of 8.95 years. 48.6% of patients were male. On patients’ date of sign up they 
were phenotyped by biochemical and haematological investigations, anthropometric 
measurements and lifestyle questionnaires. This date was used as the beginning of the follow 
up period. 2,794 patients had cancer incidents during the follow-up period.  
3.3.1.2 SHARE 
Two further, independent cohorts were analysed for replication. The second data source was 
SHARE. This is a cohort in which individuals volunteer to allow their medical records to be 
used for scientific research, and is open to anyone in Scotland over the age of 16. The 
characteristics of this cohort are shown in table 5 below. 
Table 6 - Mean Characteristics of SHARE Patients Stratified by NAFLD Status at Age 60 (Beginning of Follow-Up Period) 
Characteristic Non NAFLD NAFLD p 
Number 19035 7856  
% Diabetic 1.65% (n = 314) 8.17% (n = 6418) < 0.0001 
Female 52.45% (n = 9984) 65.10% (n = 5114) < 0.0001 
Follow-up Length 13.92 years(SD = 7.45) 6.91 years(SD = 4.31) < 0.0001 
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This comprised 62,438 patients with EHRs available once patients with exclusions for 
alternate causes of raised ALT livers were removed.188 This cohort was used for replication 
of findings in GoDARTS. The mean age in SHARE was 57.0 years, and 61.6% were female.  
3.3.1.3 Tayside and Fife 
Replication of results was also undertaken in Tayside and Fife diabetics (T&F). This cohort 
comprises all patients in the Tayside and Fife NHS region who had a diagnosis of T2DM at 
some point in their lives. Many of the patients received a diagnosis of T2DM during the 
follow up period, therefore the T2DM rate is not 100% at baseline. The characteristics of this 
cohort are shown in table 6. 
Table 7 - Mean Characteristics of Tayside and Fife Diabetics Patients Stratified by NAFLD Status at Age 60 (Beginning of 
Follow-Up Period) 
Characteristic Non NAFLD NAFLD p 
Number 5,102 6039  
% Diabetic 40.53% (n = 2068) 60.37% (n = 3646) < 0.0001 
BMI 30.55kg/m2 (SD = 6.12) 33.15kg/m2 (SD = 6.78 <0.0001 
Female 45.84% (n = 2339) 53.27% (n = 3217) < 0.0001 
Smoker 58.57% (n = 2988) 65.01% (n = 3926) <0.0001 
Follow-up Length 11.08 years (SD = 6.07) 6.21 years (SD = 4.03) < 0.0001 
 
 Like the two previous cohorts, medical records from the NHS are available for these 
patients. The cohort 16,312 patients eligible after exclusions for other hepatic insults were 
made. The mean age of these patients was 65.0 years, and 48.1% were female.  
The results from T&F were not meta analysed with GoDARTS and SHARE, as this is a 
primarily diabetic cohort, therefore does not capture those who do not go on to get diabetes. 
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The ascertainment bias in this cohort that only contains individuals who did eventually get 
diabetes is likely to have resulted in the lower point estimate for NAFLD in cancer risk that 
we have observed. To ensure there was no overlap in participants between cohorts, patients in 
SHARE who are also in GoDARTS were excluded from SHARE, and participants in 
GoDARTS or SHARE were excluded from analysis in T&F, meaning each cohort is 
completely independent. 
To allow comparison with the GoDARTS cohort, a baseline point had to be chosen from 
which to begin the follow up period in which to analyse cancer incidence in SHARE and 
T&F. The age of 60 was chosen as it is close to the mean baseline age of GoDARTS, and 
importantly close to the mean age of NAFLD diagnosis in GoDARTS (60.8 years) and in the 
literature.1 This allowed a more robust replication of findings in GoDARTS in the two 
replication cohorts, ensuring age wasn’t a source of heterogeneity in analysis. These criteria 
left 26,891 patients in SHARE and 11,141 patients in T&F suitable for analysis with a 
median follow up time of 11.0 years and 8.0 years respectively. The EMRs available for 
patients in all cohorts are from the NHS Tayside and Fife authorities.  
3.3.2 Outcomes 
All outcomes were defined using NHS medical record data, made available for participants in 
each of the three cohorts. As such, all data was recorded in the same format; all disease was 
recorded in ICD10 codes and biochemical measures in the same, relevant units.225 (E.g. Units 
per litre for ALT measurements) 
3.3.2.1 NAFLD Phenotype 
NAFLD cases and controls were defined using the liver function test alanine transaminase 
(ALT), a commonly used marker of liver damage, and a useful surrogate for NAFLD.131 A 
full description of this phenotype is given in a previous chapter. This was chosen as it is 
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commonly measured, and a large portion of the population have multiple measurements. 
Elevated ALT levels were considered to be over 30U/L for men, and over 19U/L for women 
(Normal ALT reference ranges: Males - 5-30U/L; Females – 5-19U/L.). These upper limits 
are those suggested by Prati et al. as the maximum normal values of ALT in healthy adult 
men and women.180 Raised ALT levels correlate with NAFLD and are an appropriate 
surrogate marker for the disease, provided other causes of liver disease are ruled out.131,226 
There is substantial evidence that raised ALT levels in the absence of any apparent liver 
insult are extremely likely to be caused by NAFLD.227 All samples from GoDARTS, SHARE 
and T&F were analysed in the same laboratory.  
NAFLD cases were defined as any patient who had experienced at least 2 raised ALT 
measurements, at least 3 months apart. This time scale was chosen as 3 months is a 
commonly used definition of chronic and most cases of acute hepatitis, such as drug induced, 
will have resolved.228 This also increases the specificity of the definition. 
3.3.3 Exclusions 
Patients were excluded from analysis if they had features of other chronic liver disease 
recorded in their medical records. These included: any positive serological tests for anti-
smooth muscle antibody, antinuclear antibodies or anti-mitochondrial antibodies, any positive 
serology for hepatitis B surface antigen or hepatitis C antibody, or mention of cause of liver 
disease in medical records. In GoDARTS, 1,157 patients had both immunological and 
virological screens at some point which were negative, therefore they were included in 
analysis. Patients with alcohol dependence or any documentation of alcoholic liver disease in 
their EHRs were excluded using ICD codes: “K70” and “F10”. In addition, patients who self-
reported drinking more than 20g (2.5 units) a day for women and more than 30g (3.75 units) 
a day for men were excluded. Allen et al. concluded that alcohol was not likely to explain the 
increase in cancer incidence seen with NAFLD in their study.59 
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3.3.4 Validation of Phenotype 
To validate this NAFLD phenotype, sensitivity and specificity analyses were conducted in 
GoDARTS comparing this to cases of NAFLD confirmed in EHRs with the “K76.0” ICD10 
code. Full validation of this phenotype is included in the previous chapter. The sensitivity of 
this definition was 97.4%, and the specificity was 32.0%. These analyses were also 
conducted in SHARE using the same method, with a sensitivity of 75.3% and specificity of 
54.2%, and in T&F with sensitivity of 94.6% and specificity of 38.3%. The SHARE cohort 
has lower sensitivity compared to the other two cohorts, likely due to the lower average age 
of the cohort and the lower prevalence of diabetes resulting in lower healthcare interaction, 
morbidity and mortality. Also, due to the relatively low numbers of confirmed NAFLD in 
EHRs, small differences in numbers can have large effects on sensitivity and specificity. 
To further validate this phenotype positive control tests were run against chronic kidney 
disease (CKD) in GoDARTS, as it has been shown to associate with NAFLD.189 During the 
follow up, 1,131 patients had incidence of CKD. NAFLD was found to associate with 
incidence of CKD in a cox proportional hazards model adjusted for sex, T2DM, age, and 
BMI. (HR = 1.32(1.25 – 1.39), p = 4.8x10-5)   
A positive control test with the well-known NAFLD risk variant PNPLA3 rs738409 was 
conducted. 190 In GoDARTS, 8,399 eligible participants had been genotyped for this variant. 
In a logistic regression with an additive model, adjusted for age and sex, PNPLA3 rs738409 
was associated with increased NAFLD at the beginning of the study. (OR = 1.32(1.12-1.36), 
p = 1.09x10-8) 
3.3.5 NAFLD Related Phenotype Definitions 
As well as our ALT based NAFLD definition, some patients had NAFLD confirmed in 
hospital admissions data with the ICD10 code “K76.0”. This is referred to as “NAFLD 
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hospitalisation” in subsequent sections. In GoDARTS, 0.36% of participants had this code 
reported in their medical records at any point. 
Non-Alcoholic Steatohepatitis (NASH) was phenotyped by searching admissions, deaths and 
biopsy files for cases of NASH, defined using the ICD10 codes for NASH, fibrosis and 
cirrhosis. This may have been a main cause of hospitalisation or concomitant morbidity. 
Another method of detecting NAFLD non-invasively is the Fatty Liver Index (FLI).148 This 
uses BMI, waist circumference, triglycerides and gamma-glutamyl transferase (GGT) to 
define NAFLD, and has been validated in a number of cohorts as an accurate surrogate of 
NAFLD. 4,164 patients in GoDARTS had the required data available for this measure. In 
GoDARTS, FLI correlated significantly with NAFLD as diagnosed by ALT levels. (Pearson 
correlation coefficient = 0.33 (0.31-0.36), p < 0.0001) 
The FIB-4 scoring system was also used in the GoDARTS study.153 A FIB-4 score of greater 
than 3.25 has been shown to predict advanced hepatic fibrosis, therefore this score was used 
as the cut off. This was calculated using the highest recorded AST and ALT measurements 
and platelet count before the beginning of the GoDARTS for each individual to calculate the 
highest FIB-4 score they had experienced.  
3.3.6 Mendelian Randomisation 
Mendelian randomisation methods were used to assess whether the relationship between 
NAFLD and cancer incidence was causative.229 The missense variant PNPLA3 rs734809, 
which is strongly associated with the development and progression of fatty liver disease, was 
chosen as it has been shown in a large number of studies to associate with NAFLD, and has 
been used in previous Mendelian randomisation studies on NAFLD. The ratio method was 
used to conduct this analysis.190  In GoDARTS, 7,715 patients had been genotyped for this 
variant, and 343 of these were homozygous carriers. (Minor Allele Frequency (MAF) = 
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20.6%) In SHARE, 1,755 patients had been genotyped for this variant, with 50 being 
homozygous carriers. (MAF = 23.0%)  
3.3.7 Overweight and Obesity Definitions 
In this study, overweight is defined as a BMI greater than 25kg/m2 and less than 30kg/m2. 
Obesity is defined as a BMI equal or over 30kg/m2.230 
3.3.8 Cancer Phenotype 
Cancer incident data was obtained from the Scottish cancer register, part of the Scottish 
Morbidity Record.231 This contains all diagnoses of cancer made in Scotland in NHS care, in 
ICD10 code format. This data was available for patients in GoDARTS, SHARE and T&F. 
Cases were cross checked with recorded cases in hospital admissions and death records files. 
The cancer records were identified by the relevant ICD10 codes for malignant neoplasms or 
neoplasms of unknown behaviour. These were any code including "C", "D0", "D37", "D38", 
"D39", or "D4". Obesity related cancer incidents were phenotyped similarly, but specifically 
for the 13 reported obesity related cancer sites. 220 
Cancer deaths were phenotyped based on death certificate files in EHRs. These list a main 
cause of death and contributing causes of death for each patient who has died. These were 
also cross checked with the Scottish cancer register file.  
3.3.9 Statistical Methods 
All data analysis was carried out in the statistical package R. The effects of NAFLD and 
other independent variables on cancer incidence were analysed using a Cox proportional 
hazards model (CPH). Patients were censored at the point at which they had a cancer incident 
recorded, death, or September 2016 when the follow-up period ended. Patients with missing 
data were excluded from analysis. 
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To assess whether NAFLD affected cancer death risk in the presence of non-cancer death as a 
competing risk regressions (CRR) using Fine and Gray’s method were run. Logistic 
regression (LR) models were used to evaluate the effect of NAFLD on death cause.  
In the GoDARTS cohort models were adjusted for sex, age, BMI, T2DM, and smoking 
status. In GoDARTs, models with BMI replaced by weight or waist measurement were also 
run, as these are slightly different measure of obesity and may have provided further insight 
into the associations. Hypertension, activity level, alcohol consumption and deprivation level 
were not included in the models as they did not have a significant effect on cancer incidence 
in the adjusted model. In the SHARE cohort, models were adjusted for sex and T2DM. 
Smoking and BMI data were not widely available for individuals in the SHARE cohort, 
therefore this was not controlled for in most analyses.  
3.4 Results 
3.4.1 NAFLD and Cancer Incidence 
In the GoDARTS cohort, NAFLD was associated with increased cancer incidence. During 
the follow up period, 18.5% of controls compared to 22.2% of patients with NAFLD 
Figure 3-1Forest Plot of Effects of Variables on Cancer Incidence in GoDARTS and SHARE 
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developed cancer. In controls, 1244 patients had cancer incidents and 1550 patients had 
incidents in NAFLD cases. Patients who had NAFLD at enrolment to GoDARTS had 
increased cancer incidence independent of sex, age, BMI, smoking status, and diabetes status 
(HR = 1.31(1.27 – 1.35), p = 1.8x10-10). These results are shown in Figure 3-1 below. 
 
Using the same covariates, the Fatty Liver Index was associated with increased cancer 
incidence (HR = 1.004(1.00-1.008), p = 5.0x10-2) and FIB-4 score over 3.25 was associated 
with increased cancer risk. (HR= 1.31, 95% CI =1.29 – 1.53, p = 3.2x10-3).  
When NAFLD was not taken into account, BMI was associated with increased cancer 
incidence (HR = 1.09(1.01 – 1.18), p = 3.1x10-2). This association was completely abrogated 
when adjusted for the presence of NAFLD. Similar results were found for other markers of 
adiposity, weight and waist measurements. 
When analysis was limited to obesity related cancers, BMI was associated with increased 
cancer incidence. (HR = 1.01(1.00 – 1.03), p = 3.3x10-2) Similarly to the analysis of all 
cancer incidence, BMI was not associated with cancer incidence when NAFLD was added as 
a covariate.  
Similar results were found in the SHARE cohort. Out of 26,891 patients analysed, 5,728 had 
cancer incidents in the follow up period. NAFLD was associated with increased cancer 
incidence (HR = 1.56, (1.45- 1.67), p < 2x10-16). NAFLD hospitalisation prior to baseline 
was associated with increased cancer risk, with a hazard ratio of 2.54. (95% CI = 1.14 – 5.65, 
p = 2.3x10-2).  NASH was also associated with increased cancer incidence. (HR = 4.18(1.74- 
10.0), p = 1.4x10-3) Among the patients in SHARE, 1,912 had BMI data available. In these 
patients, when NAFLD was accounted for, BMI was not significantly associated with overall 
cancer incidence, or with obesity related cancer incidence. 
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Similar results were found in the population based diabetes cohort from Tayside & Fife. Out 
of the 11,141 patients analysed, 1,819 had cancer incidents in the follow up period after the 
age of 60. NAFLD was associated with cancer incidence in the follow up period. (HR = 
1.16(1.04-1.29), p =5.9x10-3)  
As well as increasing all primary cancer incidence, NAFLD was associated with increased 
incidence of specific cancers in GoDARTS and SHARE, shown in Figure 3-2 below.  
 
Due to lower numbers of cases, the confidence intervals for these are wider than for all 
primary cancers combined. Breast and uterine cancer analyses were limited to females, with 
prostate cancer analyses limited to males. T&F was not meta analysed in this analysis due to 
the primarily diabetic composition of the cohort, which did not capture those over 60 who did 
not go on to get T2DM. The ascertainment bias in this cohort that only contains individuals 
who did eventually get diabetes is likely to have resulted in the lower point estimate for 
NAFLD in cancer risk that we have observed. 
Figure 3-2 Hazard Ratios for Effect of NAFLD on Specific Cancer Sites in GoDARTS and SHARE Meta-Analysis 
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In the T&F cohort of the 11,141 patients analysed, 1,819 had cancer incidents in the follow 
up period after the age of 60. NAFLD was associated with cancer incidence in the follow up 
period in an adjusted cox proportional hazards model. (HR = 1.16(1.04-1.29), p =5.9x10-3) 
NAFLD hospitalisations were significantly associated with cancer incidence in the same 
model. (2.04(1.12-3.71), p = 1.9x10-2) BMI was not associated with cancer incidence when 
NAFLD was included in the analysis. When analysis was limited to obesity related cancers, 
BMI did not show any significant association with cancer incidence when NAFLD was 
adjusted for. 
3.4.2 NAFLD and Cancer Death 
The relationship between NAFLD and cancer death was analysed in GoDARTS. In a CPH 
model adjusted for age, sex, diabetes, BMI and smoking, it was found that NAFLD is 
associated with increased risk of cancer death. (HR = 1.40(1.21-1.61), p = 8.8x10-4) FLI was 
associated with increased cancer death risk in the same CPH model. . (HR = 1.009(1.002 - 
1.015), p =9.8x10-3) 
NAFLD was associated with increased risk of non-cancer death in the same model. (HR = 
1.23(1.12-1.35), p < 0.0001) To estimate the effects of NAFLD specifically on cancer death 
more accurately, competing risks analyses were run. 
A CRR using Fine and Grays’s method was run to analyse the association between NAFLD 
and cancer death with non-cancer related death as a competing risk. In a model with sex, 
T2DM, smoking, obesity and age, NAFLD increased risk of cancer with a subdistribution 
hazards ratio (SHR) of 1.28 (95% CI =1.11 - 1.47, p = 8.8x10-4).  
In SHARE, a CRR adjusted for sex and T2DM with non-cancer death as a competing risk 
was run. Patients with NAFLD had a significantly higher risk of cancer death. (SHR = 3.12 
(2.38– 4.10), p <2x10-16) 
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In T&F, in an adjusted competing risks regression with non-cancer death as a competing risk, 
NAFLD was associated with increased cancer death. (SHR = 1.40(1.20-1.63), p = 9.6x10-11) 
In those patients who died during the follow up period of GoDARTS, NAFLD was associated 
with increased chance of cancer being the main cause of death in a logistic regression 
adjusted for age, sex, T2DM, smoking and BMI (OR = 1.33 (1.10 – 1.62), p = 3.6x10-3). This 
was also found in SHARE in a logistic regression adjusted for sex and T2DM. (OR = 
1.54(1.17 – 2.03), p = 2.0x10-3)  
The same result was found in T&F, with patients with NAFLD more likely to die with cancer 
as the main cause of death. (OR = 1.44(1.32 – 1.58), p = 1.3x10-3) 
3.4.3 Cancer as a Driver of Shorter Lifespans in NAFLD Patients 
Further analysis showed that this association between NAFLD and cancer death is one of the 
major drivers of the shorter life expectancies of NAFLD patients. This is shown in the table 7 
below.  
Table 8- Proportion of All Deaths Due to Cancer Stratified by NAFLD and Type 2 Diabetes Status in GoDARTS 
 
Table 7 shows the proportion of all deaths which are attributable to cancer. For example, in 
patients with NAFLD and not diabetes, 41.25% of deaths had cancer a the main cause, and 
45.26% of all deaths in this group had cancer as a main or contributing cause. 
Group 
Cancer as Main Cause of 
Death Rate 
Cancer as Contributing Cause 
of Death Rate 
Total Number in Group 
No NAFLD or T2DM 31.33% 35.34% 382 
T2DM 
24.28% 30.29% 449 
NAFLD 41.25% 45.26% 559 
Both NAFLD and  T2DM 27.80% 31.73% 1853 
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In GoDARTS, when stratified by cancer death and non-cancer death, NAFLD had no effect 
on age of death in the non-cancer group. NAFLD was associated with lower death age in 
those patients who died with cancer as a main cause. (p = 6.1x10 -5, β = -2.91, 95% CI= (-
2.18, -3.63), adjusted R2 = 0.05) NAFLD did not have an effect on age of death in those who 
never had a cancer diagnosis, but associated with lower age of death in those who had a 
cancer diagnosis at some point. (β = -2.07, 95% CI= (-1.54, -2.60), adjusted R2 = 0.07, p = 
1.8x10-4) 
 
Mean age of death is presented in table 8 below. This is stratified by NAFLD, T2DM and 
cancer death. 
Table 9 - Mean Death age versus Cancer Death, NAFLD and Type 2 Diabetes. (● indicates condition is present) 
Cancer as Main Cause of Death NAFLD T2DM Mean Death Age N 
   
82.7 263 
● 
  
79.2 119 
 
● 
 
83.0 328 
● ● 
 
75.9 231 
  
● 80.8 340 
● 
 
● 79.9 109 
 
● ● 79.4 1340 
● ● ● 76.6 513 
 
Similar results were found in SHARE, although these were less comparable due to the 
younger age of the SHARE cohort therefore lower numbers. NAFLD was associated with 
lower age of death in those who had a cancer diagnosis at some point in their life (β = -2.04, 
95% CI= (-0.25, -3.84), adjusted R2 = 0.07, p = 0.026), but not in those who never had a 
cancer diagnosis. This is shown in table 9 below. 
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Table 10 - Mean Death age versus Cancer Death, NAFLD and Type 5 Diabetes. (● indicates condition is present) 
Cancer as Main Cause of Death NAFLD T2DM Mean Death Age N 
   
75.5 116 
● 
  
73.2 103 
 
● 
 
76.4 270 
● ● 
 
69.8 332 
  
● 72.4 11 
● 
 
● 70.7 5 
 
● ● 73.6 89 
● ● ● 71.6 54 
 
 
3.4.4 PNPLA3 and Cancer Incidence 
 
The effects of PNPLA3 on cancer incidence during the follow up period in GoDARTS and 
SHARE were evaluated. Homozygous carriers of PNPLA3 rs738409 had increased risk of 
cancer incidence (HR = 1.27 (1.02-1.58), p = 3.1x10-2). These results were meta-analysed 
with results from SHARE, shown in Figure 3-3. 
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This association was also observed in GoDARTS when patients with liver cancer were 
excluded from analysis, as PNPLA3 rs738409 has been shown to increase liver cancer risk.232 
(HR = 1.26(1.01-1.58), p = 3.8x10-2) Similar results were found in an adjusted CRR with 
death as a competing risk. (SHR =1.24(1.00-1.54), p = 4.9x10-2) 
Mendelian randomisation analysis was conducted to estimate the effect of NAFLD on cancer 
incidence. Using the ratio method in a meta analysis of GoDARTS and SHARE, NAFLD was 
found to be significantly associated with cancer incidence, with a β estimate of 1.33(95% CI 
= 0.18 - 2.49, p = 0.023) 
Figure 3-3 Forest Plot of Effects of PNPLA3 rs738409 on Cancer Incidence in GoDARTS, SHARE and Meta-Analysis 
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3.5 Discussion 
In this study, it is shown that a significant increase in cancer incidence exists in patients with 
NAFLD. Cancer incidence and death was higher in those who had NAFLD in GoDARTS, 
SHARE, and T&F using the raised ALT definition as a surrogate of NAFLD. This 
demonstrates the generalisability of this result. This is the first truly large scale observational 
study to show these associations, as well as the first to show the effect of BMI on cancer 
incidence is driven to null when NAFLD is accounted for. In SHARE and T&F, NAFLD 
admissions were associated with increased cancer incidence. NASH also increased cancer 
incidence, with a larger effect size than NAFLD. Other non-invasive biomarkers including 
Fatty Liver Index and FIB-4 score prior to enrolment to the GoDARTS study were also found 
to increase risk of cancer during the follow-up period. These results support findings from 
other published studies that link NAFLD to cancer of all types. 59,202 It also suggests that the 
more pro-inflammatory form of NAFLD, NASH, may have more of an effect and this may 
give clues to the biological mechanism(s). 
There is emerging evidence that the association between NAFLD and cancer extends beyond 
the liver to other parts of the body. Kim et al. found in a cohort follow-up study that, in 
addition to an increased risk of liver cancer, NAFLD dramatically increased rates of 
extrahepatic cancers, including breast and colon in those who were diagnosed with NAFLD 
prior to the 10 year follow-up period.202 Allen et al similarly showed that NAFLD was 
associated with increased extrahepatic cancer risk, in sites such as the colon, lung and 
prostate.59 In the current study, an increase in cancer incidence was found in many of these 
specific sites, including breast, colon, liver, lung and prostate. Collectively, these data, 
including the results that we describe, supports the notion that NAFLD increases incident 
cancer risk. 
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NAFLD is associated with increased risk of cancer death in the follow up period in both 
GoDARTS, SHARE and T&F. This data correlates with our earlier findings that NAFLD is 
associated with increased cancer incidence, as increased incidence is naturally linked to 
increased mortality. Analysis of causes of death as reported by ICD10 codes in medical 
records showed that the deaths of patients with NAFLD were more likely to be due to cancer. 
Cancer was a key factor in the shorter lifespans of patients with NAFLD, as there was no 
significant effect of NAFLD on age of death when patients with a cancer diagnosis were 
excluded. This increase in cancer incidence and death accounts for a large proportion of the 
increase in morbidity and mortality shown in NAFLD patients in the previous chapter. 
Similar results were found in a recent study in a large Swedish cohort with biopsy confirmed 
NAFLD.60 In this study, Simon et al. found that excess death in NAFLD patients was 
primarily driven by extra-hepatic cancers and cirrhosis, while other causes such as 
cardiovascular disease and HCC had only a small effect. These findings agree with those of 
the current study, further implicating NAFLD in the development of extrahepatic cancer. 
We showed that homozygous carriers of the PNPLA3 NAFLD risk variant, rs738409, had an 
increased risk of cancer incidence. In a Mendelian randomisation analysis, we showed 
PNPLA3 rs738409 increased NAFLD incidence, NAFLD increased cancer incidence, and 
PNPLA3 rs738409 increased cancer incidence. This novel finding is supporting evidence that 
NAFLD is causally associated with increased cancer incidence.  
Substantial evidence links cancer to hyperinsulinemia. For example, hyperinsulinemia has 
been found to be a risk factor for colon cancer.233 It is also a risk factor for cancer death, 
independent of obesity.234 Patients with NAFLD are more likely to have hyperinsulinemia, 
and this is associated with reduced insulin clearance.235 This insulin excess may underlie, at 
least in part, the mechanistic basis by which NAFLD increases cancer incidence, as 
insulin/Igf-1 may promote tumour formation through mitogenic pathways downstream of 
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their receptors.236 No association was seen between T2DM and cancer when NAFLD was 
accounted for however, which suggests factors other than hyperinsulinemia are causing the 
increased cancer. 
Damage to liver cells via oxidative stress, inflammation, and disruption of cytokines, 
adipokines and lymphokines may contribute to the pathogenesis of cancer in those with 
NAFLD.205 NAFLD is a pro-inflammatory state, which may create an environment 
favourable to the development of cancer.237 Cancer has been previously linked to chronic 
inflammation, via increases in mutations, reduced apoptosis and other environmental 
changes.238 Inflammatory mediators suck as arachidonic acid, cytokines, chemokines, and 
free radicals are increased in NAFLD, and may contribute to cancer risk.238 Adipokines and 
cytokines for example are found in higher concentrations in the serum of NAFLD patients, 
which may  be factor in extrahepatic cancer development.239 Pro-inflammatory cytokines 
TNF-α (Tumour Necrosis Factor alpha) and IL-6 (Interleukin-6) are key factors in NAFLD 
inflammation, and may encourage development of neoplasia.238 Due to the diverse nature of 
cancer at different sites, it is likely that a number of different factors have effects. The larger 
effect sizes of NASH and FIB-4 on cancer incidence observed in this study are consistent 
with the notion of inflammation driving a proportion of cancer risk, as compared to simple 
steatosis. 
In a model adjusted for age and sex, BMI was found to be associated with increased cancer 
incidence. Many studies have shown increased cancer risk with increasing BMI, therefore 
this finding is consistent with previous literature. We found that BMI was not associated with 
overall cancer incidence when NAFLD was taken into account, and the same was found for 
waist and weight measurements. We also found that individuals who were obese but did not 
have NAFLD were not at increased risk of cancer incidence compared to those of a healthy 
weight. This finding supports those of Allen et al.59 When analyses were limited to so-called 
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obesity related cancers, similar results were found, as BMI was associated with cancer 
incidence, but not when NAFLD was adjusted for. This was found in all three cohorts 
analysed. The lack of independent association between BMI and cancer incidence in our 
study may suggest that NAFLD is a major component in the increased risk of cancer 
observed in overweight and obese patients.  
These findings have a number of implications for different stakeholders. For patients, 
especially those who are overweight or have T2DM, this has the most impact. The 
association between ALT and future cancer incidence may be useful as a screening tool to 
identify those with increased cancer risk. Methods of screening for cancer can be invasive 
and uptake is often low, therefore a blood based biomarker which is routinely measured in 
many individuals could be an effective adjunct to current screening methods such as 
mammograms and colorectal screening.240–242  
This finding increases the importance of creating a pharmacological intervention for NAFLD. 
The findings of this study combined with other studies linking NAFLD to extrahepatic cancer 
may also aid cancer research in pinpointing the pathways and pathologies which link excess 
body weight to cancer incidence. 
3.5.1.1 Limitations 
NAFLD Phenotype 
The NAFLD phenotype may be a limitation of this study, and this is discussed in detail in the 
previous chapter. There is substantial evidence linking ALT levels to NAFLD, but also 
evidence that NAFLD can exist in patients with normal ALT levels. Furthermore, non-
sensitive NAFLD phenotype would drive the association towards null, and therefore we 
cannot exclude the fact that the true association may be stronger than that we have observed. 
While we acknowledge that ALT levels may have a limited sensitivity for defining mild 
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NAFLD, we have shown that our ALT based definition is highly sensitive for more advanced 
cases, such as those with the Fatty Liver Index measured and those hospitalised with 
steatosis. In GoDARTS, SHARE and T&F, we estimated sensitivity to be 97.4%, 75.3% and 
94.6% respectively for such advanced cases.   
Genetic evidence for the suitability of our phenotype ascertainment is demonstrated by the 
observation that the major NAFLD susceptibility variant in PNPLA3, rs738409, was 
associated with our NAFLD phenotype with a very similar magnitude to that previously 
reported. 191 The high sensitivity of the phenotype and similar effects of other NAFLD related 
phenotypes on cancer incidence, plus previous literature linking NAFLD to cancer support 
the validity of the ALT based NAFLD phenotype. 59,202  
Whilst we show that our NAFLD phenotype is accurate, even if part of the aetiology of the 
raised ALT levels is alcohol or another cause, this is still an important and interesting result. 
The observation that when ALT levels are taken into account, BMI no longer associates with 
cancer incidence changes current understanding of the link between cancer and obesity. The 
association between raised ALT levels and future cancer incidence, even agnostic of the 
aetiology, is a valuable finding which may be used for cancer risk screening and prediction. 
We found NASH to be associated with increased cancer incidence, and suggest its associated 
hepatic inflammation may contribute to cancer risk. The majority of patients with NASH 
however also have a diagnosis of fibrosis, which could mean the effect is fibrosis rather than 
inflammation driven. 
Covariate Data Missingness 
The missingness of BMI and smoking data for patients in SHARE is a possible limitation of 
the current study.  In the analysis of cancer incidence in GoDARTS, T&F and the sub-group 
of SHARE patients with BMI data available, the inclusion of BMI as a covariate did not 
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modify the association between NAFLD and cancer. In GoDARTS also, NAFLD was not 
associated with rates of smoking when age and sex were adjusted for. Due to this, the 
analysis of NAFLD and cancer without BMI and smoking as covariates is still valid, and 
comparable with the analyses undertaken in GoDARTS. Allen et al, used similar 
methodology, as they did not correct for smoking and found that BMI played a relatively 
small part in cancer risk compared to NAFLD.59 The self-reported nature of alcohol intake in 
GoDARTS, and missingness of this data in SHARE and T&F, as well as the ubiquitous 
nature of alcohol consumption at the sub clinical level, does not allow us to exclude the 
possibility that general alcohol consumption may play a role in the relationship between 
NAFLD and cancer, however this is likely to be a limitation of the concept of NAFLD in 
general. 
BMI as a marker of Obesity 
BMI is an accurate and useful marker of obesity, although is not perfectly correlated with 
abnormal body fatness as factors such as muscle mass can impact the result.243 To assess 
whether this was a factor in the lack of association between BMI and cancer incidence, other 
measures of body fatness including waist measurement and weight were analysed. These also 
did not associate with cancer incidence when NAFLD was considered. Though other markers 
of excess body fatness exist, such as waist to hip measurements can be useful techniques, the 
fact BMI, weight nor waist measurement associated with cancer risk when NAFLD was 
considered suggests that this did not significantly impact findings. 
3.6 Conclusion 
In the current study we have shown that NAFLD is associated with increased risk of cancer 
incidence. There is also an association between NAFLD and cancer death, and cancer is a key 
factor in the shorter life expectancies associated with NAFLD patients. Furthermore, we are 
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first to show the association between BMI and cancer is driven to null when NAFLD is 
included in the model. This is further replicated in two additional, large cohorts, 
demonstrating the robust nature of this relationship. Given the large numbers of participants, 
these findings are likely generalisable to the general population. A key, novel finding of the 
study was that the missense variant PNPLA3 rs738409 is associated with increased cancer 
incidence. These findings suggests that the effect of NAFLD on cancer incidence may be 
causative, and that a major component of the association between body weight and cancer 
may be driven by NAFLD. 
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4 GWAS of NAFLD in Scottish and Indian Populations  
4.1 Abstract 
NAFLD is a common cause of liver disease and affects roughly a quarter of adults globally. 
There is a significant genetic component of NAFLD risk. The aim of this study was to find 
genetic determinants of NAFLD, and explore the effects of NAFLD variants in two Scottish 
and Indian study populations.  
In this cross-sectional cohort study, genome wide analysis studies (GWAS) were run to find 
genetic determinants of NAFLD. The GoDARTS and SHARE cohorts from Scotland, and the 
DMDSC cohort from India were the sources of data. NAFLD was defined by the presence of 
elevated ALT levels. Fatty Liver Index (FLI) and Fatty Liver Grade defined by ultrasound 
(FLG) were also available in the GoDARTS and DMDSC cohorts respectively. 
In both DMDSC and GoDARTs, PNPLA3 rs738409 was associated with increased NAFLD 
risk, with an odds ratio (OR) of 1.34 (p < 1x10-15). In GoDARTS, variants in the 
CHUK/ERLIN1 locus were genome wide significant for NAFLD (OR = 0.89(p = 2.1x10-8). 
In GoDARTS, variants in FAM19A4, EOGT, DNAH11, and TCF7L2 were genome wide 
significantly associated with FLI. 
We found that genetic variation had a significant contribution to NAFLD risk in both cohorts. 
PNPLA3 rs738409 increased risk of NAFLD in both GoDARTS and DMDSC, concurring 
with previous research that this locus is a key component of genetic NAFLD predisposition 
globally. 
4.2 Introduction 
Non-Alcoholic Fatty Liver Disease is a common cause of liver disease and is rising in 
prevalence globally.244 Research has revealed a number of genetic modifiers of NAFLD 
risk.190,245 Study of the genetics of NAFLD are a key component in the investigation to 
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understand the disease, and may provide insights that aid drug discovery and the application 
of personalised medicine.246,247 
Genetic studies of NAFLD have been undertaken extensively in European cohorts. The first 
GWAS of NAFLD by Romeo et al. found that the SNP PNPLA3 rs738409 was associated 
with increased NAFLD risk, and this has been replicated a number of times.190,248,249 Several 
other GWAS since have revealed many genetic loci which influence NAFLD, and many have 
found variants which have effects on steatosis, NASH, fibrosis and cirrhosis 
individually.245,250–252 
A number of studies have investigated the genetics of NAFLD in Indians, but a search of 
GWAS catalogue found no results for GWAS studies in Indian subjects.253 A number of 
candidate gene studies in Indian populations have found NAFLD related genetic 
variants.254,255  Due to the large and diverse nature of the population of India, many studies 
have analysed differences in genetic modifiers between different groups and regions within 
the country.256 Chatterjee et al. investigated the frequency of 34 known NAFLD risk variants, 
finding that they were overall more common in caste populations than tribal populations.99 
Diversity of phenotypes and genetic predisposition to disease has been found between Indian 
and European populations previously. For example, risk of type two diabetes (T2DM) is 
known to be heterogeneous between Europe and India, and recent findings have suggested 
this may be due to genetics.257,258 Studies have shown differences in a number of clinical 
parameters including obesity and heart disease risk.259 Investigations into whether NAFLD is 
different between white Europeans and Asian Indians have been conducted, and suggested 
that increased NAFLD risk accompanies increased insulin resistance in Indian men.260,261 
The aim of the current study was to identify genetic influences of NAFLD and NAFLD 
related phenotypes in Scottish and South Indian populations using data from electronic health 
90 
 
records. (EHRs) Further to this, the study aimed to compare the genetic modifiers in each 
cohort and evaluate differences in frequency between risk variants in each population. 
4.3 Methods 
4.3.1 Data 
The analysis for this study was conducted in the GoDARTS and DMDSC cohorts, which are 
described fully earlier in the current thesis. 
The first GWAS was conducted in Scottish data from the GoDARTS study.187 This is a 
T2DM case-control cohort with electronic health record data available for the 18,306 
participants. After exclusions were made for other causes of liver disease, there were 7,629 
individuals eligible for analysis with sufficient clinical and genotype data available. 
Further GWAS analyses were conducted in the Dr Mohan's Diabetes Specialities Centre 
(DMDSC) cohort.195 This cohort comprised 75,952 individuals who were patients of the 
DMDSC and had T2DM. These individuals were predominantly South Asian. From this 
cohort, there were 3,154 individuals who had been genotyped and had sufficient data 
available for analysis. 
4.3.2 Data Quality Control 
A number sequential steps to ensure the validity and accuracy of the genetic data was 
undertaken. These were the same for all cohorts and genotyping platforms.262 All steps were 
completed using Plink 1.9 software.263 
Firstly, individuals with missingness of genetic data greater than 0.02 were excluded. SNPs 
with missingness greater than 0.02 were also excluded. SNPs with minor allele frequency 
(MAF) lower than 0.01 were excluded. SNPs which were not in Hardy-Weinberg equilibrium 
were excluded.264 A p value threshold of 1x10-5 was used for this. Individual participants 
were excluded if they had a heterozygosity rate greater than three standard deviations from 
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the mean.265 The SNPs were pruned for linkage disequilibrium (LD) using a sliding window 
technique. This window was 50 SNPs wide, moved 5 SNPs each step and variants with 
correlation greater than 0.2 in this window were excluded.266 The cohorts were checked for 
relatedness between individuals and, those with pihat greater than 0.2 were excluded.267 
Ethnic outliers were excluded from each cohort. Using multidimensional scaling of the 
genetic data, 20 principle components were calculated.262 This was conducted for each 
cohort, plus the 1000 Genome cohort (1000G).268 Each cohort was plotted with respect to the 
first two principle components against the 1000G cohort, which was labelled with ethnicity. 
Ethnic outliers were then removed from each cohort. 
4.3.3 Measures 
An in depth analysis and description of the phenotypes used in the current analysis is 
included in a previous chapter of the current thesis. A brief outline of each is included below. 
In GoDARTS, two phenotypes were analysed. These are described in detail in the NAFLD 
phenotype chapter earlier in the thesis. The first was NAFLD, which was defined by two 
raised ALT measurements (>19U/L for women and >30U/L for men) at least 3 months 
apart.180 The sign up date to GoDARTS was taken as baseline, therefore any patient with 2 
raised ALT levels at least 3 months apart before this date was considered a case. 
The second phenotype analysed in GoDARTS was the Fatty Liver Index.148 This combines 
BMI, waist circumference, GGT and triglycerides using the formula below. This was 
calculated using measurements for each patient which were taken closest to their sign up 
date. A full description of FLI is given in a previous chapter. 
In the DMDSC cohort, NAFLD was also defined using ALT levels, which is also discussed 
previously in this thesis. Due to the lack of longitudinal data a single raised ALT rather than 
two raised measurements three months apart was used to define NAFLD. Fatty Liver Grade 
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(FLG) was also available for a number of patients in the DMDSC cohort. This was an ordinal 
scale of fatty infiltration of the liver, from 0-3; none, mild, moderate and severe fatty 
infiltration respectively.143 This was measured by abdominal ultrasound, a commonly used 
and accurate method of detecting steatosis.30 
4.3.4 Statistical Analyses 
Data were analysed using GWAS methodology, in the Plink 1.9 software program.263 
Genome wide significance was considered to be p < 5x10-8. Any p values below 5x10-6 were 
considered suggestive signals. 
Data were analysed separately by cohort, with meta analyses conducted of all cohorts for the 
NAFLD phenotype. Where NAFLD was the outcome variable, this was analysed in an 
adjusted binary logistic regression. Adjusted linear regression was used for continuous 
outcome variables.  
Each model was adjusted for a number of covariates, depending on the data available. Ten 
principle components for the genetic data were calculated for each cohort, and these were 
included as covariates in the statistical models. 
Where many significant results from the same gene were found, LD pruning was performed 
for the display of the results. Results were pruned with SNPs with Pearson’s R2 > 0.8 being 
omitted from results tables.  
 The analysis in GoDARTS was adjusted for 10 principal components, age, sex, T2DM and 
BMI. The individuals in GoDARTS have been genotyped in phases and on different GWAS 
chips. Individuals genotyped on each chip were analysed together, then the results from the 
meta-analysed. Analysis of FLI was not adjusted for BMI as the calculation of the FLI score 
already includes BMI. 
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In analysis of NAFLD conducted in DMDSC, the logistic regression model was adjusted 10 
PCs, sex, age and BMI. All patients in this cohort had T2DM, so this was not included in the 
model. GWAS of FLG in the DMDSC cohort was adjusted for the same covariates. 
Manhattan plots and QQ plots were generated for each GWAS analysis using the “calibrate” 
and “qqman” R packages.269–271 
4.4 Results 
4.4.1 GoDARTS Data 
A GWAS of NAFLD in GoDARTS was run. The Manhattan plot for this analysis is shown 
below in figure 4-1 with the quantile-quantile (Q-Q) plot for this analysis in figure 4-2. 
 
 
 
 
 
Figure 4-1Manhattan Plot of GoDARTS NAFLD GWAS 
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A number of variants in ERLIN1, BLOC1S2 and PNPLA3 were genome wide significant for 
NAFLD, shown in table 10 below. All of the genome wide significant variants in 
chromosome 10 were in high LD (Pearson’s R2 > 0.8), as were the variants in chromosome 
22 in PNPLA3. (Pearson’s R2 > 0.9) An LD pruned table of results is shown below. (Table 
10) 
Table 11 - Genome wide significant variants for NAFLD in GoDARTS 
Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
Effect 
Allele 
Frequency 
p-value Odds Ratio Cochrane's 
Q 
I2 
10 ERLIN1 10:101,880,479 rs11594323 A 0.421 3.19E-08 0.816 0.333 11.96 
22 PNPLA3 22:44,324,727 rs738409 G 0.203 1.09E-08 1.3207 0.2074 36.43 
 
Figure 4-2 Q-Q Plot of GoDARTS NAFLD GWAS 
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A GWAS of FLI was run in the GoDARTS cohort. The QQ plot and Manhattan plot for this 
analysis are shown below in figure 4-3 and figure 4-4. 
 
 
DNAH11 rs117146188 reached genome wide significance, and several variants reached 
suggestive significance, shown in table 11 below. 
Figure 4-3 Manhattan Plot for GoDARTS FLI GWAS 
Figure 4-4 Q-Q Plot for GoDARTS FLI GWAS 
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Table 12 Genome wide significant and suggestive significance reaching variants in GWAS of FLI in GoDARTS. 
Chromosome Gene  Chromosome 
Position 
SNPID Effect 
Allele 
Effect 
Allele 
Frequency 
P Beta Cochrane's 
Q 
I2 
4 FSTL5  4:162,824,685 rs190994066 T 0.025 4.19E-07 -7.0671 0.2391 28.83 
6 HLA-
DOB 
6:32,756,390 rs114032730 A 0.028 1.17E-07 -6.6811 0.2026 34.95 
6 PSMB9 6:32,859,137 rs7761882 A 0.030 3.02E-07 -6.5979 0.5054 0 
7 DNAH11  7:21,883,902 rs117146188 G 0.0138 2.71E-08 -9.3876 0.1968 35.89 
22 GGT1 22:24,994,708 rs2017188 C 0.0352 1.94E-07 2.3655 0.3577 2.74 
 
A number of variants in GGT1 were close to genome wide significance for association with 
increased FLI. These were all in extremely high LD (> 0.99 Pearson’s R2), therefore likely 
represent one signal. Serum GGT levels have a moderate level of heritability, and some 
known genetic influences.272  The GGT1 variants which were close to genome wide 
significance in the present study are at a locus which has previously been associated with 
serum GGT levels.273 The liver enzyme GGT is a component of the FLI, therefore this GGT1 
locus may represent a confounding variable.148 This may cause individuals to have higher FLI 
scores simply because they carry genetic variation in GGT1, rather than due to increased 
levels fatty liver itself. 
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To overcome this and increase the sensitivity of the analysis, a GWAS of FLI was run again, 
with GGT1 rs2017188 included as a covariate. The Manhattan plot and QQ plots for this 
analysis are shown in figures 4-5 and 4-6 below. 
 
 
Genome wide significant results were found in four different genes, shown in table 12 below. 
Figure 4-5 Manhattan Plot for GoDARTS FLI GWAS with GGT1 covariate 
Figure 4-6 Q-Q Plot for GoDARTS FLI GWAS with GGT1 covariate 
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Table 13 - Genome wide significant variants for FLI in GoDARTS 
 
  
Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
Effect 
Allele 
Frequency 
p-value Beta Cochrane's 
Q 
I2 
3 FAM19A4 3:68,998,611 rs1898616 G 0.608 4.00E-08 3.5115 0.369 0 
3 FAM19A4 3: 69,008,245 rs7427984 A 0.581 2.79E-08 3.4907 0.7684 0 
3 EOGT 3:69,014,707 rs1506986 A 0.624 7.74E-09 3.7184 0.4439 0 
3 EOGT 3:69,020,937 rs9853718 G 0.594 2.74E-08 3.5525 0.6323 0 
7 DNAH11 7:21,883,902 rs117146188 G 0.0138 1.12E-08 -14.0018 0.0786 60.69 
7 DNAH11 7:21,924,439 rs76307823 C 0.126 1.14E-08 -14.9095 0.3062 15.51 
7 DNAH11 7:21,930,208 rs77888218 T 0.128 7.70E-09 -15.0827 0.2727 23.04 
10 TCF7L2 10:114,754,071 rs34872471 C 0.333 2.69E-08 -3.7337 0.1759 42.46 
10 TCF7L2 10:114,754,784 rs35198068 C 0.334 4.80E-08 -3.662 0.148 47.65 
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4.5 DMDSC Data 
A GWAS was run for the NAFLD phenotype in the DMDSC cohort, with 3,123 eligible 
participants. The Manhhattan plot for this analysis is shown below in figure 4-7, and the Q-Q 
plot below in figure 4-8. 
 
Figure 4-7 Manhattan Plot for DMDSC NAFLD GWAS 
Figure 4-8 Q-Q Plot for DMDSC NAFLD GWAS 
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A number of variants in PNPLA3 were genome wide significantly associated with NAFLD, 
all of which were in very high LD (Pearson’s R2 > 0.99). The PNPLA3 rs738409 variant was 
among these with an OR of 1.39, and is likely to be the cause of the signal. The results for 
PNPLA3 SNPs rs738409 and rs12485100 (which had the lowest p-value out of the SNPs in 
high LD) are shown in table 13 below. 
Table 14- Genome wide significant variants for NAFLD in DMDSC 
Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
Effect 
Allele 
Frequency 
p-value Odds Ratio 
22 PNPLA3 22:44,325,516 rs12485100 T 0.242 5.5E-08 1.39 
22 PNPLA3 22:44,324,727 rs738409 G 0.252 3.0E-08 1.40 
 
Further to the GWAS on NAFLD, a GWAS was run with FLG as the phenotype, with 2,013 
eligible participants included in analysis. The Manhattan plot and Q-Q plot for this analysis is 
shown below in figure 4-9 and 4-10 respectively. 
 
Figure 4-9 Manhattan Plot for DMDSC FLG GWAS 
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No variants reached genome wide significance for this phenotype, though two variants 
reached suggestive significance. These are shown in table 14 below. 
Table 15 - Suggestive significance reaching SNPs for FLG in DMDSC cohort 
Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
Effect Allele 
Frequency 
Beta SE p-value 
6 POU5F1 6:31,148,349 rs114773933 
 
G 0.0176 -0.4205 0.08824 2.02E-06 
7 PDE1C 7:32,063,068 rs13239020 C 0.0127 -0.48 0.1037 3.92E-06 
Figure 4-10 Q-Q Plot for DMDSC FLG GWAS 
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4.6 Meta Analysis of Scottish and Indian Cohorts 
The results of GWAS analyses in the Scottish and Indian cohorts were meta analysed. The 
results for the meta analysis of NAFLD in the GoDARTS and DMDSC cohorts are displayed 
in the Manhattan plot and QQ plot in figures 4-11 and 4-12 below. 
 
Genome wide significant signals were found in PNPLA3 around the rs738409 locus, the same 
as was in individual GWAS of GoDARTS and DMDSC. SNPs around ERLIN1 rs10883447 
were also genome wide significant, although these SNPs were not analysed in the DMDSC 
GWAS as they were excluded during the QC process. The significant variants were pruned 
for LD greater than 0.8. This shown in table 16 below. 
Figure 4-11 Manhattan Plot of DMDSC NAFLD GWAS 
Figure 4-12 Q-Q Plot of DMDSC NAFLD GWAS 
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Table 16 - Genome wide significant SNPs for NAFLD in meta analysis of GoDARTS and DMDSC 
Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
P OR Cochrane's Q I2 
10 ERLIN1 10:101,903,906 rs10883447 G 3.19E-08 0.816 0.333 11.96 
22 PNPLA3 22:44,324,727 rs738409 G 5.37E-16 1.3423 0.4636 0 
 
A forest plot of the association between PNPLA3 rs7384098 and NAFLD in the GoDARTS 
and DMDSC cohorts, as well as the meta analysis, is shown below in figure 4-13. 
 
Further investigation in ERLIN1 SNPs in the meta analysis was conducted, as the genome 
wide significant SNPs were not found in the DMDSC cohort. A number of ERLIN1 SNPs 
were analysed both in GoDARTS and DMDSC, though these did not reach genome wide 
significance. These variants were not nominally associated with NAFLD in DMDSC, 
although showed the same direction of effect as in GoDARTS. Similarly to GoDARTS, these 
Figure 4-13 Forest plot for PNPLA3 rs738409 in GoDARTS, DMDSC and 
meta-analysis 
104 
 
were in high LD, with R2 >0.93. The SNP ERLIN1 rs11594323 is shown as an example in 
table 16 below, with results from GoDARTS and DMDSC. 
Table 17 - ERLIN1 rs1077821 in GoDARTS and DMDSC NAFLD GWAS 
  
A forest plot of the rs1077821 variant in ERLIN1, in the GoDARTS, DMDSC and meta-
analyses is shown in figure 4-14 below. 
 
4.7 Analysis of Known NAFLD Risk Variants 
Following the GWAS analysis, the results were probed for the associations between the 
relevant phenotype and known NAFLD risk altering variants. Genetic variants with robust 
and validated associations with NAFLD were selected from previous literature. The 
Cohort Chromosome Gene Chromosome 
Position 
SNPID Effect 
Allele 
P OR Cochrane's 
Q 
I2 
GoDARTS 10 ERLIN1 10:101,888,520 rs1077821 T 2.096e-08 0.8138 0.3584 6.93 
DMDSC 10 ERLIN1 10:101,888,520 rs1077821 T 0.5031 0.9577 / / 
Figure 4-14 Forest Plot for ERLIN rs1077821 in GoDARTS, DMDSC and meta-analysis 
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associations between these variants, and the phenotypes analysed in the current study are 
shown in table 17 below. 
Table 18 Associations between known NAFLD risk variants and NAFLD phenotypes in GoDARTS, DMDSC and meta-
analysis 
 
A number of known NAFLD risk variants, which were not genome wide significant in the 
GWAS results, reached nominal significance. (p < 0.05) These are highlighted in yellow. 
 
4.8 Discussion 
The GWAS analyses in the current study revealed several genetic loci which have significant 
effects on NAFLD in both GoDARTS and DMDSC cohorts. 
  
GoDARTS 
NAFLD 
GoDARTS FLI DMDSC 
NAFLD 
DMDSC FLG Meta NAFLD 
Gene  SNP p OR p Beta p OR p Beta p OR 
PNPLA3 rs738409 1.09E-
08 
1.3207 0.2477 0.8816 2.46E-
11 
1.352 0.0137 0.0663 5.37E-
16 
1.3423 
ERLIN1 rs1077821 2.096E-
08 
0.8138 0.412 0.524 0.5031 0.9577 0.519 0.01936 2.25E-
4 
0.90 
LYPAL1 rs12137855 0.1195 0.9363 0.93 0.0645 / / / / 0.1195 0.936 
HSD17B13 rs6834314  0.2191 0.8522 0.337 -0.671 0.995 0.936 0.918 0.00367 0.237 0.959 
TM6SF2 rs58542926 0.3251 1.075 0.843 -0.233 0.16 1.092 0.000194 0.141 0.0405 1.115 
NCAN rs2228603 0.972 1.003 0.176 -1.58 0.0342 1.21 0.001236 0.174 0.229 1.074 
PPP1R3B rs4240624 0.866 1.01 0.18 -2.305 0.241 1.089 0.161 -0.063 0.428 1.027 
GCKR  rs780094  0.367 1.035 0.12455 0.998 / / / / 0.367 1.035 
FDFT1 rs2645424  0.7544 1.012 0.4713 -0.455 / / / / 0.7544 1.012 
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4.8.1 NAFLD in GoDARTS 
Two genome wide significant variants were found for NAFLD in GoDARTS. These were in 
PNPLA3 and ERLIN1. Both of these genes have previously been reported as having 
significant effects on NAFLD risk in GWAS and candidate gene studies. 
The PNPLA3 rs738409 locus showed the strongest association with NAFLD, with an OR of 
1.32. This SNP was the first NAFLD risk variant discovered by GWAS; a finding which has 
been replicated in numerous studies in a variety of populations and ethnicities.190,274,275 These 
GWAS and candidate gene studies have found rs738409 to be associated with a range of 
NAFLD phenotypes, including serum ALT,  fibrosis, cirrhosis and hepatocellular 
carcinoma(HCC).274,276Studies have sought to elucidate the mechanism by which PNPLA3 
rs738409 increase NAFLD risk, highlighting several effects.  
PNPLA3 is the gene which codes for the protein adiponutrin, which is mainly found in 
adipocytes and hepatocytes.277 Its functions include the production and breakdown of fats in 
hepatocytes.278 PNPLA3 rs738409 is a missense variant which interrupts the lipolysis of 
triglycerides in the liver.279 It is also associated with decreased release of very-low-density-
lipoproteins from the liver.248 These effects cause disruption in the lipid homeostasis of the 
liver, increasing the amount of fats stored which becomes steatosis. 
The PNPLA3 rs738409 variant is also associated with increased NASH risk, and histological 
severity of liver disease.280 It is also associated with increased risk of fibrosis, cirrhosis and 
HCC, which has prompted research into whether these associations are driven simply by 
increased steatosis or another mechanism of PNPLA3.281 In a meta analysis, Singal et al. 
found that PNPLA3 increased risk of progression to fibrosis in patients with steatosis 
regardless of cause.276 They showed rs738409 increased fibrosis risk in patients with hepatitis 
C virus (HCV), and others have found increased risk of alcoholic liver disease in those who 
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carry the rs738409 variant.282 PNPLA3 is highly expressed in hepatic stellate cells (HSC), 
which are the responsible for the production of the extracellular matrix which characterises 
fibrosis.283 The rs738409 variant increases the HSC’s pro-inflammatory and pro-fibrogenic 
properties when in an activated state due to hepatocellular injury.284 
The association between NAFLD and PNPLA3 rs73809 in GoDARTS is not novel, but acts 
as a good positive control and validation of the phenotype. An ALT based NAFLD definition 
is unable to provide any classification of the severity of the disease, but individuals with the 
full spectrum of NAFLD were included in the study. It is probable that this signal reflects 
both steatogenic and fibrogenic effects of PNPLA3, but simple steatosis in NAFLD is many 
times more common than the more advanced stages such as fibrosis and cirrhosis.5 A larger 
proportion of this signal therefore likely represents increased frequency of steatosis in carriers 
of the rs738409 variant.54 
We found that PNPLA3 rs738409 is associated with NAFLD with an OR of 1.32, in an 
additive model. This OR is lower than some previously published estimates, some of which 
are as high as 2.40.274 The effects of PNPLA3 rs738409 on NAFLD have been described a 
number of times in European cohorts.232,285 These studies have used a number of different 
NAFLD definitions and related phenotypes however which makes comparison of point 
estimate of PNPLA3 effects difficult. Sookoian et al. performed a meta analysis of studies 
investigating PNPLA3 rs738409 and NAFLD, finding an overall odds ratio of 3.26 for 
homozygous wild type versus heterozygotes (CC versus CG).83 They also found significant 
association between PNPLA3 rs738409 and ALT levels across a number of studies. Dai et al. 
found a lower OR of 2.27 for CC versus CG genotypes in their analysis.275 The inclusion 
criteria for this study required that NAFLD be diagnosed by MRI, ultrasound or liver biopsy, 
which are more accurate than LFTs for NAFLD diagnosis, but are predominantly performed 
only when liver disease is suspected.30,135,286 This means that asymptomatic cases are likely to 
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be untested and therefore misclassified. The differences in phenotypes may explain some of 
the variability in odds ratios. 
Variants in ERLIN1 were found to reduce NAFLD risk with odds ratios of ~0.81 in 
GoDARTS. ERLIN1 (Endoplasmic Reticulum lipid raft protein 1) encodes a prohibitin 
protein that defines lipid-raft-like domains of the endoplasmic reticulum.287 Lipid rafts are 
structures made of lipids and proteins which are represent in plasma membranes, in this case 
of the endoplasmic reticulum(ER). Disordering of the ER lipid raft can disrupt the function of 
the ER, including cell signalling.288 ER function is a key factor in NAFLD, as ER stress can 
contribute to several mechanisms which increase hepatic steatosis, fibrosis and cell death.289  
The protein encoded by ERLIN1 binds to cholesterol and regulates the SREBP signalling 
pathway.290 ERLIN proteins restrict the release of SREBP from the ER, and it has been 
shown that in the absence of ERLIN proteins, SREBP activity is increased.290 SREBPs are 
transcription factors which bind to sterol regulatory elements and upregulate them to produce 
more enzymes which are required for sterol biosynthesis.291,292  SREBPs are key regulators of 
cell lipid homeostasis, involved in a number of processes including; global lipid synthesis and 
growth, fatty acid synthesis, energy storage and cholesterol regulation.293 SREBPs are 
associated with NAFLD through several pathways, increasing steatosis and inflammation, 
partially through increased ER stress.294 Genetic variants in the genes which encode SREBPs 
have been linked to NAFLD.295 
ERLIN1 is part of a cluster involving the genes CHUK-CWF19L1-ERLIN1, and a number of 
variants in these genes are in LD. The variants in CHUK and CWF19L1 form one haplotype 
block in very high LD (>0.99), and the variants in ERLIN another haplotype block with high 
LD with each other (>0.82 -0.99). These two haplotype blocks are also in high LD, with 
Pearson’s R2 ~0.80 between variants in each block. This cluster has been linked to NAFLD 
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previously, with associations with ALT, NAFLD defined by CT scan and NASH.287,296,297 
Three variants in ERLIN1; rs10883451, rs1408579 and rs2862954; were found to be genome 
wide significantly associated in a meta-analysis of ALT and NAFLD.296 
It is unclear whether both of these gene haplotype blocks have independent effects on 
NAFLD, or if just one of the genes is the causative source of the association. No previously 
published studies have reported analysis of this. The CHUK gene encodes a protein kinase 
which inhibits the essential transcription nuclear factor-kappa-beta (NF-κB) complex.131 NF-
κB is associated with the regulation of cell activities including inflammation and cell death.298 
Given what is known about the function of each gene, it is plausible that both CHUK and 
ERLIN1 have independent effects on NAFLD, although further research is required to 
characterise their relationship to NAFLD clearly. 
Furthermore, there is evidence that these variants in ERLIN1 are expression trait quantitative 
loci (eQTL).299 ERLIN1  is a cis-eQTL for, a neighbouring gene.296 CWF19-like 1 cell cycle 
control (CWF19L1) variants were found to be associated with NAFLD and ALT levels in the 
study by Feitosa et al.296 In the UK BioBank cohort, the CWF19L1 rs17729876 variant is 
associated with T2DM, and chronic liver disease.300 Data from The Human Protein Atlas 
show CWF19L1 is associated with increased liver cancer 
mortality(http://www.proteinatlas.org).301 This locus is also linked to increased cholesterol 
levels.302 These findings may suggest that the association between ERLIN1 and NAFLD is 
due through expression of CWF19L1. 
4.8.2 FLI in GoDARTS 
A GWAS analysis of Fatty Liver Index in GoDARTS found one genome wide significant 
signal, DNAH11 rs117146188 and showed a number of variants which were close to genome 
wide significance. Ten of these variants were in the GGT1 gene, in high LD. (R2 > 0.99) This 
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result was germane as gamma-glutamyltransferase (GGT) is a biomarker which is used in the 
calculation of FLI. The GGT1 gene encodes GGT, and variants in this gene have been 
reported to influence serum GGT levels. The GGT1 variant rs2006227 is among those 
reported to influence serum GGT levels, and was among the ten GGT1 SNPs which were 
close to genome wide significance in the current study.303 It is therefore likely that the 
association between GGT1 variants and FLI is driven by the association with serum GGT 
levels, and not by altered NAFLD risk. 
To control for this genetic risk factor for GGT, and thus higher FLI, a second GWAS of FLI 
was run in GoDARTS with GGT rs2006227 included as a covariate. This produced stronger 
results, and a number of genome wide significant hits.  
DNAH11 rs117146188 was significantly associated with FLI in both analyses, adjusted and 
non-adjusted for GGT1. Two more variants in DNAH11 were also genome wide significantly 
associated with FLI; rs76307823 and rs77888218; which were in almost perfect LD (R2 = 
0.99). These two variants were in high LD with rs117146188, with a Pearson’s R2 of 0.87. 
The β estimate for rs117146188 was -14.0 per allele, a strong protective effect against high 
FLI. This effect size is large, given that FLI extends from 0 to 100.148 DNAH11 (Dynein 
Aaxonemal Heavy Chain 11) encodes a ciliary outer dynein arm protein, and is involved in 
the movement of respiratory cilia.304 It has not previously been linked to NAFLD or related 
conditions. 
In the analysis adjusted for GGT1 three more variants were significantly associated with FLI; 
FAM19A4, EOGT and TCF7L2. Two variants in FAM19A4 (Family with Sequence Similarity 
1 member A4) which were in high LD (R2= 0.93) were genome wide significantly associated 
with FLI; rs1898616 and rs7427984. The function of FAM19A4 is not clear, though it has 
been found to have a role in regulation of macrophages in response to inflammation.305 
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FAM19A4 is an eQTL of EOGT, which may explain the association seen between FAM19A4 
and FLI.306  
Two variants in EOGT (rs1506986 and rs9853718) were significantly associated with FLI in 
the GWAS adjusted for GGT1, and were in high LD.(R2 > 0.99) EOGT(EGF Domain 
Specific O-Linked N-Acetylglucosamine Transferase) encodes a protein which is active in the 
ER of the cell and catalyses the transfer of N-acetylglucosamine (GlcNAc) to extracellular 
proteins.307 The adding of GlcNAc (O-GlcNAcylation) activates or deactivates enzymes and 
transcription factors, and is a mechanism of regulation. In the liver, this process is a key 
factor in regulation of metabolism.308 O-GlcNAcylation is associated with hepatic insulin 
resistance and disruption of a number of processes in the liver, including gluconeogenesis, 
glycolysis and glycogenesis. 309,310 Studies have suggested that this is in some part through 
regulation of the FXR gene, which regulates SREBP-1c, a key regulator of hepatic lipid 
homeostasis.293 The variants in EOGT which were significant in the current study have no 
reported associations with clinical outcomes in published literature, though data from the IEU 
OpenGWAS system shows EOGT rs1506986 is associated with microalbumin in urine and 
eosinophil count.311 In the UK Biobank data, EOGT rs9853718 is associated with abdominal 
aortic aneurysm.300,312 
TCF7L2 (Transcription Factor-7–Like 2) rs34872471 and rs35198068 were both genome 
wide significantly associated with FLI in the GWAS adjusted for GGT1. These variants are in 
high LD. (R2 > 0.99) TCF7L2 influences the transcription of a number of genes, and notably 
regulates glucose metabolism in the pancreas and liver.313 rs34872471 is associated with 
increased T2DM risk, which has been shown in a number of populations.314,315 It is also 
associated with decreased blood pressure.312 This locus is in almost perfect LD with the 
common T2DM risk variant rs7903146 (R2 > 0.99), which likely explains these associations. 
This variant increased diabetes risk by altering incretin action, and is associated with 
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cardiovascular disease.316,317 It has been reported to increase NAFLD risk independently of 
diabetes in several studies.254,318 The current study concurs with these results, and confirms 
that there is increases steatosis in carriers of the TCF7L2 rs7903146 variant. 
4.8.3 NAFLD in DMDSC 
Variants in the PNPLA3 gene around the rs738409 locus were genome wide significantly 
associated with NAFLD. All significant variants were in almost perfect LD (R2 > 0.99). The 
OR for NAFLD was 1.39 for rs738409. This variant has previously been reported to be a risk 
factor for NAFLD in Indians, as well as South Indians specifically.255,256,319 Bale et al. found 
that PNPLA3 was associated with NAFLD risk for North Indians compared to South 
Indians.256 The findings of the current study confirm the relationship between PNPLA3 
rs738409 and NAFLD, and act as a positive control, validating the NAFLD phenotype. 
4.8.4 FLG in DMDSC 
No variants were genome wide significantly associated with Fatty Liver Grade in the 
DMDSC cohort. Two variants however reached suggestive significance. POU5F1 
rs114773933 showed suggestive significance for negative association with FLG. POU5F1 
(POU Domain, Class 5, Transcription Factor 1) encodes a transcription factor protein which 
regulates cell differentiation.320 This variant has not been linked to clinical outcomes in any 
published literature. This pathway has been linked to NASH, as Chien et al. showed that 
POU5F1 could improve effectiveness transplanting pluripotent stem cells to treat both 
steatosis and steatohepatitis.321 Park et al. showed similar results, with stem cells induced by 
POUF51 and HNF1α improved chronic liver injury.322 It has also been implicated in liver 
cancer, as  POU5F1 drives self-renewal of liver cancer cells.323 The current study suggests a 
role of the POUF51 transcription factor and a variant of its associated gene in the 
development of steatosis.  
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PDE1C rs13239020 was negatively associated with FLG, with a suggestive p value. PDEC1 
(Phosphodiesterase 1C) encodes an enzyme regulates proliferation and migration of vascular 
smooth muscle cells.324 The PDE1C enzyme downregulates glucose dependent insulin 
secretion, and inhibition of PDE1C upregulated insulin secretion.324 Patients with NAFLD 
have impaired incretin effect.325 The association between PDE1C and FLG in the current 
study may be a result of this alteration of insulin secretion.  
4.8.5 Meta-Analysis 
The PNPLA3 variant rs738409 was found to be genome wide significantly associated with 
NAFLD in both the GoDARTS and DMDSC cohorts, as well as the meta analysis. Both had 
similar odds ratios with GoDARTS = 1.32 and DMDSC = 1.39, and both European and 
South Asian populations are reported to have a MAF of ~0.22 for this variant.326  
The association between this locus and NAFLD has been demonstrated in both European and 
South Indian populations in previous literature.42,327 Previous literature has found that there 
are ethnic differences in the magnitude of the NAFLD risk associated with PNPLA3 
rs738409. In a meta analysis of 13 articles, Dai et al. showed that this variant had a larger 
effect in Caucasian individuals compared to Asian individuals. However, the Asian cohorts 
meta analysed in this study were predominantly Chinese, and may be different to Indian 
populations with respect to PNPLA3. Gnomad reports differences in MAF for rs738409, with 
MAF = 0.3816 in East Asians and MAF = 0.22 in South Asians.326 The estimate for Asian 
individuals in the Dai et al study therefore may not be applicable to the DMDSC cohort. Due 
to the differences in NAFLD case ascertainment, and overall differences in the data, we are 
unable to draw any conclusions about the relative magnitude of the PNPLA3 rs738409 effect 
in each of the cohorts. 
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The ERLIN1 locus near rs10883447 was significantly associated with NAFLD in GoDARTS, 
but were not significantly associated with NAFLD in DMDSC. Though ERLIN1 rs10883447 
was excluded in the QC process in DMDSC due to missingness > 0.02, some ERLIN1 
variants in high LD were analysed. ERLIN1 rs1077821 showed the same, protective direction 
of effect as rs10883447 did in GoDARTS. Significant heterogeneity was found between the 
results for rs1077821 in DMDSC and GoDARTS, with an I2 value of 79.37%.328 This statistic 
may suggest a difference in the effect of ERLIN1 between the cohorts, though this could be 
due to lack of experimental power. Variance at this locus is rare in the DMDSC cohort 
compared with GoDARTS, as for rs1077821, the MAFs are 0.22(DMDSC) and 0.42 
(GoDARTS). Similar differences in frequency between Europeans and South Asians are also 
reported in previous studies such as 1000 Genomes.268 The relative rarity of the effect allele 
combined with the lower number of individuals analysed (N = 3,133), could mean that the 
analysis in DMDSC was not adequately powered to detect an association. The experimental 
power was calculated with an alpha level of 0.05, giving a power of 3.1%.329  
4.8.6 Known NAFLD Variants Analysis 
Following the GWAS analysis the association results for a number of known NAFLD risk 
variants were compiled. These variants were selected based on their identification as NAFLD 
risk variants in previous literature. In the GoDARTS NAFLD phenotype, aside from the 
genome wide significant signals in PNPLA3 and ERLIN1 none of the tested variants reached 
nominal significance. Further investigation was conducted to find why many known NAFLD 
variants were not significantly associated with NAFLD in GoDARTS was undertaken. It was 
found none of the variants had significant heterogeneity of effect between individuals 
genotyped on each of the three platforms used. This non-significance of many SNPs may be a 
reflection of the phenotypes chosen. Certain NAFLD variants are associated with particular 
features and stages of NAFLD, and these may not have been picked up by our phenotype. 
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Failed replication of genetic studies is common, as Wu et al. found no association between 
NAFLD and NCAN rs2228603 in a Han Chinese population, where others had shown an 
association in previous studies.330 
Issues of statistical power may have altered the chances of seeing significant replication 
results. In GoDARTS for example, for the TM6SF2 rs58542926 variant which has a MAF of 
0.068, the statistical power for the analysis was 56.2% with an alpha level of 0.05. This 
power level is below threshold of 80%, which is the most commonly used level in medical 
studies.331 
Further to this an additive model was used, which is not the model used in the discovery of 
all of these variants. This is applicable to many of the variants tested, but this may have 
underestimated the effects of a number of SNPs as they behave in dominant, recessive or 
overdominant ways rather than additively.332,333 Other models were tested for a number of 
variants and it was found that NCAN rs2228603 was significantly associated with NAFLD in 
a recessive model in GoDARTS. (OR =2.08(1.08 - 4.16), p = 0.031) 
 GWAS analyses reported in previous literature have also included different covariates in 
their analyses, and this may have had an influence on the lack of replication in the current 
GWAS.252,334 For example, the NAFLD risk variant TM6SF2 rs58542926 was not 
significantly associated with NAFLD in the GWAS in GoDARTS, but was when run in an 
unadjusted model. (1.13(1.01 - 1.26), p = 0.035) These factors, as well as differences in 
phenotype, data collection, cohort, ethnicity and genotyping platform, can make the 
interpretation of negative results in GWAS analyses challenging. 
In the DMDSC cohort, a number of known NAFLD variants were associated with NAFLD. 
PNPLA3 rs738409 was found to be genome wide significantly associated with NAFLD, 
though ERLIN1 variants were not tested in this analysis as they were excluded during the QC 
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process. The NCAN variant rs2228603 was associated with NAFLD with an OR = 1.21. 
NCAN is involved in cell adhesion and migration in the nervous system, which is increasingly 
thought to play a role in metabolism.335 This variant has been reported to increase NAFLD 
risk in a number of studies primarily among Europeans.335,336 A study in a Han Chinese study 
failed to replicate this finding.330 A study in an Indian population found associations between 
this variant and ALT levels, as well as NAFLD although this was not adjusted for multiple 
testing.100 The current study confirms the association with ALT levels, and suggests further 
that there may be an association with NAFLD. 
A number of known NAFLD variants were nominally associated with FLG in the DMDSC 
cohort. PNPLA3 rs734409 was associated with increased FLG, with a β estimate of 0.0663. 
Though the effect size was modest, the same direction of effect for this variant on NAFLD 
and related phenotypes is present. 
TM6SF2 rs58542926 was significantly associated with increased FLG, with a β of 0.141. 
TM6SF2 (Transmembrane 6 Superfamily Member 2) is a key regulator of liver fat 
metabolism.337 This variant has been linked with NAFLD and NAFLD progression to NASH 
in a number of studies.191,338,339 The NCAN variant rs2228603 was also associated with 
increased FLG in the current study. 
In the meta-analysis of NAFLD between DMDSC and GoDARTS data, other than the 
genome wide significant variants in PNPLA3 and ERLIN1, none of the tested variants 
reached nominal significance.  
4.8.7 Limitations and Comparability of Results 
The definition of NAFLD in GoDARTS and DMDSC may be a weakness of the current 
study. This is discussed in depth in a previous chapter of this thesis outlining the NAFLD 
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definition. Despite some patients presenting with NAFLD without raised ALTs, we 
demonstrated that the NAFLD definition in GoDARTS is sensitive and reliable.340 
The Fatty Liver Grade phenotype in the DMDSC cohort was based on abdominal ultrasound 
scans, a non-invasive and accurate method of diagnosis.196,341 It has been shown that grading 
of steatosis level can predict the histologic severity of liver disease with some accuracy, but 
intra-observer variability can affect the reliability of this phenotype.342 This issue is apparent 
in all measures which require assessment from an observer, and are not fully quantitative. It 
was shown in an earlier chapter that the FLG phenotype correlated well with ALT, as well as 
other known metabolic and anthropomorphic features such as HbA1c, BMI and Waist. In the 
analysis of known NAFLD variants, SNPs from PNPLA3, NCAN and TM6SF2 were 
nominally associated with FLG, which is further validation of the accuracy of this phenotype. 
The NAFLD phenotype based on raised ALT levels in the DMDSC cohort was less specific 
than the NAFLD phenotype in GoDARTS due to the unavailability of certain data. This 
NAFLD phenotype is developed and discussed in depth in a previous chapter, along with 
some of its limitations.  In DMDSC, data about alcohol intake is unavailable, which increases 
risk of alcoholic liver disease (ALD) cases being classified as NAFLD. In GoDARTS, access 
to EHRs for enrolled participants allowed the exclusion of other causes of liver disease, such 
as immunological or viral insults. This was not possible in the DMDSC cohort, meaning that 
the NAFLD and FLG phenotypes likely included patients with non-NAFLD related liver 
disease as cases. 
Comparison of results may yield insights about the drivers of NAFLD in each population. 
However, the GWAS studies run in the GoDARTS and DMDSC cohorts have a number of 
differences which make the direct comparison of results challenging. Differences in the data 
availability and source mean that comparing the variants discovered by GWAS between each 
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cohort is not a reliable way of determining differences in which variants affect NAFLD in 
each cohort. 
There were large inconsistencies in the amount of data available for individuals in each 
cohort. In the GoDARTS cohort EHRs from the NHS were used as the source of data. This 
gave us access to longitudinal measurements for ALT, allowing a NAFLD definition with 
increased specificity and sensitivity. The DMDSC data had ALT measurements from clinic 
visits, and the NAFLD definition was based on a single measurement taken at the beginning 
of the study period. The heterogeneity between these phenotypes could cause differences in 
the variants which are found to be significant by the GWAS, which reduces the validity of 
direct comparison. 
Related to the differences in the data available, is the source of data and way in which it was 
collected. These were longitudinal datasets and contained many years’ worth of 
measurements for each patient, pre and post study commencement. The DMDSC data on the 
other hand was from EHRs from private clinic visits. Individuals had measurements taken on 
their first and subsequent visits to the clinics, most of which were at time of T2DM diagnosis. 
This disparity in the way the data was collected could have affected the NAFLD phenotype 
and therefore the results of the GWAS. 
The GoDARTS cohort comprises both T2DM patients and healthy controls whereas the 
DMDSC cohort is solely individuals with T2DM. This is another factor which may impact 
the prevalence and presentation of NAFLD in the cohort under analysis, thus altering results 
and inferences drawn from them.  
The analysis of known NAFLD variants in the GWAS results had some issues which may 
have caused many of the non-significant results for each SNP. A number of these issues are 
119 
 
discussed above some of these issues are discussed above, and outline why interpretation of 
negative results from GWAS can have limited usefulness due to these factors. 
 
4.9 Conclusion 
A number of genetic loci which influence NAFLD risk were found in GWAS analyses. 
PNPLA3 rs738409 was a significant risk factor for NAFLD in both the Scottish and Indian 
cohorts, with similar effect size and similar minor allele frequency. This demonstrates that 
both populations share a common genetic risk factor, and that the NAFLD seen in Scotland 
and India is in many ways the same. This combined with previous research demonstrate that 
PNPLA3 rs738409 is a key NAFLD risk variant in populations across the world. The 
ERLIN1 locus around the missense variant rs10883447 was also associated with increased 
NAFLD risk in the Scottish population, but not the Indian population. Differences in 
phenotype, as well as lack of statistical power are likely to have contributed to this difference 
between cohorts. 
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5 GLP1R, GCG and GCGR Genes and NAFLD 
5.1 Abstract 
Dual agonist medications for glucagon-like peptide-1 receptor/glucagon receptor (GLP-
1R/GCGR) have shown promising results in treatment of obesity and type 2 diabetes mellitus 
(T2DM). Given the overlap in pathophysiology and epidemiology of these conditions and 
non-alcoholic fatty liver disease (NAFLD), dual agonists are being considered for treatment 
of NAFLD. The aim of this study was to investigate the effects of GLP1R, GCG and GCGR 
genetic variants on NAFLD rate. 
Analyses for this cohort study were conducted in the GoDARTS and SHARE cohorts, two 
Scottish cohorts of 13,695, and 62,438 individuals respectively. Meta-analysis of these 
cohorts was also conducted. Further replication was conducted in the DMDSC cohort, 
consisting of 3,154 South Indian individuals with T2DM. The NAFLD phenotype was 
defined as at least 2 elevated ALT measurements recorded at least 3 months apart. Common 
variants (>1% MAF) from GLP1R, GCG and GCGR were selected for analysis, some of 
which are known to affect T2DM and metabolic factors. 
Two variants from GLP1R were associated with NAFLD rate. In the meta-analysis, 
rs6923761 recessively increased NAFLD risk in a model adjusted for sex, age and T2DM. 
(OR = 1.15(1.01 - 1.31), p = 0.032) Another missense variant in GLP1R, rs1042044, 
decreased NAFLD risk. (OR = 0.88, p = 0.018) The GCGR variant rs140065949 was 
associated with increased NAFLD. (OR = 1.40, p = 0.029) A number of statistically 
significant gene/gene interactions were found. 
These findings demonstrate that GLP1R and GCGR variants are associated with NAFLD risk. 
This combined with previous literature on these SNPs support the notion that co-agonism for 
GLP1R and GCGR may be effective treating NAFLD. 
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5.2 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
globally, affecting around 25.2% of adults worldwide.1 It is a prevalent comorbidity of 
obesity, and frequently occurs in individuals with and type 2 diabetes (T2DM).343 There is 
currently no specific pharmacological intervention recommended for NAFLD. 
Dual agonist medications for glucagon-like peptide-1 receptor/glucagon receptor (GLP-
1R/GCGR) have had promising results in treatment of obesity and T2DM.344 GLP-1 is an 
incretin which increases secretion of insulin, lowering blood glucose levels.345 Glucagon, 
conversely, raises blood glucose levels; stimulating the liver to convert glycogen to glucose 
and release this into the bloodstream.346 Despite this, glucagon has thermogenic and catabolic 
effects which are desirable for the treatment of obesity and diabetes, and is therefore a 
promising treatment target.344 Another desirable effect of glucagon is the reduction in food 
intake. 
These effects are combined into GLP1/GCGR co-agonists. These upregulate GLP1 and GCG 
receptors, and have been shown to reduce obesity, and enhance insulin secretion.347 Although 
some of the effects of these receptors are diametrically opposed with regards to blood glucose 
levels, it appears that the increased   activation counteracts the undesirable gluconeogenesis 
and glycogenolysis stimulating effects of glucagon.344 
344 The effects of increased GCGR and GLP1R activation, as well as the effects of 
GLP1R/GCGR coagonists are shown in figure 5-1 below. 
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Given the overlap in pathophysiology between obesity and T2DM, and NAFLD, dual agonist 
medications for GLP1R and GCGR have been investigated as a potential therapy for 
NAFLD. Preliminary studies have shown a reduction in hepatic steatosis and inflammation as 
a result of GLP1R/GCGR co-agonists.97 It is thought that the action of GLP1R and GCGR 
together will decrease the amount of triglycerides stored in the liver, and improve hepatic 
insulin resistance. 
Investigation of genetic variants associated with the mechanisms by which diseases and 
medications work can reveal important information. This can be used to develop medications, 
and to stratify individuals. GLP1R and GCGR each have a gene which codes for them.348,349 
Variations in these can affect the function of the receptors; for example rare defects in GCGR 
can cause non-insulin-dependent diabetes mellitus.349 Variants in GLP1R have been found to 
influence drug response.350 
The aim of this study was to investigate the effects of common genetic variants in GLP1R, 
GCG and GCGR on NAFLD. This will aid the investigation into GLP1R/GCGR co-agonists 
Figure 5-1Effects of increased GLP1R and GCGR activation, and role of GLP1R/GCGR coagonists. 
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for NAFLD, and help achieve personalised medicine through genetic stratification for 
individuals if these co-agonists become a mainstream therapy for NAFLD. 
5.3 Methods 
The GoDARTS study was used as a discovery cohort.187 This is a T2DM case-control cohort 
with electronic health record data available for the 18,306 participants and genetic data 
available for many of these. Of these individuals, 10,021 had at least one of the variants of 
interest genotyped and were suitable for analysis once exclusions for alternate causes of liver 
disease were made. 
The analyses were also conducted in the SHARE cohort for validation, and meta-analysis of 
results.188 This cohort comprised 73,024 individuals, 3,068 of whom had been genotyped and 
were suitable analysis. 
Supplementary validation was conducted T2DM cohort from Dr Mohan's Diabetes 
Specialities Centre (DMDSC).195 This cohort comprised 75,952 individuals who were 
patients of the DMDSC and had T2DM. These individuals were predominantly South Asian. 
From this cohort, there were 3,154 individuals who had been genotyped and had sufficient 
data available for analysis. 
5.3.1 Measures 
The main outcome measure of this study was NAFLD. This phenotype was defined by raised 
alanine transaminase levels, a simple and reliable biomarker for NAFLD.31,158 Any serum 
ALT measurement greater than 30 U/L for men and greater than 19 U/L per litre for women 
was considered elevated, based on the values suggested by Prati et al.180 
In the DMDSC cohort, longitudinal measures of ALT levels were not available, so a single 
raised ALT measure was used to define NAFLD. This was measured at patients’ first visit to 
the DMDSC T2DM clinic. 
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5.3.2 Exclusions 
To ensure the specificity of the NAFLD definition individuals with features of alternate 
causes of liver disease were excluded. any positive serological tests for anti-smooth muscle 
antibody, antinuclear antibodies or anti-mitochondrial antibodies,  any positive serology for 
hepatitis B surface antigen or hepatitis C antibody, or mention of cause of liver disease in 
medical records. Individuals with alcohol dependence or any documentation of alcoholic liver 
disease in their EHRs were excluded. In addition, individuals who self-reported drinking 
more than 20g a day for women and more than 30g a day for men were excluded. 
In the DMDSC cohort, medical record data which could be used to rule out those with 
alterative causes of liver disease was not available. A data field noting whether the patient 
consumed alcohol ever or never was available, so this variable was included as a covariate in 
all models. 
5.3.3 Genetic Variants Analysed 
The genetic variants analysed in this study are shown in table 18. Global MAFs were taken 
from gnomAD v2.1.1.351 
Table 19- Frequencies and functions of GLP1R and GCG, GCGR SNPs analysed in the current study 
Gene SNP GoDARTS 
MAF 
SHARE 
MAF 
Global 
MAF 
Effect Description Reference 
Allele 
Alternate 
Allele 
GLP1R rs6923761 0.359 0.349 0.229 p.Gly168Ser Missense G A 
GLP1R rs1042044 0.582 0.578 0.565 p.Leu260Phe Missense A C 
GLP1R rs10305420 0.407 0.391 0.307 p.Pro7Leu Missense C T 
GCGR rs140065949 0.017 0.027 0.027 
 
Intron C T 
GCG rs4664447 0.022 0.021 0.036 
 
Intron T C 
GCGR rs28454947 0.161 0.196 0.175 p.Gly229Gly Synonymous T C 
GCGR rs5386 0.090 0.095 0.070 p.Ala155Ala Synonymous C G 
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 These were three common missense variants in GLP1R, plus three common variants in 
GCGR and one in GCG. Variants with a minor allele frequency MAF of over 1% were 
selected. Three of these variants (rs28454947, rs5384, rs2272030) were found to be in LD 
(R2 > 0.9), therefore only the most common - rs28454947 - was analysed from these. The 
correlation matrix of the SNPs in GLP1R, GCG and GCGR is shown in figure 5-1 below. 
 
5.3.4 Analysis Methods 
The association between the genetic variants of interest and NAFLD was assessed in a 
logistic regression model. They were tested in a number of unadjusted and unadjusted 
models. The adjusted models contained age, sex, and T2DM as covariates. A secondary 
adjusted model included these variables, plus BMI also. A large number of individuals in the 
SHARE cohort were missing BMI data, therefore models with and without BMI as a 
covariate were used. These models were run in GoDARTS, SHARE and then an individual 
participant data (IPD) meta-analysis of GoDARTS and SHARE cohorts.  
Figure 5-2 Correlation Matrix of Candidates SNPs 
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There were several sources of heterogeneity between the Scottish cohorts, and the DMDSC 
cohort, which led to this cohort not being included in the meta-analysis. The main difference 
was the NAFLD phenotype, which was based on a single ALT measurement rather than 2 
which were 3 months apart. Other differences in the data availability and the way in which it 
was collected mean that it was not suitable for meta analysis. 
5.4 Results 
5.4.1 Single SNP Analyses 
The effects of each SNP on NAFLD rate were analysed individually in a series of unadjusted 
and unadjusted models. The results of these analyses are shown in tables 1, 2, and 3 for 
GoDARTS, SHARE and the meta-analysis respectively. 
5.4.1.1 GoDARTS 
A number of variants had significant effects on NAFLD in each cohort respectively as well as 
the meta-analysis. In GoDARTS, the GLP1R SNP rs6923761 was close to significance in the 
unadjusted and adjusted models, with an OR of 1.14 in each. (p = 00.058 – 0.085) In a 
dominant model with adjustment for age, sex and T2DM, the SNP rs1042044 had a 
significant association with NAFLD. (OR = 0.88(0.78 - 0.99), p = 0.037) In GCGR, the SNP 
rs28454947 was associated with NAFLD in the adjusted models, with an OR of 1.14(1.01 - 
1.28) in the model adjusted for sex, age, T2DM and BMI. (p = 0.037) Full results are shown 
in table 19. 
Table 20 - The associations between variants in GLP1R, GCG and GCGR, and NAFLD in the GoDARTS cohort 
Variant Unadjusted Adjusted for age, sex, and T2DM Adjusted for age, sex, 
T2DM and BMI 
Model 
rs6923761 
GLP1R 
OR = 1.14 , 
( 0.998 - 1.3 ), 
p = 0.0538 
OR = 1.14, 
( 0.983 - 1.32 ), 
p = 0.0854 
OR = 1.14 , 
( 0.983 - 1.32 ), 
p = 0.0833 
Recessive 
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rs1042044 
GLP1R 
OR = 0.943 , 
( 0.849 - 1.05 ) , 
p = 0.273 
OR = 0.886 , 
( 0.788 - 0.997 ) , 
p = 0.0447 
OR = 0.88 , 
( 0.781 - 0.992 ) , 
p = 0.0367 
Recessive 
rs10305420 
GLP1R 
OR = 1.04 , 
( 0.961 - 1.12 ), 
p = 0.356 
OR = 1.05 , 
( 0.965 - 1.14 ), 
p = 0.268 
OR = 1.06 , 
( 0.976 - 1.15 ), 
p = 0.166 
Additive 
rs140065949 
GCGR 
OR = 1.16 , 
( 0.864 - 1.59 ), 
p = 0.329 
OR = 1.18 , 
( 0.857 - 1.65 ), 
p = 0.32 
OR = 1.22 , 
( 0.885 - 1.71 ), 
p = 0.23 
Additive 
rs4664447 
GCG 
OR = 1.3 , 
( 0.937 - 1.81 ), 
p = 0.124 
OR = 1.31 , 
( 0.916 - 1.89 ), 
p = 0.147 
OR = 1.34 , 
( 0.931 - 1.94 ), 
p = 0.121 
Dominant 
rs28454947 
GCGR 
OR = 0.897 , 
( 0.615 - 1.33 ), 
p = 0.579 
OR = 0.734 , 
( 0.491 - 1.11), 
p = 0.138 
OR = 0.731 , 
( 0.484 - 1.12), 
p = 0.141 
Recessive 
rs5386 
GCGR 
OR = 1.49, 
( 0.731 - 3.36 ), 
p = 0.296 
OR = 1.27 , 
( 0.587 - 3 ), 
p = 0.566 
OR = 1.29 , 
( 0.592 - 3.08 ), 
p = 0.539 
Recessive 
 
5.4.1.2 SHARE 
In SHARE, the GLP1R variant rs10305420 was associated with NAFLD in a model adjusted 
for sex, age and T2DM. (OR = 1.18(1.02 - 1.37), p = 0.025) The SNP rs6923761 was close to 
significance in the same model, with the same direction of effect as was found in GoDARTS. 
(OR = 1.37, (1.0 - 1.9), p = 0.059) The results of all analyses are shown in table 20. 
Table 21 - Table 20 - Associations between variants in GLP1R, GCG and GCGR, and NAFLD in the SHARE cohort 
Variant Unadjusted Adjusted for age, sex, and 
T2DM 
Adjusted for age, sex, T2DM 
and BMI 
Model 
rs6923761 
GLP1R 
OR = 1.38 , 
( 1.03 - 1.88 ), 
p = 0.0362 
OR = 1.37 , 
( 0.996 - 1.9 ), 
p = 0.0585 
OR = 1.19 , 
( 0.749 - 1.96 ), 
p = 0.485 
Recessive 
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rs1042044 
GLP1R 
OR = 0.973 , 
( 0.762 - 1.23 ) , 
p = 0.824 
OR = 0.892 , 
( 0.685 - 1.15 ) , 
p = 0.39 
OR = 1.01 , 
( 0.657 - 1.5 ) , 
p = 0.977 
Recessive 
rs10305420 
GLP1R 
OR = 1.14 , 
( 0.999 - 1.31 ), 
p = 0.0532 
OR = 1.18 , 
( 1.02 - 1.37 ), 
p = 0.025 
OR = 1.07 , 
( 0.85 - 1.34 ), 
p = 0.586 
Additive 
rs140065949 
GCGR 
OR = 1.04 , 
( 0.703 - 1.58 ), 
p = 0.857 
OR = 1.14 , 
( 0.744 - 1.79 ), 
p = 0.563 
OR = 1.94 , 
( 0.85 - 5.62 ), 
p = 0.159 
Additive 
rs4664447 
GCG 
OR = 0.715 , 
( 0.479 - 1.1 ), 
p = 0.112 
OR = 0.643 , 
( 0.413 - 1.03 ), 
p = 0.0566 
OR = 0.954 , 
( 0.484 - 2.11 ), 
p = 0.899 
Dominant 
rs28454947 
GCGR 
OR = 0.76 , 
( 0.51 - 1.16 ), 
p = 0.191 
OR = 0.693 , 
( 0.447 - 1.1 ), 
p = 0.108 
OR = 0.823 , 
( 0.425 - 1.76 ), 
p = 0.587 
Recessive 
rs5386 
GCGR 
OR = 6.14 , 
( 1.3 - 110 ), 
p = 0.075 
OR = 5.01 , 
( 1.01 - 91.2 ), 
p = 0.12 
OR = 2.09 , 
( 0.411 - 38.2 ), 
p = 0.48 
Recessive 
 
5.4.1.3 Meta-Analysis 
The IPD meta-analysis of GoDARTS and SHARE revealed a number of SNPs which were 
significantly associated with NAFLD. The GLP1R SNP rs6923761 was associated with 
NAFLD in the model adjusted for sex, age and T2DM. (OR = 1.15(1.01 - 1.31), p = 0.032) In 
the same model, rs1042044 was also associated with NAFLD. (OR = 0.88, (0.794 - 0.98), p = 
0.018) 
The GCGR variant rs140065949 was associated with increased NAFLD risk in adjusted 
models, with an OR of 1.40(1.04 - 1.89) in a model adjusted for sex, age, T2DM and BMI. (p 
= 0.029) The variant rs5386 was associated with increased NAFLD risk in an unadjusted 
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model. (OR = 2.06, (1.10 - 4.30), p = 0.036) This was close to significance in the model 
adjusted for age, sex and T2DM. All results are shown in table 4. 
Table 22 - Associations between variants in GLP1R, GCG and GCGR, and NAFLD in the IPD meta-analysis of the 
GoDARTS and SHARE cohorts 
Variant Unadjusted Adjusted for age, sex, and T2DM Adjusted for age, sex, T2DM 
and BMI 
Model 
rs6923761 
GLP1R 
OR = 1.16 , 
( 1.03 - 1.3 ), 
p = 0.0146 
OR = 1.15 , 
( 1.01 - 1.31 ), 
p = 0.032 
OR = 1.14 , 
( 0.989 - 1.31 ), 
p = 0.0722 
Recessive 
rs1042044 
GLP1R 
OR = 0.944 , 
( 0.86 - 1.04 ) , 
p = 0.232 
OR = 0.881 , 
( 0.794 - 0.978 ) , 
p = 0.0176 
OR = 0.883 , 
( 0.788 - 0.989 ) , 
p = 0.031 
Recessive 
rs10305420 
GLP1R 
OR = 1.05 , 
( 0.983 - 1.12 ), 
p = 0.145 
OR = 1.05 , 
( 0.984 - 1.13 ), 
p = 0.134 
OR = 1.04 , 
( 0.966 - 1.12 ), 
p = 0.291 
Additive 
rs140065949 
GCGR 
OR = 1.21 , 
( 0.956 - 1.55 ), 
p = 0.12 
OR = 1.29 , 
( 1.01 - 1.67 ), 
p = 0.0483 
OR = 1.4 , 
( 1.04 - 1.89 ), 
p = 0.0285 
Additive 
rs4664447 
GCG 
OR = 1.04 , 
( 0.808 - 1.35 ), 
p = 0.763 
OR = 1.01 , 
( 0.772 - 1.34 ), 
p = 0.931 
OR = 1.26 , 
( 0.915 - 1.75 ), 
p = 0.166 
Dominant 
rs28454947 
GCGR 
OR = 0.928 , 
( 0.707 - 1.23 ), 
p = 0.597 
OR = 0.873 , 
( 0.654 - 1.18 ), 
p = 0.363 
OR = 0.901 , 
( 0.643 - 1.28 ), 
p = 0.55 
Recessive 
rs5386 
GCGR 
OR = 2.06 , 
( 1.1 - 4.3 ), 
p = 0.0361 
OR = 1.92 , 
( 0.993 - 4.1 ), 
p = 0.0685 
OR = 1.59 , 
( 0.792 - 3.49 ), 
p = 0.218 
Recessive 
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5.4.2 Analysis of Multiple SNPs 
5.4.2.1 GLP1R Missense Variants 
Further meta-analysis was conducted to stratify individuals into groups based on the GLP1R, 
GCG and GCGR variants that were informative about NAFLD risk. In the meta-analysis, the 
GLP1R missense variants rs6923761 and rs1042044 were in moderate linkage disequilibrium 
(LD), with a Pearson correlation of 0.62. Individuals were stratified by those who carried a 
NAFLD risk genotype in either/both of rs6923761 and rs1042044, and those who had a risk 
genotype for neither. The risk genotype for rs6923761 homozygosity for the mutant allele. 
(AA) The risk genotype in rs1042044 was homozygosity for the wild type allele. (AA) 
Individuals with at least one of these risk genotypes are henceforth referred to as being in the 
GLP1R risk group, or having the GLP1R risk genotype. 
In GoDARTS and SHARE combined, there were 3,734 individuals with risk genotypes for 
either of rs6923761 or rs1042044, and 8,002 individuals who were without risk genotypes for 
either variants. The individuals with a GLP1R risk genotype for at least one of these genes 
had increased risk of NAFLD in the model adjusted for sex, age, T2DM and BMI. (OR = 
1.15(1.04 - 1.27), p = 0.0055)  The results for each model are shown in table 22, where the 
effect of having at least one of these risk variants versus carrying none of the risk genotypes 
is shown. 
Table 23 - Association between the GLP1R risk genotype and increased NAFLD risk 
Cohort Unadjusted Adjusted for age, sex, and T2DM Adjusted for age, sex, T2DM 
and BMI 
GoDARTS OR = 0.997 , 
( 0.91 - 1.09 ) , 
p = 0.947 
OR = 1.15 , 
( 1.04 - 1.27 ) , 
p = 0.00747 
OR = 1.16 , 
( 1.05 - 1.29 ) , 
p = 0.00509 
SHARE OR = 1.19 , 
( 0.975 - 1.47 ) , 
OR = 1.26 , 
( 1.01 - 1.58 ) , 
OR = 1.09 , 
( 0.778 - 1.54 ) , 
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p = 0.0904 p = 0.0389 p = 0.622 
Meta-
Analysis 
OR = 1.01 , 
( 0.927 - 1.09 ) , 
p = 0.885 
OR = 1.12 , 
( 1.02 - 1.22 ) , 
p = 0.0138 
OR = 1.15 , 
( 1.04 - 1.27 ) , 
p = 0.00553 
 
5.4.2.2 GLP1R, GCG and GCGR Variants – Combinations and Interactions 
In GoDARTS, individuals who carried risk genotypes for both GLP1R and GCGR were at the 
highest risk of NAFLD. They had higher NAFLD risk compared to individuals with no risk 
variants in GLP1R or GCGR, (OR = 1.96(1.23- 3.24), p = 0.0066) and those who carried a 
risk variant in just one of these genes. (OR = 1.72(1.08 - 2.86), p = 0.029) 
The GCGR variant rs140065949 showed different effects in individuals with and without the 
GLP1R risk genotype. This is shown in table 6.  
Table 24 - The effects of GCGR variant rs140065949 on NAFLD rate in GoDARTS, stratified by the presence of the GLP1R 
risk genotype 
GLP1R Risk 
Group 
Unadjusted Adjusted for age, sex, and T2DM Adjusted for age, sex, T2DM and 
BMI 
Non-Risk OR = 1.1 , 
(0.83 - 1.46), 
p = 0.529 
OR = 1.14 , 
(0.849 - 1.55), 
p = 0.391 
OR = 1.32 , 
( 0.934 - 1.88 ), 
p = 0.125 
Risk OR = 1.52, 
(0.979 - 2.47), 
p = 0.0735 
OR = 1.71, 
( 1.07 - 2.83 ), 
p = 0.0304 
OR = 1.65, 
( 0.952 - 3.05 ), 
p = 0.0887 
 
This GCGR variant was associated with increased NAFLD in those who carried the GLP1R 
risk genotype, but showed no association in non-carriers. 
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The interactions between the GLP1R, GCG and GCGR variants were tested for any 
association with NAFLD in a model adjusted for age, sex, T2DM and BMI. The results are 
shown in table 24. 
Table 25 - Association between NAFLD and the statistical interaction of the GLP1R, and GCG and GCGR variants in 
GoDARTS 
 
rs6923761 rs1042044 
rs140065949 OR = 1.28, 
(0.701 - 2.39), 
p = 0.422 
OR = 1.93, 
(0.791 - 5.54), 
p = 0.179 
rs4664447 OR = 0.551 , 
(0.288 - 1.06), 
p = 0.0728 
OR = 0.32, 
( 0.149 - 0.701), 
p = 0.00377 
rs28454947 OR = 0.977, 
(0.491 - 1.96), 
p = 0.947 
OR = 0.426, 
(0.195 - 0.947), 
p = 0.0337 
rs5386 OR = 0.316, 
(0.0661 - 1.39), 
p = 0.131 
OR = 0.23, 
(0.0465 - 1.33), 
p = 0.0789 
 
 The rs1042044 AA genotype had an interaction with both rs4664447and rs28454947 that 
had a significant effect on NAFLD rate, with OR’s of 0.32 and 0.43 respectively. 
5.4.2.3 Supplementary Analysis in DMDSC Cohort 
The GLP1R variant rs6923761 was additively associated with increased NAFLD risk in a 
model adjusted for age, sex, BMI and alcohol.(OR = 1.14(1.01 - 1.28), p =  0.033) The other 
GLP1R variant for which data was available (rs1042044) showed no significant association 
with NAFLD, nor did the GCGR variants rs5386 or rs140065949. No interactions between 
variants were found. 
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5.5 Discussion 
The findings of the current analysis are that genetic variants in GLP1R and GCGR have 
associations with NAFLD rate. Two missense variants in GLP1R were found to be associated 
with NAFLD in the meta-analysis; rs6923761 and rs1042044. In GCGR, the intronic variant 
rs140065949 was associated with increased NAFLD in adjusted models, and the SNP rs5386 
associated with NAFLD in an unadjusted model. GLP1R rs6923761 was associated with 
increased NAFLD risk in the DMDSC cohort also. 
The wild type AA genotype homozygotes of GLP1R rs1042044 were at higher risk of 
NAFLD in our meta-analysis. The effect was also statistically significant in GoDARTS, and 
had a similar effect size although not significant in SHARE. A small number of studies have 
investigated this variant previously, with Sheikh et al. finding higher morning cortisol levels 
in children carrying the variant.352 This SNP was in partial LD (0.62) with rs6923761, and 
this association could represent the same signal. 
Homozygous carriers of the rs6923761 variant (AA genotype) were at increased NAFLD risk 
in the meta–analysis. Similar effect sizes, with p-values close to significance were also seen 
in GoDARTS and SHARE. In the DMDSC cohort, this variant was additively associated with 
NAFLD.  
Previous literature on GLP1R rs6923761 has investigated a number of parameters associated 
with obesity, metabolism and T2DM. Sathananthan et al. found that the rs6923761 minor 
allele (A) decreased responsiveness to infused GLP-1.350 They found this variant to be 
associated with lower beta-cell responsiveness, as individuals with at least one copy of the 
minor allele excreted significantly less insulin. Other studies have found reduced insulin in 
minor allele carriers also, as well as lower basal levels of GLP-1.353,354 Another study found 
that rs6923761 minor allele homozygotes has poorer response to gliptins for HbA1c 
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reduction.355 Based on these findings, rs6923761 appears to be a loss of function variant for 
GLP1R activity. In line with previous literature, our findings suggests that the rs6923761 
variant decreases the function of the GLP-1 receptor, and thereby increases NAFLD risk. 
GLP-1 has several physiological functions which are relevant to NAFLD.356 GLP-1 promotes 
glucose dependent insulin secretion, and is therefore a key factor in blood glucose 
homeostasis. It also decreases hepatic lipogenesis and increases fatty acid oxidation in the 
liver, as well as insulin sensitivity.357,358 Research into whether GLP-1 could be an effective 
treatment has been undertaken. Infused GLP-1 has been found to prevent NAFLD in mice.359  
Despite these effects of GLP-1, the administration of GLP-1 may not be an effective therapy 
for NAFLD. GLP-1 has a half-life of 90 seconds in the body, making it unviable as a drug in 
that form.360 Further to this, NAFLD patients have been found to have normal GLP-1 levels, 
despite decreased incretin effect.361 This may be due to the GLP-1 resistance which has been 
found in NAFLD.362 GLP-1 receptors have been found to be downregulated in individuals 
with NAFLD, causing this resistance and lowering the effect of GLP-1.363 DPP4, which 
deactivates the GLP-1 enzyme, has also been observed to be higher in patients with NAFLD, 
further decreasing the effectiveness of GLP-1.364  
To achieve the desired increase in incretin effect, agonism of the GLP-1 receptor has been 
targeted with a number of drugs.365 The increased effect of GLP-1 associated with GLP1R 
agonists increases insulin sensitivity and production.102 GLP1R agonists have shown positive 
effects on NAFLD  in a number of studies, with a study in mice showed that GLP1R agonists 
reduced oxidative stress as well as hepatic fat.359,366 The improvement in glycaemia seen with 
the administration of GLP1R agonists correlated with reduction in liver fat observed.366  
Further to this, GLP1R agonism exhibited anti-inflammatory effects in the liver.367  This is 
via the downregulation pro-inflammatory cytokines and transcription factors.368 Decreasing 
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hepatic steatosis and inflammation are key factors in the treatment of NAFLD and averting 
serious liver damage associated with progressive stages. 
The current study found that patients with loss of function variants in GLP1R had increased 
NAFLD risk, which is consistent with previous research suggesting agonism of GLP-1R 
should be beneficial for NAFLD. Patients with different GLP1R genotypes may have 
different response to GLP1RAs. These findings may be used for applied personalised 
medicine in those with NAFLD, matching patients to the drugs and doses which would be the 
most effective and safe. 
Significant associations between NAFLD and genetic variants in GCGR; the gene which 
encodes the receptor for glucagon; were found. We found the GCGR variant rs140065949 
was associated with increased NAFLD risk in the meta-analysis, in a model adjusted for sex, 
age, T2DM and BMI. This SNP is intronic and doesn’t appear in any previously published 
studies. This is also true of the synonymous variant rs5386 which associated with increased 
NAFLD in an unadjusted model. In a recessive model, rs5386 was close to significance in the 
model adjusted for sex, age, and T2DM in the meta-analysis, and also close to significance in 
the unadjusted analysis in SHARE. The intronic GCG variant rs4664447 had a significant 
interaction with rs1042044 in GLP1R. In carriers of the rs1042044 C allele (non-NAFLD risk 
allele), rs4664447 was associated with increased NAFLD risk. However, in those who were 
homozygous for the wild type rs1042044 A allele, rs4664447 was associated with an almost 
50% reduction in NAFLD risk. A previous study found variation in rs4664447 was associated 
with decreased insulin, GLP1R and glucagon levels, although this was for the T>G variation 
unlike the T>C variation analysed in the current study. 
Glucagon is a hormone which primarily acts to raise glucose and fatty acid concentrations in 
the bloodstream.346 It has a number of significant effects in the liver. Glucagon stimulates the 
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glycogenosis in the liver, where stored glycogen is released into the bloodstream in the form 
of glucose.369 It also stimulates gluconeogenesis and lipolysis in the liver, as well as 
decreasing rate of fatty acid synthesis.  
The findings of previous research combined with the current study suggest a role of the 
GCGR gene in NAFLD, and warrant further research into the functions of these variants and 
their relationship with NAFLD. NAFLD has been linked to GCGR signalling. Kazda et al. 
found that GCGR antagonism increases hepatic steatosis.370 Nason et al. found that reduced 
GCGR signalling increases fatty acid oxidation in the liver, and reduced liver triglyceride 
levels.371 It has also been shown that a high fat diet reduces glucagon receptor content in rat 
livers. Glucagon resistance has been suggested as a cause of lowered effect of GCG in the 
liver for glucose production. Despite several effects which are associated with poor 
glycaemic control, including high blood glucose and hyperinsulinemia, agonism of the 
glucagon receptor has been studied as a therapy for various metabolic conditions.372,373 These 
include thermogenic and catabolic effects.371 GCGR is associated with increased energy 
expenditure and reduced food intake.374 This effect has been combined with GLP1R agonism, 
in a number of GLP1R/GCGR co-agonist drugs.375 
GLP1R and GCGR co-agonists are a class of drug which has been investigated as a therapy 
for obesity and T2DM. Farooq et al. showed enhanced insulin as a results of GLP1R/GCGR 
co-agonism, and obesity reducing effects have been shown in rodents.102,103 They can also 
lower cholesterol and increase insulin sensitivity.347 Elvert et al. found mixed results in crab-
eating macaque monkeys, as GLP1R/GCGR co-agonism increased weight loss and insulin 
secretion, but was associated with lower glycaemic control long term.376 These effects make 
GLP1R/GCGR co-agonists worthy of further investigation for treatment of number of obesity 
related conditions. 
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Co-agonism for GLP1R and GCGR has also been investigated as a therapy for NAFLD, and 
shown promising results. Patel et al. found that co-agonism for these receptors reduced 
hepatic steatosis as well as lipotoxicity.97 Similar findings have also been made in mice.375 As 
well as simple steatosis, GLP1R/GCGR co-agonists have been found to improve NASH and 
fibrosis.101 Kannt et al. found that a GLP1R/GCGR co-agonist reduced the histological 
severity of NASH.377 As well as their individual effects, GLP-1 and glucagon are linked as 
GLP-1 inhibits glucagon secretion when blood glucose levels are raised.361 
The results of our study are consistent with this, as we show that loss of function of GLP1R 
increases risk of NAFLD, and therefore it can be extrapolated that upregulation of GLP1R 
will reduce NAFLD. We also showed effects of variants in GCGR, which further advocates a 
beneficial effect of GLP1R and GCGR co-agonism on NAFLD. We found that individuals 
who carried risk variants in both GLP1R and GCGR were at greater risk than those who 
carried no risk variants, or just one risk variant. The GCGR variant rs140065949 had a 
significant effect on NAFLD risk only in those who carried the GLP1R risk genotype. The 
GLP1R variant rs1042044 also had a significant interaction with two GCGR variants, which 
suggests interplay between the pathways associated with these two genes. 
Stratification by genotype may be an effective means of ensuring optimal treatment, should 
GLP1R/GCGR co-agonists become widely used. Individuals with different GLP1R and 
GCGR genotypes may benefit differently or not at all from GLP1R/GCGR co-agonists. With 
the advent of precision medicine, this may help ensure individuals are treated as effectively 
and economically as possible. 
The main goal of this study was to analyse the effects of GLP1R, GCG and GCGR variants 
on NAFLD in two Scottish cohorts. Analysis of these variants in the DMDSC cohort did 
however show that the GLP1R rs6923761 variant has effects on NAFLD in South Asians 
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also. Previous research has shown improvements a number of clinical outcomes including 
HbA1c and ALT levels in an Indian population with a GLP-1R agonist.378 This combined 
with research showing effects of the NAFLD risk variant PNPLA3 rs738409 in European and  
South Indian, as well as a previous chapter in the current thesis showing the same, suggest at 
least some commonality in the genetic risk architecture and disease pathology between 
Caucasian and South Indian individuals.256 
5.5.1 Limitations 
A limitation of the present study is the NAFLD phenotype. This was defined by the presence 
of raised ALT levels. There is evidence of NAFLD in individuals with normal ALT levels in 
some studies, especially in South Asians.379 BMI is also less effective as a predictor of 
NAFLD in South Asian populations.380 However, overall ALT is an effective and practical 
means for defining NAFLD in large populations.381 The longitudinal nature of the data used 
in this study improves the accuracy of the definition also, as does using the ULN’s suggested 
by Prati et al., which are lower than many previously used limits, as this increases the 
sensitivity of the definition.180 The missingness of BMI data for individuals without T2DM in 
SHARE also reduced the cohort size available for analysis, and lowered experimental power. 
The replication of results in the DMDSC cohort has some value, as it shows that the GLP1R 
rs6823761 variant has a significant effect on NAFLD. The power of this analysis is low 
however, with only 3,154 participants, and data for only four out of the seven variants was 
available. 
 The difference in NAFLD phenotype ascertainment between DMDSC and the GoDARTS 
and SHARE cohorts limit the comparability of results. This means that it is not possible to 
determine whether the lack of association between the GLP1R rs1042044 variant and 
NAFLD in DMDSC is due to true differences in the populations, or due to these confounding 
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factors. Compared with GoDARTS and SHARE, the NAFLD phenotype was more likely to 
include patients with non-NAFLD liver insults as cases. This was due to lack of availability 
of data for this. Alcohol was controlled for in this analysis as a binary trait, but there was no 
indication in the data whether individuals consumed harmful amounts of alcohol, likely to 
cause liver disease. Likewise, the data did not have sufficient information to be able to 
exclude individuals with alternate causes of liver disease such as virological or 
immunological insults. 
 
5.6 Conclusion 
We found effects of a number of genetic variants in GLP1R and GCGR on NAFLD. Two 
missense variants in GLP1R were associated with NAFLD rate. There is evidence in previous 
literature that these variants decrease the activity of GLP-1 receptors, supporting the notion 
that GLP-1 receptor agonism may be beneficial for NAFLD. The GCGR variant rs140065949 
was associated with increased NAFLD risk in the adjusted models. This likewise suggests a 
role of GCGR in NAFLD. Individuals who had risk genotypes in both GLP1R and GCGR 
were at greatest NAFLD risk, and the effect of the GCGR variant was only seen in carriers of 
the GLP1R risk genotype. These results combined with previous studies suggest that co-
agonism of GLP1R and GCGR may be an effective therapeutic approach for NAFLD. 
Stratifying individuals by the genetic variants we found to affect NAFLD may aid treatment 
of NAFLD and other obesity related conditions. 
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6 Endothelin Genes and NAFLD 
6.1 Abstract 
Endothelin is a vasoconstrictor which has significant effects in the liver, including 
modulating hepatic glucose output, and increasing risk of non-alcoholic steatohepatitis 
(NASH). Endothelin receptor antagonists (ETRA) have been studied in animal models as a 
potential NASH treatment. The aim of this study was to investigate the role of genetic 
variants which affect endothelin and endothelin receptor expression in NASH. 
Analyses for this cohort study were conducted in the GoDARTS cohort, a Scottish cohort of 
13,695, individuals. Replication was conducted in the SHARE cohort, with 3,068 individuals, 
and in the MDRF cohort with 3,068 genotyped individuals. The primary outcome of the study 
was Non-Alcoholic Steatohepatitis (NASH), which was defined by diagnoses in medical 
records. Genetic variants in EDN1, PHACTR1, EDNRA and EDNRB were selected for 
analysis based on previous literature linking them to endothelin and endothelin receptor 
expression respectively. 
In GoDARTS, three variants in EDNRA were significantly associated with NASH; 
rs17612742 – OR = 1.59(0.99 -4.02), p = 0.04); rs1878406 and rs6841581– OR = 1.81(1.16 – 
2.73), p = 0.006). In SHARE, FIB4 index was significantly associated with the same variants 
in EDNRA; rs6841581 – β= 0.25(0.077 -0.42), p = 4.6x10-3; rs1878406 – β = 0.26(0.087 – 
0.43), p = 3.2x10-3; rs17612742 – β = 0.24(0.075 – 0.41), p = 4.7x10-3. A number of other 
associations between endothelin SNPs and NASH related phenotypes were found. 
Genetic variants which are known to affect endothelin and endothelin receptor expression 
have significant effects on NASH and related phenotypes, including portal hypertension. 
These findings have relevance to research into ETRAs as NASH treatment, and to research 
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into the understanding of the pathogenesis of NASH in general. They may be useful for 
genetic stratification with respect to therapeutic intervention in NASH.  
 
6.2 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
globally. It is estimated to affect around 25.2% of adults worldwide.4,34 It is a prevalent 
comorbidity of obesity, and frequently occurs in individuals type 2 diabetes (T2DM).382 
There is currently no specific pharmacological intervention recommended for NAFLD, 
though a number of drug targets and pathways are currently being investigated, including 
antagonism of endothelin-1. (ET1)  
Endothelin is a vasoconstrictor, which when overexpressed contributes to hypertension, heart 
disease, and a number of other conditions.383,384 Endothelin acts on endothelin receptors, 
which come in two main types; Endothelin receptor A (ETA) and Endothelin receptor B 
(ETB).385 When activated ETA receptors’ main role is vasoconstriction. ETB receptors on the 
other hand have a role in vasodilation, as nitric oxide is released when they are activated.386 
Several genes are associated with the production, reception and action of endothelin. 
PHACTR1 has been found to regulate endothelin expression, by regulating the endothelin 1 
gene.114 (EDN1) The EDN1 gene itself has several variants which influence levels of 
endothelin in the body, and have been associated with clinical outcomes.112 The endothelin 
receptor A and B genes (EDNRA and EDNRB) each encode their respective receptor.113 
Endothelin has significant effects in the liver, and is a key regulator of hepatic blood flow. 
The liver has an important role in the removal of ET1 from the bloodstream and in patients 
with liver disease,  including NASH, high serum levels of ET1 have been observed.384,387 As 
well as alterations in hepatic blood flow, ET1 is associated with increased activation and 
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proliferation of hepatic stellate cells (HSCs). This is important in NAFLD as HSCs are the 
main producers of the extracellular matrix that characterises hepatic fibrosis.111,388Increased 
glycogenolysis and hepatic glucose output are also associated with ET1.387 In rats and in 
humans with cirrhotic livers, increased expression of endothelin receptors has been 
found.109,389 These findings demonstrate an association between the ET1 pathway in NASH 
and fibrosis. 
Following on from research into the link between endothelin and NASH, investigations into 
the use of endothelin receptor antagonists (ETRA) have been conducted. . The main role of 
these drugs is the reduction of pulmonary hypertension, as they block the vasoconstrictive 
effect of ET1. 108,390 ETRAs have been shown to reduce liver fibrosis in rats.391 Similar 
results were found in mice, as the ETRA ambrisentan reduced progression of hepatic fibrosis 
by inhibiting hepatic stellate cell activation.107 Some promising effects of ETRAs for treating 
NASH in a small human study have been found, but further research is required.392 Figure 6-
1 below illustrates the interaction between endothelin, its receptors and the processes of 
vasoconstriction and hepatic stellate cell activation, as well as the site of ETRA action. 
 
 
ET1 Receptor B 
Figure 6-1Endothelin Action on Vascular Muscle and Hepatic Stellate Cells 
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The aim of this study was to investigate the relationship between endothelin related genetic 
variants and NASH related outcomes. Genetic variants known to correlate with endothelin 
and endothelin receptor (ETR) activity were selected for this analysis. The main outcome 
phenotype was NASH, fibrosis and NAFLD hospitalisation also included. A significant effect 
of ET1 or ETR related variants would further clarify the role of the endothelin pathway in 
NASH, and may be useful for stratification of patients if an ETRA therapy is approved. To 
investigate whether any associations seen were due to haemodynamic effects or direct action 
on hepatic stellate cells, portal hypertension and alcoholic liver disease were also analysed.  
The genetic variants to be analysed were selected from previous literature linking genetic 
variants to ET1 and ETR expression. Three common variants from ET1 were analysed; 
rs1800541, rs2070699, and rs5370. These variants have been linked to subarachnoid 
haemorrhage, hypertension and ischemic stroke.113,393 Also analysed was rs9349379 variant 
in PHACTR1, which has been linked to ischemic heart disease. 114 This variant is close to the 
EDN1 locus, and is known to regulate ET1 expression.394   
Variants associated with endothelin receptors were analysed. Variants in EDNRA were 
investigated as this gene has been linked to conditions including hypertension.112,395 The 
SNPs rs6841581, rs17612742, and rs1878406, which are in very high linkage disequilibrium, 
have shown association with ischemic stroke and ischemic heart disease, through increased 
ETR activity.115,300,396 The SNP EDNRA rs4593108 has also shown associations with 
ischemic heart disease, through ETR activity increases.397 Common variants in EDNRB, 
which has been associated with Hirschsprung disease, were also selected for analysis; 
rs3818416 and rs5351.398 
144 
 
6.3 Methods 
6.3.1 Data  
The GoDARTS study was used as a discovery cohort.187 This is a T2DM case-control cohort 
with electronic health record data available for the 18,306 participants and genetic data 
available for many of these. The SHARE cohort was also analysed, and had 3,068 individuals 
with sufficient phenotypic and genotypic data available for analysis. The DMDSC cohort was 
included in further analysis, and had 2,013 individuals with adequate data for analysis. Full 
descriptions of these cohorts and phenotypic outcomes are presented in a previous chapter of 
the current thesis.       
6.3.2 SNPs 
Candidate SNPs which have previously been linked to ET1 and ETA activity were selected 
for analysis. These are shown in table 25 below, with frequencies from dbSNP.399 
Table 26 - Endothelin and Endothelin Receptor related genes; numbers and Minor Allele Frequencies (MAF) 
Gene SNP 
GoDARTS Allele Frequencies 
GoDARTS 
MAF 
SHARE 
MAF 
MDRF 
MAF 
 
dBSNP 
Reported 0 1 2 
EDN1 rs1800541 4424 1888 224 0.179 0.177 
 
0.243 0.246 
EDN1 rs5370 5838 3555 579 0.236 0.232 
 
0.367 0.228 
EDN1 rs2070699 1823 3016 1270 0.455 0.474 
 
0.363 0.443 
PHACTR1 rs9349379 3414 4606 1675 0.41 0.409 
 
0.490 0.401 
EDNRA rs4593108 4494 1909 221 0.177 0.174 
 
0.363 0.176 
EDNRA rs17612742 7277 2306 209 0.139 0.137 
 
0.137 
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0.206 
EDNRA rs1878406 7258 2344 213 0.141 0.14 
 
0.203 0.146 
EDNRA rs6841581 7267 2334 217 0.141 0.141 
 
0.221 0.148 
EDNRB rs3818416 374 2454 3783 0.756 0.753 
 
0.805 0.748 
EDNRB rs5351 988 3187 2442 0.610 0.605 
 
0.583 0.574 
 
A number of these variants were in high linkage disequilibrium (LD), which is shown in the 
correlation matrix in table 26. A number of other EDNRA SNPs were in extremely high LD 
with the SNPs of interest (r2 > 0.995), therefore were not analysed. These included: 
rs6842241, rs1801708, rs11413744, rs6537481, rs786205230, and rs6841473.  
Table 27 - Correlation matrix of SNPs in EDNRA in the GoDARTS cohort 
 
rs4593108 rs17612742 rs1878406 rs6841581 
rs4593108 1 
 
  
rs17612742 0.0662 1   
rs1878406 0.0646 0.964 1 
 
rs6841581 0.0676 0.968 0.994 1 
 
The two SNPs in EDRNB which were analysed were in moderate LD, with a Pearson’s R2 of 
0.70. 
Further to these five SNPs, three variants known to associate with NAFLD and NASH risk 
were analysed in the model with NASH in GoDARTS to test for any interactions or 
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alterations of associations with NASH and endothelin related SNPs. These were PNPLA3 
rs738409, TM6SF2 rs58542926 and HSD17Β13 rs6834314, shown in table 27. 
Table 28 - NAFLD and NASH related genes from previous literature; numbers and MAFs. 
Gene SNP 0 1 2 
GoDARTS 
MAF 
dBSNP 
Reported 
PNPLA3 rs738409 6797 3417 446 0.202 0.278 
TM6SF2 rs58542926 11220 1664 76 0.0701 0.0653 
HSD17B13 rs6834314 4673 3557 690 0.277 0.251 
 
6.3.3 Outcomes 
6.3.3.1 NASH 
The main phenotype investigated in this study was NASH. This was defined by the presence 
of the relevant NASH ICD-10 codes in admissions and deaths records for participants in 
GoDARTS at any point in their life. These were: "K75.8", "K740.", "K74.1", "K74.2", 
"K72.9", and "K74.6".225 Similar methods of using an ensemble of ICD-10 codes to classify 
NAFLD and its subsequent stages have been used previously, using codes for NAFLD, 
NASH, fibrosis, cirrhosis, cryptogenic cirrhosis and unspecified hepatic failure.59,400,401 
6.3.3.2 Fibrosis 
Fibrosis was also investigated in this study. This was defined by the presence of the relevant 
fibrosis ICD-10 codes in admissions and deaths records for participants in GoDARTS at any 
point in their life. These were the same as the NASH codes, with the omission of the “K75.8” 
code.  
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6.3.3.3 NAFLD Hospitalisation 
This was defined by the presence of NAFLD ICD-10 codes, or subsequent stages of NAFLD 
including NASH and fibrosis in admissions and deaths records ever. The ICD-10 codes used 
were “K76.0”, plus the codes used for NASH: "K75.8", "K74.0", "K74.1", "K74.2", "K72.9", 
and "K74.6".  
6.3.3.4 Ischaemic Heart Disease 
As a positive control to validate the effects of the genetic variants of interest, associations 
with ischaemic heart disease were tested. This condition was phenotyped using admissions 
and deaths data, which were searched for the occurrence of any ICD-10 code relating to 
ischemic heart disease. These were: “I20”, “I21”, “I22”, “I23”, “I24”, “I25”, and “I26”. In 
GoDARTS, 2,789 individuals had a diagnosis of ischemic heart disease at some point. 
6.3.3.5 Portal Hypertension 
To investigate the mechanism by which endothelin and endothelin receptor variants 
potentially altered NASH risk, portal hypertension was analysed. This was phenotyped with 
the ICD10 code “K76.6”. 
6.3.3.6 FIB-4 Index 
The FIB-4 index was developed as a non-invasive assessor of fibrosis, and FIB-4 score over 
3.25 is known to correlate with high likelihood of advanced fibrosis.153 This was calculated 
using individuals’ most recent measurements for the component biomarkers. When analysed 
as a continuous variable, FIB-4 was log transformed, as it was not normally distributed. 
6.3.3.7 ALT to AST Ratio 
ALT to AST ratio was calculated using patients most recent ALT and AST measurements 
prior to sign up to GoDARTS. ALT to AST ratio is a commonly used biomarker for liver 
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damage, particularly NAFLD.402,403 ALT and AST measurements were analysed versus the 
selected genetic variants separately, as well as a ratio. 
6.3.3.8 APRI  
The APRI score is an index of fibrosis which is calculated as the ratio of AST to platelet 
count.152 It has been shown to accurately diagnose hepatic fibrosis.  
 
6.3.4 Outcomes in MDRF Cohort: 
6.3.4.1 NAFLD 
NAFLD defined by the presence of elevated ALT levels was one of the phenotypes present in 
the MDRF cohort data. Patients in the MDRF cohort had a number of biochemical markers 
measured on their first visit to the clinic, and ALT was measured at this point.180 The 
thresholds for ALT levels in this study were 19U/L for women, and 30U/L for men.180 
6.3.4.2 ALT to AST Ratio 
Similarly to the previous ALT based NAFLD definition, this measure uses biochemical 
measurements taken at patients’ first visit to the MDRF clinic. ALT and AST measurements 
were analysed versus the selected genetic variants separately, as well as a ratio. 
6.3.4.3 Fatty Liver Grade 
Fatty Liver Grade (FLG) was assessed by abdominal ultrasound, and is a measure of the fatty 
infiltration of the liver.196 FLG was measured on a scale of 0 to 3, with these levels 
representing degrees of fatty infiltration of the liver; none, mild, moderate and severe 
respectively. This was analysed as a continuous trait, and also dichotomised as 0 versus 1, 2 
and 3; i.e. no fatty infiltration of the liver versus any level of fatty infiltration of the liver. 
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6.3.5 Exclusions 
To ensure the specificity of the NAFLD definition individuals with features of alternate 
causes of liver disease were excluded. Individuals with any positive serological tests for anti-
smooth muscle antibody, antinuclear antibodies or anti-mitochondrial antibodies, any positive 
serology for hepatitis B surface antigen or hepatitis C antibody, or mention of cause of liver 
disease in medical records were excluded. Individuals with alcohol dependence or any 
documentation of alcoholic liver disease in their EHRs were excluded. In addition, 
individuals who self-reported drinking more than 20g a day for women and more than 30g a 
day for men were excluded. 
6.3.6 Statistical Methods 
All analyses were adjusted for age, sex, and type 2 diabetes (T2DM). Continuous variables 
were analysed using a linear regression and binary variables were analysed with a logistic 
regression. All analyses were carried out in the statistical package R. This was a cross 
sectional study, as outcome phenotypes were assessed as the presence of a condition ever 
before the last follow up date.  
 
6.4 Results 
6.4.1 Results in GoDARTS 
Genetic variants associated with ET1 and ETA were tested for associations with NASH, and 
related phenotypes. A number of endothelin related SNPs in or near EDNRA and EDN1 had 
significant associations with NASH, and NASH related phenotypes. The key findings from 
this study are reported below. 
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6.4.1.1 Ischemic Heart Disease 
Positive control tests were run with genetic variants associated with ET1 and ETA, and 
coronary heart disease. The EDNRA variant rs6841581 showed an association with ischaemic 
heart disease, with an odds ratio of 1.11(95% CI = 1.00 - 1.23), p = 0.039), as did rs1878406. 
(OR = 1.11(1.01 - 1.23), p = 0.037)  
6.4.1.2 NASH 
Three variants in EDNRA were significantly associated with NASH; rs17612742 – OR = 
1.59(0.99 -4.02), p = 0.04); rs1878406 and rs6841581 (due to high LD) – OR = 1.81(1.16 – 
2.73), p = 0.006);  
In a recessive model, EDNRA rs4593108 was non-significantly associated with NASH, with 
similar OR to other EDNRA variants. (OR =1.86(0.65 - 4.22), p = 0.18) 
The known NAFLD and associated condition risk variants PNPLA3 rs738409, TM6SF2 
rs58542926 and HSD17Β13 rs6834314 were added to the models to test for any interactions 
with EDNRA variants. It was found that the EDNRA variants which associated with NASH 
behaved additively with these variants, and no interaction was found. 
6.4.1.3 Fibrosis 
None of the variants analysed were significantly associated with fibrosis. 
6.4.1.4 NAFLD Hospitalisation 
EDNRA variants were significantly associated with NAFLD hospitalisation. These were: 
rs1878406 – OR = 1.46(1.04 – 2.00) p = 0.023; rs6841581 – OR = 1.46(1.04 – 2.00), p = 
0.024. EDNRA rs17612742 and rs4593108 were both close to statistical significance for 
NAFLD hospitalisation, with similar odds ratios as seen for NASH. 
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6.4.1.5 Fatty Liver Index 
The variant EDNRA rs6841581 was associated with increased FLI: rs6841581 – β = 1.66(SE 
= 0.87), p = 0.048. The other two variants in EDNRA which are in high LD with rs6841581 
(rs17612742 and rs1878406) were close to statistical significance with similar beta estimates. 
6.4.1.6 GGT 
Three variants in EDNRA were associated with increased serum GGT: rs17612742 - β = 
10.04(SE = 3.00), p = 0.00084; rs1878406 - β = 10.35(SE = 3.02), p = 0.00062; rs6841581 – 
β = 10.76(SE = 3.01), p = 0.00036) 
6.4.1.7 FIB4 
EDNRA rs4593108 was associated with increased FIB4 index in a recessive model. (β 
=0.79(SE = 0.37), p = 0.031. 
EDN1 rs2070699 was associated with lower FIB4 index. (β = -0.77(SE = 0.31), p = 0.012) 
6.4.1.8 APRI Score 
EDNRA rs4593108 was recessively associated with APRI score. (β = 0.34(SE = 0.12), p = 
0.0048) 
6.4.1.9 Portal Hypertension 
Variants in EDNRA were associated with increased portal hypertension. rs6841581 – OR = 
2.40(1.014 -5.16), p = 0.032 and rs1878406 – OR = 2.42(1.017 - 5.21), p = 0.031) EDNRA 
rs4593108 was close to statistical significance for association with portal hypertension. (OR 
= 2.04(0.85 - 4.48), p =0.089) 
6.4.1.10 ALT to AST Ratio 
None of the variants analysed were associated with ALT to AST ratio. 
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6.4.2 Analysis in SHARE Cohort 
To validate findings, a number of phenotypes were analysed in SHARE, with the EDN1, 
EDNRA, EDNRB and PHACTR1 SNPs of interest. 
6.4.2.1 NASH 
Homozygous carriers of EDNRA rs4593108 had increased risk of NASH. (OR = 4.04(0.92 - 
1.24), p = 0.029) 
PHACTR1 rs9349379 was recessively associated with increased NASH risk. (OR = 2.39(1.02 
- 5.24), p = 0.034) 
6.4.2.2 Fibrosis 
Homozygous carriers of EDNRA rs4593108 also had increased risk of fibrosis.(OR = 
4.54(0.70 - 6.94), p =0.05) 
PHACTR1 rs9349379 was recessively associated with increased fibrosis risk. (OR = 
2.41(0.97- 5.53), p = 0.044) 
6.4.2.3 NAFLD Hospitalisation 
EDNRA rs4593108 was associated with increased NAFLD hospitalisation. (OR = 4.05(0.95 -
12.0), p = 0.026) 
For the variants in EDNRA that were significant in GoDARTS, although the p values were 
not significant, the direction of effect was the same as in GoDARTS. For example for 
NAFLD Hospitalisation: rs1878406- OR = 1.36(0.84 - 2.1297), p = 0.19; rs6841581 – OR = 
1.36, (0.83 - 2.12), p = 0.20; rs17612742 - OR = 1.39(0.85 - 2.17), p = 0.16. 
6.4.2.4 FIB4 
FIB4 index was significantly associated with variants in EDNRA, with the results as follows. 
rs6841581 – β= 0.25(0.077 -0.42), p = 4.6x10-3; rs1878406 – β = 0.26(0.087 – 0.43), p = 
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3.2x10-3; rs17612742 – β = 0.24(0.075 – 0.41), p = 4.7x10-3. PHACTR1 rs9349379 was 
recessively associated with increased FIB index. (β =4.22(SE = 2.12), p = 0.47) 
These variants were also associated with greater odds of having experienced FIB4 index 
greater than 3.25. The results were as follows: rs6841581 – OR = 2.24(1.20 - 4.10), p = 
9.2x10-3; rs1878406 – OR = 2.30(1.24 - 4.19), p = 7.2x10-3; rs17612742 – OR = 2.32(1.27 - 
4.16), p = 5.0x10-3. 
6.4.2.5 Portal Hypertension 
Variants in EDNRA were associated with increased portal hypertension. rs6841581 – OR = 
2.39(1.31 - 4.17), p = 0.003; rs17612742 – OR = 2.44(1.34 - 4.25), p = 0.0023; rs1878406 – 
OR = 2.40(1.31 - 4.18), p = 0.0029. 
6.4.3 Analysis in MDRF Cohort 
6.4.3.1 NAFLD 
A single variant in EDNRA (rs4593108) was close to statistical significance for NAFLD. (OR 
= 0.90134 (0.80 -1.01), p = 0.085) 
6.4.3.2 ALT to AST Ratio 
None of the variants tested were significantly associated with ALT to AST ratio. 
Two variants in EDN1 were associated with ALT level in recessive models; rs5370 –β= 
3.66(1.36 - 2.69), p = 0.0073 and rs2070699 – β= -2.70(1.29 - 2.09), p = 0.037 
6.4.3.3 Fatty Liver Grade 
Two variants in EDNRA were close to statistical significance for a Fatty Liver Grade Greater 
than 0. (rs17612742 - OR = 1.24(0.99 - 1.58), p = 0.07; rs1878406 – OR = 1.22(0.97 - 1.54), 
p = 0.088;   
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6.5 Discussion 
We found significant associations between genetic variants in endothelin and endothelin 
receptor A, and NASH, plus NASH related phenotypes in GoDARTS and SHARE. In the 
MDRF cohort, we found variants significantly associated with ALT levels, and close to 
significance for NAFLD and FLG. A number of these variants have been linked to 
upregulation of the endothelin pathway in previous studies. 
We found two independent variants in EDNRA to be associated with a number of the NASH 
related outcomes that were analysed in this study. The first locus contained rs17612742, 
rs1878406 and rs6841581, all of which were in high LD. (Pearson’s R2 = 0.96 -0.99) 
Associations were found for these SNPs for NASH, NAFLD hospitalisation, FLI, portal 
hypertension and ischemic heart disease in GoDARTS. In SHARE, associations were found 
for FIB4 index and portal hypertension. Although the same direction of effect for these SNPs 
was seen in GoDARTS and SHARE for associations with NASH, fibrosis and NAFLD 
hospitalisation, none were statistically significant, likely due to low power. In the MDRF 
cohort, rs17612742 and rs1878406 were close to significance for association with increased 
risk of Fatty Liver Grade greater than 0. i.e presence of fatty infiltration of the liver. 
This locus is known to associate with both carotid intima media thickness (cIMT) and plaque, 
and is thought to upregulate the activity of the endothelin receptor.404 GWAS studies have 
found that this locus is associated with increased systolic blood pressure, and increased pulse 
pressure.312 It has also been associated with increased risk of coronary artery disease, thought 
to be a result of increased cIMT and plaque.405 Association between this EDNRA locus and 
GGT was observed. GGT is often used as a marker of liver damage, but is also associated 
with ischemic heart disease.148,406 In SHARE, these three EDNRA SNPs were significantly 
associated with increased FIB-4 index, a useful marker of fibrosis. These findings are 
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consistent with this EDNRA locus being associated with increased endothelin receptor 
activity. 
The second locus was at EDNRA rs4593108, which was in extremely low LD with the 
previous EDNRA locus around rs17612742. (Pearson’s R2 < 0.07) In GoDARTS, we found 
associations with this SNP for FIB4 and APRI. It was also close to significance for NASH, 
NAFLD hospitalisation and portal hypertension. In SHARE, it was associated with NASH, 
NAFLD hospitalisation, and fibrosis. In MDRF, it was also close to significant association 
with increased NAFLD. (As defined by raised ALT levels) This locus has been reported to 
associate with a number of clinical outcomes, including coronary heart disease.397 Studies 
have also found that it is associated with increased risk of myocardial infarction.407 These 
findings suggest that this variant is associated with upregulation of endothelin A receptors. 
Significant associations between the PHACTR1 variant rs9349379 and NASH, fibrosis and 
FIB index were found in SHARE, but not replicated in GoDARTS or MDRF. This variant 
has been found to associate with increased coronary artery disease risk in a number of 
studies.408 It is also associated with carotid plaque. 409 It has recently been demonstrated that 
PHACTR1 rs9349379 regulates the EDN1 gene.114 The minor allele carriers were found to 
have higher EDN1 expression, and higher ET1 levels. 
The findings of the current study suggest that the upregulation of endothelin and the 
endothelin A receptors plays a major role in development of NASH and fibrosis. Leivas et al. 
found that expression of ETA and ETB receptors was increased in the livers of cirrhotic 
patients, and was directly associated with portal hypertension in these individuals. Tsuchiya 
et al. found that in cirrhotic rats, higher endothelin activity was associated with hepatic 
ischemia and reperfusion injury, as well as lowered survival.410 Serum levels of endothelin 
are increased in cirrhotic patients, and the levels of endothelin correlate with the severity of 
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liver damage as well as portal hypertension.411 These findings, combined with our results 
linking endothelin and endothelin receptor related genetic variants suggest an important role 
for endothelin in liver disease, especially fibrosis. 
Endothelin is associated with a number of effects and pathways which may be responsible for 
these associations, and may contribute to the pathophysiologies of NASH and fibrosis. 
Endothelin is a vasoconstrictor, and acts to increase blood pressure.383 EDNRA (Endothelin 
receptor A) is a sub-type of endothelin receptor which increases vasoconstriction when 
activated, which raises blood pressure.412 Haemodynamic changes and effects are present in 
fibrosis and cirrhosis.413  Hypertension of the hepatic artery is caused by increased 
extrahepatic hyperdilation, and the resulting increased inflow of blood.414 This increase in 
vasodilators which cause this hyperdilation is thought to be due to portosystemic shunting 
and bacteria translocation.415 Portal hypertension is a key element of cirrhosis. Additionally 
to increased inflow to the portal vein, portal hypertension is increased by the build-up of 
extracellular matrix causing increased resistance to blood flow, as well as active 
vasoconstriction within the liver.416 Portal hypertension is a major factor in the development 
of complications in liver disease.417 Moller et al. found increased circulating endothelin in 
patients with cirrhosis, causing significant changes in hepatic haemodynamics.411,415 
Endothelin has been shown to decrease splanchnic blood flow.418 There a number of 
pathways which endothelin could affect to alter splanchnic circulation including through 
nitric oxide(NO), arachidonic acid metabolites or bacteria.415,419,420  
Hepatic ischemia is a feature of severe liver disease, and in particular microvascular 
circulation is impaired in NAFLD.421 It has been found that steatotic livers are less tolerant of 
hepatic ischemic reperfusion injuries.422 Tsuchiya et al. found increased the ischemia of the 
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liver seen in cirrhotic rats was reduced with the administration of ETA receptor 
antagonists.410,423  
Endothelin is associated with increased secretion of inflammatory cytokines.424 These include 
TNF-α, IL-1 and IL-6, which are important inflammatory markers in the development of 
NASH.425 As well as hepatic inflammation, these cytokines have a role in increasing the 
extracellular matrix production associated with fibrosis.424 The ET1/ETA pathway is 
associated with increased myocardial fibrosis, through fibroblast proliferation and 
extracellular matrix deposition.426 Increased ET1 levels, as well as increased numbers of ETA 
receptors have also been seen in patients with pulmonary fibrosis.427 The increased heart and 
lung fibrosis associated with ET1 may have mechanisms in common with the increased 
NASH and fibrosis observed in the current study. 
Hepatic stellate cells (HSC) play a major role in fibrosis, and are an important factor in the 
association between endothelin and fibrosis.428 HCSs are normally inactive and have a role in 
the storage of vitamin A. When activated in response to liver damage, HSCs produce the 
extracellular matrix which forms the scar tissue seen in fibrosis.16,388 Collagen is one of the 
key components of this extracellular matrix, and can increase risk of progressing to cirrhosis.  
Endothelin increases both HSC proliferation and activation.429 This thought to be modulated 
by ETA receptors. Indeed, Cho et al. found that an ETA receptor antagonist blocked the 
formation and deposition of collagen in rats with liver fibrosis.110 This may explain a portion 
of the increased fibrosis risk in carriers of EDNRA risk variants associated with higher ETA 
receptor activity.388 This forms a vicious cycle, as when hepatic stellate cells are activated; 
such as in NASH or fibrosis; secretion of ET1 is increased.391  
The combined effect of these mechanisms and processes likely explain the increased NASH 
and fibrosis in those carrying genetic variants associated with higher ETR activity. This 
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suggests the use of drugs which interrupt and reduce the effects of ET1 this may have a role 
in fighting NASH, fibrosis and cirrhosis on several fronts. Endothelin receptor antagonists 
(ETRAs) are a class designed to down regulate endothelin receptors. These drugs have been 
used to treat pulmonary arterial hypertension primarily.390 They have been investigated as 
potential treatments for a number of other conditions including renal failure, sickle cell 
disease, and cancer.430–432 
Studies have investigated the use of ETRAs for the treatment of NASH and fibrosis.107,391 
Studies on rats have yielded promising results for the treatment of cirrhosis. Cavasin et al. 
found that antagonism of ETA receptors reduced hepatic portal blood pressure, and suggested 
a selective ETA receptor antagonist should be more effective than a dual antagonist, so as to 
preserve the beneficial effects of ETB receptor activation. (relaxation of sinusoids and 
systemic vasodilation) 433 These results were mirrored by De Gottardi et a., as they found 
only ETA receptors to reduce portal hypertension.434 
Despite past research suggesting a therapeutic role of ETRAs for NASH, and the success 
some have had in therapy for a number of conditions, serious negative side effects have been 
observed. Cases of liver toxicity have been found in patients being treated with ETRAs, some 
of which have been fatal.435 This is another aspect of ETRA which requires further research 
to fully understand the effects of the drugs and provide safe and effective treatment. 
The results of this study may have clinical relevance through stratification of patients, should 
a therapy based on ETRAs be approved. The patients who carry the EDNRA risk variants and 
therefore have greater endothelin receptor activity, may perhaps benefit more from ETRAs 
than those with the wild type allele. This is an opportunity for applied personalised medicine. 
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6.5.1.1 Limitations and Future Work 
The major limitation of this study is lack of experimental power, due to low numbers of 
individuals diagnosed with NASH and related phenotypes in medical records. The under 
diagnosis of NAFLD and related phenotypes in clinical settings is discussed previously in 
this thesis. The phenotypes NASH, fibrosis and NAFLD hospitalisation each had fewer than 
100 cases in patients who had been genotyped in both GoDARTS and SHARE. This makes 
the detection of genetic effects extremely underpowered, especially with binary outcomes.  
As discussed in previous chapters, many patients in the GoDARTS and SHARE cohorts are 
likely to have had undiagnosed NASH, fibrosis and cirrhosis, which reduced effect size and 
the statistical significance of findings. The same issue was found for other, continuous 
phenotypes including FIB4, FLI, APRI and GGT. 
A number of results in GoDARTS were not statistically significant when replicated in 
SHARE, though had the same direction of effect and similar effect sizes. The results of this 
current study are not strong enough to conclusively demonstrate the role of EDN1 and 
EDNRA variants in NASH and fibrosis, but the effects seen are concurrent with previous 
research and are biologically plausible.  
Multiple testing may have been an issue in this study. Each variant was tested in models with 
a number of NAFLD related phenotypes. This may have increased the number of significant 
results simply by chance. Techniques such as Bonferonni can be used to avoid this, but can 
blunt the sensitivity of analysis. 
To take this research further, replication and further analyses in a larger cohort with access to 
high quality phenotype data is necessary. The challenge of diagnosing NAFLD causes a large 
underdiagnosis of NAFLD in clinical settings, which makes this kind of data rare.25 Further 
to this, retrospective cohort studies investigating liver damage outcomes in those who were 
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prescribed ETRAs for pulmonary hypertension may be an effective method of using existing 
data to assess the efficacy of ETRAs for liver damage. 
 
6.6 Conclusion 
To conclude, we have shown that variants in EDNRA and EDN1 which are known to 
associate with upregulated endothelin receptor activity have significant effects on NASH, 
NAFLD hospitalisation, and indexes of fibrosis. Given the association of these variants with 
the development of atherosclerosis and heart failure with preserved ejection fraction, these 
data in NASH raise the possibility that endothelin receptor antagonism may target multiple 
underlying pathologies. Genetic profiling may also allow for targeted therapy in patients with 
established NASH and fibrosis.  
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7  Discussion 
7.1 Summary of Findings 
7.1.1 NAFLD Phenotype 
A NAFLD phenotype based on two raised ALT measurements at least 3 months apart, in the 
absence of other causes of liver disease was developed. A number of ALT thresholds were 
discussed, and those suggested by Prati et al. were (>19U/L for women, >30U/L for men) 
selected as there is good evidence that these are the upper limits of ALT levels in healthy 
individuals.180 Measures were at least 3 months apart to remove the possibility of acute liver 
damage (e.g. drug induced) being classified as NAFLD. This definition was validated against 
NAFLD diagnoses from EHRs, and was 96% sensitive in GoDARTS. It correlated well with 
other known NAFLD risk factors such as BMI, age, T2DM and cholesterol. The established 
NAFLD risk SNP rs738409 was strongly associated with this NAFLD phenotype, providing 
more validation. 
Individuals with NAFLD were found to have increased morbidity compared with those 
without NAFLD, as they had more hospital admissions, even when liver related admissions 
were excluded. Those with NAFLD also lived shorter lives, also when liver related death was 
excluded. This demonstrated the established underdiagnosis of NAFLD in clinical settings, as 
well as the effect of NAFLD on extrahepatic morbidity and mortality.25 This has been 
explored in previous literature, with cardiovascular disease and cancer found to contribute 
significantly to these associations.58,59 The link between NAFLD and cancer was investigated 
in detail in the following chapter. 
The development of an accurate and practical method for the diagnosis of NAFLD in large 
retrospective cohorts is an important step in the field of NAFLD research. This method of 
NAFLD diagnosis could allow analysis of NAFLD epidemiology, pathology and genetic 
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determinants in cohorts which previously lacked a suitable NAFLD definition. As NAFLD 
diagnosis is so challenging, as simple and commonly measured definition such as this may 
allow analysis with many more cases compared with biopsy based definitions for example. 
 
7.1.2 NAFLD and Cancer 
The aim of this chapter was to analyse the relationship between cancer incidence and death, 
and NAFLD. We found that NAFLD was significantly associated with increased risk of 
cancer incidence in GoDARTS, SHARE and Tayside and Fife Diabetic cohort (T&F). BMI 
was associated with increased cancer incidence in an unadjusted model. When NAFLD was 
accounted for, BMI was no longer associated with cancer incidence. The same results was 
found when analysis was limited to previously reported BMI related cancers.221 This result 
was consistent with another study into NAFLD and cancer, where Allen et al. found BMI 
made little to no difference to cancer risk in those without NAFLD.59 These results combined 
suggest previous results linking BMI to cancer have been driven by NAFLD. NAFLD was 
significantly associated with increases in specific cancer incidence, including prostate, breast, 
colon, lung and liver cancers. In GoDARTS, the common NAFLD risk variant PNPLA3 was 
significantly associated with increased cancer incidence, further validating the results of this 
study. 
We also found NAFLD increased risk of cancer death in GoDARTS, SHARE and T&F. 
Cancer was found to be the predominant cause of early death in those with NAFLD, as when 
cancer deaths were excluded, NAFLD was not significantly associated with age of death. In 
GoDARTS, individuals with NAFLD who did not have T2DM, and did not have cancer at 
any point in their lives, lived lives of similar length to those who did not have NAFLD. 
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Similar findings were made by Simon et al. in a large Swedish cohort where extrahepatic 
cancer was the predominant cause of early death in NAFLD.60 
These findings suggest that cancer is a major part of the epidemiology of NAFLD. This may 
also give clues as to the pathogenesis of certain cancers, and help the prevention of cancers 
through interventions against NAFLD. NAFLD is associated with numerous pathways which 
may influence cancer development. Hyperinsulinemia has been linked to a number of 
cancers, and is highly prevalent in those with NAFLD.236,436 The pro-inflammatory state 
created by NAFLD may cause increased cancer risk, as increases in cytokines, adipokines 
and lymphokines increase cell proliferation, migration and hinder apoptosis.238,239 
7.1.3 NAFLD GWAS 
GWAS analyses of NAFLD in GoDARTS and DMDSC revealed PNPLA3 rs738409 has a 
significant effect on NAFLD risk in both cohorts, with similar odds ratios. Though the data 
and NAFLD phenotypes were slightly different, this shows that this locus is an important 
factor in the development of NAFLD in both populations. Variants in ERLIN1, a SREBP 
signalling regulator, were also associated with reduced NAFLD risk in GoDARTS. This 
association was not seen in DMDSC, likely due to insufficient statistical power. 
Fatty Liver Index was analysed in GoDARTS, and a number of genetic variants were close to 
genome wide significance. Variants in GGT1 were close to significance, and as GGT is 
included in the calculation of FLI.148 A second GWAS of FLI was run in GoDARTS adjusted 
for this GGT1 locus, so as to remove the variance in FLI caused by this. This produced 
stronger results, with a number of genome wide significant hits. Significant signals were seen 
in chromosome 3 in the FAM19A4 and EOGT genes, which have roles in inflammation and 
metabolism respectively.305,307 Variants in DNAH11 were genome wide significantly 
associated with decreased FLI, though this locus has not previously been associated with 
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NAFLD or associated pathways.304 Two variants in TCF7L2 were genome wide significantly 
associated with FLI. One of these was the variant rs7903146, which is a large T2DM risk 
factor, and has independent effects on NAFLD risk.254,317 No genome wide significant 
associations were found for Fatty Liver Grade in the DMDCS cohort. 
7.1.4 NAFLD and GLP1R, GCG and GCGR Genes 
GLP1R/GCGR co-agonist medications have been used to treat diabetes and obesity, and have 
recently been investigated as a potential treatment for NAFLD.97,101,103 Variants in the genes 
associated with these receptors have been linked to their activity, and a number of relevant 
metabolic pathways.349,355 We sought to investigate whether variation in these genes was 
associated with risk of NAFLD in the GoDARTS, SHARE and DMDSC cohorts. We found 
two missense variants in GLP1R; rs1042044 and rs6923761; were significantly associated 
with NAFLD in the meta analysis of GoDARTS and SHARE. Carrying a risk genotype for 
either one of these GLP1R SNPs was associated with increased risk of NAFLD. The 
rs140065949 variant in GCGR was also significantly associated with NAFLD. Statistically 
significant interactions were found as well, as the effect of GCGR rs140065949 was 
significant in carriers but not non-carriers of GLP1R risk genotypes.  
These findings suggest a role of GLP1R and GCGR genes in the development of NAFLD, 
and complement previous research suggesting that these receptors influence NAFLD risk. 
These findings also agree that GLP1R/GCGR co-agonism ought to have beneficial effects on 
NAFLD, and that patients with different genotypes may have different drug response. They 
may have utility in implementing personalised medicine in those treated with GLP1R/GCGR 
agonists, should they be approved for treatment of NAFLD.  
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7.1.5 NAFLD and Endothelin Genes 
Endothelin receptor agonists have been investigated as a treatment for hepatic fibrosis.391 
Endothelin increases activation and proliferation of the HSCs which produce ECM which is 
present in fibrosos.428 Studies have found increased endothelin in cirrhotic livers, and 
increased presence of endothelin receptors on HSCs.437 Antagonisation of the endothelin 
receptor by ETRA drugs has been found to reduce hepatic fibrosis.391  
The current study aimed to investigate the role of genetic variants related to endothelin 
function and NAFLD in the GoDARTS, SHARE and DMDSC cohorts. We found variants in 
EDN1 and EDNRA to be significantly associated with NASH, NAFLD hospitalisation, 
fibrosis and portal hypertension. The variants in EDNRA have been associated with increased 
endothelin receptor activity in previous literature.112,113 The variant in EDN1 was has also 
been linked to increased endothelin.112 These findings are consistent with previous literature 
suggesting down regulation of the endothelin receptor will reduce NAFLD and fibrosis. The 
findings of the current study could also be useful in stratifying patients by genotype for 
treatment with ETRAs, as different genotypes may respond differently. 
7.2 Clinical Implications of the Current Study 
The findings of the current study have major implications for a large number of individuals. 
NAFLD is a common condition, affecting around 25.2% of adults globally.54 The current 
study showed that the vast majority of patients with NAFLD have not been admitted to 
hospital for their condition, and are likely undiagnosed, which is consistent with previous 
findings.25 Roughly 2% of patients with NAFLD has this listed as a cause of death in the 
GoDARTS cohort. Despite this, NAFLD patients have much more morbidity, and died on 
average 1.93 years younger than those without NAFLD, after adjusting for age, sex, BMI and 
diabetes. This is also consistent with previous reports about mortality and NAFLD.58  
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Further to this, we showed NAFLD was associated with increased cancer incidence and 
cancer death, and that BMI was no longer associated with cancer incidence when NAFLD 
was accounted for. Screening for NAFLD may allow better prediction and targeted screening 
for cancers. Our results demonstrated this association with a NAFLD definition based on 
ALT, a cheap and commonly measured biomarker. This could be applied retrospectively, 
with patients with raised ALTs in the past referred for screening. It may also be applied 
prospectively, with increased ALT testing and routine ALT measurements used to flag those 
who are at risk.  
Knowledge of the association between NAFLD and cancer should mean that even moderate 
NAFLD is taken seriously and interventions to try and reduce its severity attempted more 
often. Though there is no recommended pharmacological treatment, lifestyle interventions 
such as weight loss, exercise, smoking cessation and  lowering alcohol intake can improve 
patients’ condition.96,200,438,439 
In 2016, It was estimated to cost the USA $103 billion dollars per year, with prevalence rates 
still rising.440 Given the under diagnosis and underreporting of NAFLD in clinical settings, 
this number is likely much higher in reality.25 If extrahepatic outcomes associated with 
NAFLD are included, this figure would again rise dramatically. The direct cost of cancer 
healthcare in the USA is estimated to be $173 billion for example.441 
Further to the clinical implications, these findings suggest that more intensive research into 
NAFLD Is required, particularly with the aim of producing an effective drug for the therapy 
of NAFLD and diagnostic methods. Improved diagnostic methods would improve patient 
care through targeted screening for cancer, but also improve NAFLD research, as a high 
quality NAFLD phenotype would allow effective clinical trials to be run. 
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The associations with NAFLD and  GLP1R/GCGR genes, and endothelin genes give further 
clues as to the pathological nature of NAFLD, and may relevant to applying precision 
medicine in NAFLD if drugs involved in their respective pathways are approved for NAFLD. 
Genotyping patients has become more and more affordable, and many consider personalised 
medicine for all just years away, with every patient being genotyped.442,443  
7.3 Strengths and Limitations 
This thesis used data derived from EHRs and existing high quality research studies for 
clinical variables. Large amounts of longitudinal data were available allowing long follow-up 
periods with many events, which enabled adequately powered analyses to be run in most 
cases. Access to genetic data for a large number of these patients allowed for a number of 
interesting and productive genetic studies to be undertaken.  
The limitations associated with a NAFLD phenotype based on elevated ALT levels have been 
discussed in previous sections of the current thesis. We demonstrated the accuracy of the 
phenotype, validating it against NAFLD diagnosed in medical records and positive controls 
such as CKD, and the PNPLA3 rs738409 variant. 
Observational studies have a number of limitations compared with randomised control 
trials.444,445 A common issue is confounding factors. This was countered in the current study 
using several techniques. Analyses were adjusted for sex, age, T2DM status, and BMI where 
appropriate, and cancer analyses were also adjusted for smoking status. This helped mitigate 
the possibility of interpreting the effects these NAFLD correlates, as effects of NAFLD itself. 
Exclusions for a number of different liver disease causes were made when defining the 
NAFLD phenotype, further removing confounding factors. 
Selection bias is another issue which can affect observational studies. In the case of the 
current study this may have been introduced when defining NAFLD cases and controls. For 
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example, patients with more morbidities may interact more with healthcare services, and 
therefore have more ALT measurements taken, giving them more of chance of having raised 
measurements. The longitudinal nature of the data associated with each cohort meant that 
each patient on average had 20 ALT measurements, and almost all had more than two 
measurements. The make-up of the GoDARTS cohort; primarily a T2DM research cohort; 
has roughly a 60% to 40% split of diabetic to non-diabetic patients, and was designed to limit 
selection bias of just having T2DM patients.187 The Tayside and Fife cohort allowed 
replication of results in a cohort which used population level data also. 
7.4 Future Work 
The findings of the current thesis suggest a number of future paths for impactful research, 
using currently available datasets and potentially expanding to use more. 
Research into cancer genetics has uncovered a number of risk genotypes, some which have 
been used for applied personalised medicine, such as BRCA.446 Analysis of the genetics 
which predispose to cancer specifically in people with NAFLD may help to reveal the nature 
of the relationship between NAFLD and cancer, as well as be another opportunity for applied 
personalised medicine. 
We found NAFLD was associated with a number of extrahepatic cancers, and previous 
studies have reported links to other extrahepatic conditions such as CKD.189 NAFLD could 
potentially be used to predict future incidence of these conditions. Further to this, genetic 
predictors of NAFLD may help in the prediction of other disease, as was shown by our 
Mendelian randomisation analysis for NAFLD and cancer. 
The GWAS analysis of FLI in GoDARTS revealed variants in the GGT1 gene close to 
genome wide statistical significance. This was controlled for in a subsequent GWAS, which 
produced clearer and more significant results. An investigation into the effects of the GGT1 
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variant on FLI and whether a patient’s genotype could be included in the FLI calculation 
could improve its utility as a NAFLD biomarker. 
Conceptually, NAFLD as a diagnosis has its roots as an alternative explanation for liver 
damage which was previously thought to only be caused by alcohol consumption.32 This 
nomenclature is dated and updating it to “MAFLD” has been suggested and adopted by many 
in the field.34,447 It is increasingly understood that the alcohol and non-alcohol related causes 
of NAFLD exist together and contribute to the disease as its seen globally.33,448 Most adults in 
Europe drink some amount of alcohol, with many drinking harmful levels. 449 The current 
study excluded those who consumed excessive alcohol, but an effective and sensitive 
approach to understanding the condition may be controlling for alcohol consumption instead. 
Binge drinking is common in Scotland, and has been found to increase risk of liver disease, 
even in those who do not exceed weekly limits.448 Though research into alcohol use is often 
challenging, understanding the role of drinking and particularly binge drinking in NAFLD 
may be key to understanding the disease. Contributions from a wide variety of factors are 
known to affect NAFLD, and lifestyle factors in particular have not been described fully in 
the literature. A key feature of the SHARE cohort is the ability to contact individuals in 
recruit by phenotype studies, and this could be utilised to survey the lifestyle of NAFLD 
cases and controls.188 This would also help the understanding of MAFLD specifically, taking 
into accounts all aspects of risk. 
Genetic research published in high impact journals can often be Western centric in their 
cohorts, and thus analysis of genetic modifiers of disease susceptibility.450–452 Many reported 
genetic associations differ between ethnicities and significant genetic variation exists between 
South Indians and Europeans. There are many genetic variants which the two populations do 
not share in common. The GWAS analyses conducted in the current study used genotyping 
platforms which were developed mainly in Western countries.453 Access to genotypic data for 
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variants specific to the South Indian population provides an opportunity to investigate 
whether there are any ethnicity specific genetic risk factors for NAFLD. This may further aid 
the understanding of NAFLD in South Indian populations, and also generally in all 
ethnicities. It also may provide the basis for personalised medicine for South Indian patients. 
7.5 Conclusion 
To conclude, the current thesis shows the development and validation of a NAFLD definition 
based on elevated ALT levels in the absence of alternative causes of liver disease. We show 
increased risk of cancer incidence and death in those with NAFLD, and that cancer is the 
main factor in the shortened lifespans seen in patients with NAFLD. We found PNPLA3 
rs738409 was a key component of genetic risk for NAFLD in both Scottish and Indian 
populations, and showed significant effects of several other genetic variants. Variants in 
GCGR and GLP1R had significant effects on NAFLD risk, further demonstrating a role of the 
receptors which they code for in NAFLD, as well as providing an opportunity for 
personalised medicine, should GLP1R/GCGR co-agonists be approved for use in treatment of 
NAFLD. Variants previously shown to affect the activity of endothelin had detectable effects 
on the susceptibility to NAFLD in our cohorts, providing another possibility for the 
application of personalised medicine. These findings suggest patients’ genotypes may 
influence the efficacy of endothelin receptor antagonists in the treatment of NAFLD. 
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